BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P; CheckMate 025 Investigators. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373:1803-1813. [PMID: 26406148 DOI: 10.1056/nejmoa1510665] [Cited by in Crossref: 3796] [Cited by in F6Publishing: 4063] [Article Influence: 474.5] [Reference Citation Analysis]
Number Citing Articles
1 Wen J, Zhao Y, Fang CX, Wu XH. Association between serum baseline C1q and IgG levels and the efficacy of combined immunotherapy in patients with esophageal squamous cell carcinoma: a retrospective study. Immunopharmacol Immunotoxicol 2023;45:83-8. [PMID: 35997274 DOI: 10.1080/08923973.2022.2115926] [Reference Citation Analysis]
2 Li Y, Flavell RR, Juarez R, Chow M, Wu C, Tsai K, Daud A, Behr SC. Retrospective study of the incidence of sarcoidosis-like reaction in patients treated with immunotherapy. Clin Radiol 2023;78:e131-6. [PMID: 36344282 DOI: 10.1016/j.crad.2022.09.127] [Reference Citation Analysis]
3 Dianat-Moghadam H, Sharifi M, Salehi R, Keshavarz M, Shahgolzari M, Amoozgar Z. Engaging stemness improves cancer immunotherapy. Cancer Lett 2023;554:216007. [PMID: 36396102 DOI: 10.1016/j.canlet.2022.216007] [Reference Citation Analysis]
4 Reese S, Calderon L, Khaleel S, Hakimi AA. Current and Future Biomarkers in the Management of Renal Cell Carcinoma. Urologic Clinics of North America 2023;50:151-159. [DOI: 10.1016/j.ucl.2022.09.003] [Reference Citation Analysis]
5 Chang WH, Hsu SW, Zhang J, Li JM, Yang DD, Chu CW, Yoo EE, Zhang W, Yu SL, Chen CH. MTAP deficiency contributes to immune landscape remodelling and tumour evasion. Immunology 2023;168:331-45. [PMID: 36183155 DOI: 10.1111/imm.13587] [Reference Citation Analysis]
6 Tian J, Chen JH, Chao SX, Pelka K, Giannakis M, Hess J, Burke K, Jorgji V, Sindurakar P, Braverman J, Mehta A, Oka T, Huang M, Lieb D, Spurrell M, Allen JN, Abrams TA, Clark JW, Enzinger AC, Enzinger PC, Klempner SJ, Mccleary NJ, Meyerhardt JA, Ryan DP, Yurgelun MB, Kanter K, Van Seventer EE, Baiev I, Chi G, Jarnagin J, Bradford WB, Wong E, Michel AG, Fetter IJ, Siravegna G, Gemma AJ, Sharpe A, Demehri S, Leary R, Campbell CD, Yilmaz O, Getz GA, Parikh AR, Hacohen N, Corcoran RB. Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial. Nat Med 2023. [DOI: 10.1038/s41591-022-02181-8] [Reference Citation Analysis]
7 Zhai Y, Liu X, Huang Z, Zhang J, Stalin A, Tan Y, Zhang F, Chen M, Shi R, Huang J, Wu C, Wu Z, Lu S, You L, Wu J. Data mining combines bioinformatics discover immunoinfiltration-related gene SERPINE1 as a biomarker for diagnosis and prognosis of stomach adenocarcinoma. Sci Rep 2023;13:1373. [PMID: 36697459 DOI: 10.1038/s41598-023-28234-7] [Reference Citation Analysis]
8 Roze S, Bertrand N, Eberst L, Borget I. Projecting overall survival in health-economic models: uncertainty and maturity of data. Curr Med Res Opin 2023;:1-8. [PMID: 36628431 DOI: 10.1080/03007995.2023.2167442] [Reference Citation Analysis]
9 Nicolaides S, Boussioutas A. Immune-Related Adverse Events of the Gastrointestinal System. Cancers 2023;15:691. [DOI: 10.3390/cancers15030691] [Reference Citation Analysis]
10 Kase AM, George DJ, Ramalingam S. Clear Cell Renal Cell Carcinoma: From Biology to Treatment. Cancers 2023;15:665. [DOI: 10.3390/cancers15030665] [Reference Citation Analysis]
11 Liu Y, Wu D, Chen H, Yan L, Xiang Q, Li Q, Wang T. Construction and verification of a novel prognostic risk model for kidney renal clear cell carcinoma based on immunity-related genes. Front Genet 2023;14. [DOI: 10.3389/fgene.2023.1107294] [Reference Citation Analysis]
12 Sivapalan L, Murray JC, Canzoniero JV, Landon B, Jackson J, Scott S, Lam V, Levy BP, Sausen M, Anagnostou V. Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy. J Immunother Cancer 2023;11. [PMID: 36657818 DOI: 10.1136/jitc-2022-005924] [Reference Citation Analysis]
13 Xu Q, Zhou Y, Zhang H, Li H, Qin H, Wang H. Bibliometric Analysis of Hotspots and Frontiers of Immunotherapy in Pancreatic Cancer. Healthcare 2023;11:304. [DOI: 10.3390/healthcare11030304] [Reference Citation Analysis]
14 Chawla NS, Sayegh N, Prajapati S, Chan E, Pal SK, Chehrazi-raffle A. An Update on the Treatment of Papillary Renal Cell Carcinoma. Cancers 2023;15:565. [DOI: 10.3390/cancers15030565] [Reference Citation Analysis]
15 Jiang A, Ye J, Zhou Y, Zhu B, Lu J, Ge S, Qu L, Xiao J, Wang L, Cai C. Copper Death Inducer, FDX1, as a Prognostic Biomarker Reshaping Tumor Immunity in Clear Cell Renal Cell Carcinoma. Cells 2023;12:349. [DOI: 10.3390/cells12030349] [Reference Citation Analysis]
16 Anno T, Tanaka N, Takamatsu K, Hakozaki K, Kufukihara R, Baba Y, Takeda T, Matsumoto K, Morita S, Kosaka T, Mikami S, Nishihara H, Mizuno R, Oya M. Prognostic role of the innate immune signature CD163 and "eat me" signal calreticulin in clear cell renal cell carcinoma. Cancer Immunol Immunother 2023. [PMID: 36646952 DOI: 10.1007/s00262-023-03369-8] [Reference Citation Analysis]
17 Banavasi H, Kim S, Alkassis S, Daoud A, Laktineh A, Nagasaka M, Sukari A, Soubani AO. Immune Checkpoint Inhibitor-induced Pneumonitis: Incidence, Clinical Characteristics, and Outcomes. Hematol Oncol Stem Cell Ther 2023;16:144-50. [PMID: 34688626 DOI: 10.1016/j.hemonc.2021.09.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Zhang W, Ling Y, Li Z, Peng X, Ren Y. Peripheral and tumor-infiltrating immune cells are correlated with patient outcomes in ovarian cancer. Cancer Med 2023. [PMID: 36645174 DOI: 10.1002/cam4.5590] [Reference Citation Analysis]
19 Paragliola RM, Torino F, Barnabei A, Iannantuono GM, Corsello A, Locantore P, Corsello SM. Bone Metabolism Effects of Medical Therapy in Advanced Renal Cell Carcinoma. Cancers (Basel) 2023;15. [PMID: 36672478 DOI: 10.3390/cancers15020529] [Reference Citation Analysis]
20 Ren A, Tong X, Xu N, Zhang T, Zhou F, Zhu H. CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities. Vaccines (Basel) 2023;11. [PMID: 36680011 DOI: 10.3390/vaccines11010165] [Reference Citation Analysis]
21 Santoni M, Rizzo A, Kucharz J, Mollica V, Rosellini M, Marchetti A, Tassinari E, Monteiro FSM, Soares A, Molina-Cerrillo J, Grande E, Battelli N, Massari F. Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. Cancer Immunol Immunother 2023. [PMID: 36633661 DOI: 10.1007/s00262-022-03349-4] [Reference Citation Analysis]
22 Alradhi M, Zhang Z, Safi M, Al-Danakh A, Aldhbi M, Baldi S, Kui L, Alradhi A, Hamri SB, Lun Lo K, Zhao Y, Jin Y. A novel nomogram and prognostic factor for metastatic renal cell carcinoma survival in the era of immune checkpoint inhibitors (ICIs). Front Pharmacol 2022;13:996404. [PMID: 36686665 DOI: 10.3389/fphar.2022.996404] [Reference Citation Analysis]
23 Ding L, Chen X, Zhang W, Dai X, Guo H, Pan X, Xu Y, Feng J, Yuan M, Gao X, Wang J, Xu X, Li S, Wu H, Cao J, He Q, Yang B. Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling. J Clin Invest 2023;133. [PMID: 36594471 DOI: 10.1172/JCI154754] [Reference Citation Analysis]
24 Matsubara Y, Toriyama K, Kadowaki S, Ogata T, Nakazawa T, Kato K, Nozawa K, Narita Y, Honda K, Masuishi T, Bando H, Ando M, Tajika M, Oze I, Hosoda W, Muro K. The impact of combined PD-L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma. Esophagus 2023. [PMID: 36595124 DOI: 10.1007/s10388-022-00978-7] [Reference Citation Analysis]
25 Doppalapudi SK, Kaldany A, Lichtbroun B, Singer EA. The Role of Immunotherapy in Renal Cell Carcinoma. Handbook of Cancer and Immunology 2023. [DOI: 10.1007/978-3-030-80962-1_232-1] [Reference Citation Analysis]
26 Velev M, Dalban C, Chevreau C, Gravis G, Negrier S, Laguerre B, Gross-goupil M, Ladoire S, Borchiellini D, Geoffrois L, Joly F, Priou F, Barthelemy P, Laramas M, Narciso B, Thiery-vuillemin A, Berdah J, Ferrari V, Dominique Thomas Q, Mione C, Curcio H, Oudard S, Tantot F, Escudier B, Chabaud S, Albiges L, Thibault C. Efficacy And Safety Of Nivolumab In Bone Metastases From Renal Cell Carcinoma: Results Of The Getug — Afu 26 Nivoren Multicenter Phase Ii Study. European Journal of Cancer 2023. [DOI: 10.1016/j.ejca.2022.12.028] [Reference Citation Analysis]
27 Monteiro FSM, Soares A, Rizzo A, Santoni M, Mollica V, Grande E, Massari F. The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A Systematic Review and Meta-Analysis. Clinical Genitourinary Cancer 2023. [DOI: 10.1016/j.clgc.2023.01.005] [Reference Citation Analysis]
28 Vikram R, Jonasch E. Renal Tumors. Oncologic Imaging : a Multidisciplinary Approach 2023. [DOI: 10.1016/b978-0-323-69538-1.00019-7] [Reference Citation Analysis]
29 Liatsou E, Tsilimigras DI, Malandrakis P, Gavriatopoulou M, Ntanasis-Stathopoulos I. Current status and novel insights into the role of metastasectomy in the era of immunotherapy. Expert Rev Anticancer Ther 2023;23:57-66. [PMID: 36527305 DOI: 10.1080/14737140.2023.2160323] [Reference Citation Analysis]
30 Gross EE, Li M, Yin M, Orcutt D, Hussey D, Trott E, Holt SK, Dwyer ER, Kramer J, Oliva K, Gore JL, Schade GR, Lin DW, Tykodi SS, Hall ET, Thompson JA, Parikh A, Yang Y, Collier KA, Miah A, Mori-vogt S, Hinkley M, Mortazavi A, Monk P, Folefac E, Clinton SK, Psutka SP. A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy. Urologic Oncology: Seminars and Original Investigations 2023;41:51.e25-51.e31. [DOI: 10.1016/j.urolonc.2022.08.013] [Reference Citation Analysis]
31 Mahdavi Sharif P, Pastaki Khoshbin A, Nasrollahzadeh E, Keshavarz-fathi M, Rezaei N. Tumor immunology. Clinical Immunology 2023. [DOI: 10.1016/b978-0-12-818006-8.00003-7] [Reference Citation Analysis]
32 Ding M, Wang Q, Zhu W, Chang J, Liao H, Xiao G. DNA methylation-mediated low expression of ZNF582 promotes the proliferation, migration, and invasion of clear cell renal cell carcinoma. Clin Exp Nephrol 2023;27:24-31. [PMID: 36129555 DOI: 10.1007/s10157-022-02275-0] [Reference Citation Analysis]
33 Takahashi R, Asanuma H, Mizuno R, Oya M. Current clinical perspective of urological oncology in the adolescent and young adult generation. Int J Clin Oncol 2023;28:28-40. [PMID: 36527578 DOI: 10.1007/s10147-022-02251-4] [Reference Citation Analysis]
34 Buller DM, Antony M, Ristau BT. Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma: Current Landscape and Future Direction. OTT 2023;Volume 16:49-64. [DOI: 10.2147/ott.s393296] [Reference Citation Analysis]
35 McQuade JL, Hammers H, Furberg H, Engert A, André T, Blumenschein G Jr, Tannir N, Baron A, Larkin J, El-Khoueiry A, Carbone DP, Thomas JM, Hennicken D, Coffey M, Motzer RJ. Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab. JAMA Oncol 2023;9:102-11. [PMID: 36480191 DOI: 10.1001/jamaoncol.2022.5409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Delcuratolo MD, Tucci M, Turco F, Di Stefano RF, Ungaro A, Audisio M, Samuelly A, Brusa F, Audisio A, Di Maio M, Scagliotti GV, Buttigliero C. Therapeutic sequencing in advanced renal cell carcinoma: How to choose considering clinical and biological factors. Crit Rev Oncol Hematol 2023;181:103881. [PMID: 36427772 DOI: 10.1016/j.critrevonc.2022.103881] [Reference Citation Analysis]
37 Jeong SU, Hwang HS, Park JM, Yoon SY, Shin SJ, Go H, Lee JL, Jeong G, Cho YM. PD-L1 Upregulation by the mTOR Pathway in VEGFR-TKI-Resistant Metastatic Clear Cell Renal Cell Carcinoma. Cancer Res Treat 2023;55:231-44. [PMID: 35240013 DOI: 10.4143/crt.2021.1526] [Reference Citation Analysis]
38 Prakash A, Gates T, Zhao X, Wangmo D, Subramanian S. Tumor-derived extracellular vesicles in the colorectal cancer immune environment and immunotherapy. Pharmacol Ther 2023;241:108332. [PMID: 36526013 DOI: 10.1016/j.pharmthera.2022.108332] [Reference Citation Analysis]
39 Medikonda R, Pant A, Lim M. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors. Adv Exp Med Biol 2023;1394:73-84. [PMID: 36587382 DOI: 10.1007/978-3-031-14732-6_5] [Reference Citation Analysis]
40 Cao B, Zhao R, Li H, Xu X, Gao J, Chen L, Wei B. Inhibition of androgen receptor enhanced the anticancer effects of everolimus through targeting glucose transporter 12. Int J Biol Sci 2023;19:104-19. [PMID: 36594084 DOI: 10.7150/ijbs.75106] [Reference Citation Analysis]
41 Shi Z, Liu X, Chen M, Zhang N, Guan H, Ye D. The risks of hematological toxicities of nivolumab in cancer patients: A PRISMA-compliant meta-analysis. Medicine (Baltimore) 2022;101:e32393. [PMID: 36596018 DOI: 10.1097/MD.0000000000032393] [Reference Citation Analysis]
42 Shi H, Tang H, Li Y, Chen D, Liu T, Chen Y, Wang X, Chen L, Wang Y, Xie H, Xiong B. Development of a series of quinazoline-2,5-diamine derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors. Eur J Med Chem 2022;248:115064. [PMID: 36621137 DOI: 10.1016/j.ejmech.2022.115064] [Reference Citation Analysis]
43 Hua SH, Viera M, Yip GW, Bay BH. Theranostic Applications of Glycosaminoglycans in Metastatic Renal Cell Carcinoma. Cancers (Basel) 2022;15. [PMID: 36612261 DOI: 10.3390/cancers15010266] [Reference Citation Analysis]
44 Dimino A, Brando C, Algeri L, Gristina V, Pedone E, Peri M, Perez A, De Luca I, Sciacchitano R, Magrin L, Bazan Russo TD, Bono M, Barraco N, Contino S, La Mantia M, Galvano A, Badalamenti G, Russo A, Bazan V, Incorvaia L. Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors. Cancers (Basel) 2022;15. [PMID: 36612211 DOI: 10.3390/cancers15010216] [Reference Citation Analysis]
45 Wang LL, Saidian A, Pan E, Panian J, Derweesh IH, Mckay RR. Adjuvant Therapy in Renal Cell Carcinoma: Are we ready for prime time? KCA 2022. [DOI: 10.3233/kca-220014] [Reference Citation Analysis]
46 Kato T, Yumiba S, Nakata W, Nakano K, Nagahara A, Matsuzaki K, Hayashi Y, Hatano K, Kawashima A, Takao T, Nishimura K, Nakai Y, Nakayama M, Nishimura K, Takada S, Tsujihata M, Uemura M, Nonomura N, Imamura R. A comparative study on nivolumab and axitinib as secondary treatment in patients with metastatic renal cell carcinoma: A multi-institutional retrospective study in Japan. Int J Urol 2022. [PMID: 36578154 DOI: 10.1111/iju.15130] [Reference Citation Analysis]
47 Tang W, Xu N, Zhou J, He Z, Lenahan C, Wang C, Ji H, Liu B, Zou Y, Zeng H, Guo H. ALKBH5 promotes PD-L1-mediated immune escape through m6A modification of ZDHHC3 in glioma. Cell Death Discov 2022;8:497. [PMID: 36566230 DOI: 10.1038/s41420-022-01286-w] [Reference Citation Analysis]
48 Han X, Goh KY, Lee WX, Choy SM, Tang HW. The Importance of mTORC1-Autophagy Axis for Skeletal Muscle Diseases. Int J Mol Sci 2022;24. [PMID: 36613741 DOI: 10.3390/ijms24010297] [Reference Citation Analysis]
49 Porciello N, Franzese O, D'Ambrosio L, Palermo B, Nisticò P. T-cell repertoire diversity: friend or foe for protective antitumor response? J Exp Clin Cancer Res 2022;41:356. [PMID: 36550555 DOI: 10.1186/s13046-022-02566-0] [Reference Citation Analysis]
50 Bručić LJ, Krečak I. Therapy-related myelodysplastic syndrome with monosomy 7 and metastatic renal cell carcinoma successfully treated with nivolumab: two birds with one stone. Ann Hematol 2022. [DOI: 10.1007/s00277-022-05082-5] [Reference Citation Analysis]
51 Catalano M, Roviello G, Galli IC, Santi R, Nesi G. Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge. Front Med (Lausanne) 2022;9:1014257. [PMID: 36606052 DOI: 10.3389/fmed.2022.1014257] [Reference Citation Analysis]
52 Borges R, Pelosine AM, de Souza ACS, Machado J Jr, Justo GZ, Gamarra LF, Marchi J. Bioactive Glasses as Carriers of Cancer-Targeted Drugs: Challenges and Opportunities in Bone Cancer Treatment. Materials (Basel) 2022;15. [PMID: 36556893 DOI: 10.3390/ma15249082] [Reference Citation Analysis]
53 Golkaram M, Kuo F, Gupta S, Carlo MI, Salmans ML, Vijayaraghavan R, Tang C, Makarov V, Rappold P, Blum KA, Zhao C, Mehio R, Zhang S, Godsey J, Pawlowski T, DiNatale RG, Morris LGT, Durack J, Russo P, Kotecha RR, Coleman J, Chen YB, Reuter VE, Motzer RJ, Voss MH, Liu L, Reznik E, Chan TA, Hakimi AA. Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape. Genome Med 2022;14:143. [PMID: 36536472 DOI: 10.1186/s13073-022-01146-3] [Reference Citation Analysis]
54 Shi-Yao Wei, Bei Feng, Min Bi, Hai-Ying Guo, Shang-Wei Ning, Rui Cui. Construction of a ferroptosis-related signature based on seven lncRNAs for prognosis and immune landscape in clear cell renal cell carcinoma. BMC Med Genomics 2022;15:263. [PMID: 36528763 DOI: 10.1186/s12920-022-01418-2] [Reference Citation Analysis]
55 Ou Yamaguchi, Kazuyuki Atarashi, Kenichi Yoshimura, Ayako Shiono, Atsuhito Mouri, Fuyumi Nishihara, Yu Miura, Kosuke Hashimoto, Yoshiaki Miyamoto, Hitoshi Uga, Nobuo Seki, Tomoko Matsushima, Norihiro Kikukawa, Kunihiko Kobayashi, Kyoichi Kaira, Hiroshi Kagamu. Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1. BMC Cancer 2022;22:1325. [PMID: 36528575 DOI: 10.1186/s12885-022-10445-2] [Reference Citation Analysis]
56 Larroquette M, Lefort F, Heraudet L, Bernhard JC, Ravaud A, Domblides C, Gross-Goupil M. Therapeutic Management of Metastatic Clear Cell Renal Cell Carcinoma: A Revolution in Every Decade. Cancers (Basel) 2022;14. [PMID: 36551715 DOI: 10.3390/cancers14246230] [Reference Citation Analysis]
57 Wang H, Xu Y, Zuo F, Liu J, Yang J. Immune-based combination therapy for esophageal cancer. Front Immunol 2022;13:1020290. [PMID: 36591219 DOI: 10.3389/fimmu.2022.1020290] [Reference Citation Analysis]
58 Guillaume Z, Auvray M, Vano Y, Oudard S, Helley D, Mauge L. Renal Carcinoma and Angiogenesis: Therapeutic Target and Biomarkers of Response in Current Therapies. Cancers (Basel) 2022;14. [PMID: 36551652 DOI: 10.3390/cancers14246167] [Reference Citation Analysis]
59 Bialek J, Yankulov S, Kawan F, Fornara P, Theil G. Role of Nivolumab in the Modulation of PD-1 and PD-L1 Expression in Papillary and Clear Cell Renal Carcinoma (RCC). Biomedicines 2022;10. [PMID: 36552000 DOI: 10.3390/biomedicines10123244] [Reference Citation Analysis]
60 Aimudula A, Maimaitiming A, Zhang J, Dong X, zhang Y, Zhang R. Comprehensive analysis prediction prognosis and immune therapy value of angiogenesis-associated genes in kidney renal clear cell carcinoma.. [DOI: 10.21203/rs.3.rs-2225684/v1] [Reference Citation Analysis]
61 Lange M, Clarisse B, Leconte A, Dembélé K, Lequesne J, Nicola C, Dubois M, Derues L, Gidron Y, Castel H, Joly F. Cognitive assessment in patients treated by immunotherapy: the prospective Cog-Immuno trial. BMC Cancer 2022;22:1308. [DOI: 10.1186/s12885-022-10384-y] [Reference Citation Analysis]
62 Jahangir M, Yazdani O, Kahrizi MS, Soltanzadeh S, Javididashtbayaz H, Mivefroshan A, Ilkhani S, Esbati R. Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy. Cancer Cell Int 2022;22:401. [PMID: 36510217 DOI: 10.1186/s12935-022-02816-3] [Reference Citation Analysis]
63 Li R, Ferdinand JR, Loudon KW, Bowyer GS, Laidlaw S, Muyas F, Mamanova L, Neves JB, Bolt L, Fasouli ES, Lawson ARJ, Young MD, Hooks Y, Oliver TRW, Butler TM, Armitage JN, Aho T, Riddick ACP, Gnanapragasam V, Welsh SJ, Meyer KB, Warren AY, Tran MGB, Stewart GD, Cortés-Ciriano I, Behjati S, Clatworthy MR, Campbell PJ, Teichmann SA, Mitchell TJ. Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer. Cancer Cell 2022;40:1583-1599.e10. [PMID: 36423636 DOI: 10.1016/j.ccell.2022.11.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Kato T, Matsubara N, Shiota M, Eto M, Osawa T, Abe T, Shinohara N, Yasumizu Y, Tanaka N, Oya M, Nishimoto K, Hayashi T, Nakayama M, Kojima T, Namikawa K, Fujisawa T, Okano S, Hida E, Nakamura Y, Bando H, Yoshino T, Nonomura N. IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation. BMC Cancer 2022;22:1292. [PMID: 36494792 DOI: 10.1186/s12885-022-10398-6] [Reference Citation Analysis]
65 Berg SA, McGregor BA. The Continuing Question of Adjuvant Therapy in Clear Cell Renal Cell Carcinoma. Cancers (Basel) 2022;14. [PMID: 36551504 DOI: 10.3390/cancers14246018] [Reference Citation Analysis]
66 Rebuzzi SE, Signori A, Buti S, Banna GL, Murianni V, Damassi A, Maruzzo M, Giannarelli D, Tortora G, Galli L, Rizzo M, De Giorgi U, Antonuzzo L, Bracarda S, Cartenì G, Atzori F, Tamberi S, Procopio G, Fratino L, Lo Re G, Santoni M, Baldessari C, Astone A, Calabrò F, Brunelli M, Porta C, Rescigno P, Basso U, Fornarini G. Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program. ESMO Open 2022;7:100634. [PMID: 36493602 DOI: 10.1016/j.esmoop.2022.100634] [Reference Citation Analysis]
67 Zhao G, Zheng J, Tang K, Chen Q. EMILIN2 is associated with prognosis and immunotherapy in clear cell renal cell carcinoma. Front Genet 2022;13:1058207. [PMID: 36544490 DOI: 10.3389/fgene.2022.1058207] [Reference Citation Analysis]
68 Papathanassiou M, Tamposis I, Exarchou-kouveli KK, Kontou PI, de Paz AT, Mitrakas L, Samara M, Bagos PG, Tzortzis V, Vlachostergios PJ. Immune-based treatment re-challenge in renal cell carcinoma: A systematic review and meta-analysis. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.996553] [Reference Citation Analysis]
69 Najafi S, Majidpoor J, Mortezaee K. The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. Life Sciences 2022;310:121138. [DOI: 10.1016/j.lfs.2022.121138] [Reference Citation Analysis]
70 Reid P, Cappelli LC. Treatment of rheumatic adverse events of cancer immunotherapy. Best Practice & Research Clinical Rheumatology 2022. [DOI: 10.1016/j.berh.2022.101805] [Reference Citation Analysis]
71 Sun G, Liu H, Zhao J, Zhang J, Huang T, Sun G, Zhao S, Zhang Z, Cao H, Rong D, Kong X, Ji Q, Liu L, Wang X, Tang W, Xia Y. Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy. J Immunother Cancer 2022;10. [PMID: 36600662 DOI: 10.1136/jitc-2022-005655] [Reference Citation Analysis]
72 Yao C, Zhang T, Wu T, Brugarolas J. Facts and Hopes for Immunotherapy in Renal Cell Carcinoma. Clin Cancer Res 2022;28:5013-20. [PMID: 35819272 DOI: 10.1158/1078-0432.CCR-21-2372] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
73 Andersen BM, Reardon DA. Immunotherapy approaches for adult glioma: knowledge gained from recent clinical trials. Current Opinion in Neurology 2022;35:803-813. [DOI: 10.1097/wco.0000000000001118] [Reference Citation Analysis]
74 Sun P, Xu H, Zhu K, Li M, Han R, Shen J, Xia X, Chen X, Fei G, Zhou S, Wang R. The cuproptosis related genes signature predicts the prognosis and correlates with the immune status of clear cell renal cell carcinoma. Front Genet 2022;13. [DOI: 10.3389/fgene.2022.1061382] [Reference Citation Analysis]
75 Murianni V, Cerbone L, Rescigno P, Catalano F, Damassi A, Cremante M, Gandini A, Puglisi S, Pesola G, Banna GL, Buti S, Signori A, Fornarini G, Rebuzzi SE. Combined response of advanced cutaneous squamous cell carcinoma and renal cell carcinoma to immunotherapy: a case report. Immunotherapy 2022;14:1419-27. [PMID: 36597723 DOI: 10.2217/imt-2022-0150] [Reference Citation Analysis]
76 Basak EA, de Joode K, Uyl TJ, van der Wal R, Schreurs MW, van den Berg SA, Oomen-de Hoop E, van der Leest CH, Chaker L, Feelders RA, van der Veldt AA, Joosse A, Koolen SL, Aerts JG, Mathijssen RH, Bins S. The course of C-peptide levels in patients developing diabetes during anti-PD-1 therapy. Biomedicine & Pharmacotherapy 2022;156:113839. [DOI: 10.1016/j.biopha.2022.113839] [Reference Citation Analysis]
77 Li S, Sun Z. Fueling immune checkpoint blockade with oncolytic viruses: Current paradigms and challenges ahead. Cancer Letters 2022;550:215937. [DOI: 10.1016/j.canlet.2022.215937] [Reference Citation Analysis]
78 Ged Y, Sanchez A, Patil S, Knezevic A, Stein E, Petruzella S, Weiss K, Duzgol C, Chaim J, Akin O, Mourtzakis M, Paris MT, Scott J, Kuo F, Kotecha R, Hakimi AA, Lee CH, Motzer RJ, Voss MH, Furberg H. Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade. Clin Cancer Res 2022;28:5180-9. [PMID: 36190538 DOI: 10.1158/1078-0432.CCR-22-1389] [Reference Citation Analysis]
79 Gao Y, Su Z, Wang C, Xu J, Hu S, Zhang C, Sun P, Zhou X, Wang W, Zou T, Yang B, Cheng X, Yi X, Zheng Q. Light-Triggered Polymeric Prodrug and Nano-assembly for Chemo-Photodynamic Therapy and Potentiate Immune Checkpoint Blockade Immunotherapy for Hepatocellular Carcinoma. Materials & Design 2022. [DOI: 10.1016/j.matdes.2022.111457] [Reference Citation Analysis]
80 Fujiwara R, Yuasa T, Yamamoto S, Fujiwara M, Takemura K, Urasaki T, Oki R, Komai Y, Oguchi T, Numao N, Yonese J. Geriatric Nutritional Risk Index as a Predictor of Prognosis in Metastatic Renal Cell Carcinoma Treated with Nivolumab. Nutrition and Cancer 2022. [DOI: 10.1080/01635581.2022.2152061] [Reference Citation Analysis]
81 Tang Y, Hu X, Wu K, Li X. Immune landscape and immunotherapy for penile cancer. Front Immunol 2022;13:1055235. [PMID: 36524123 DOI: 10.3389/fimmu.2022.1055235] [Reference Citation Analysis]
82 Kazama A, Bilim V, Tasaki M, Anraku T, Kuroki H, Shirono Y, Murata M, Hiruma K, Tomita Y. Tumor-infiltrating immune cell status predicts successful response to immune checkpoint inhibitors in renal cell carcinoma. Sci Rep 2022;12:20386. [PMID: 36437290 DOI: 10.1038/s41598-022-24437-6] [Reference Citation Analysis]
83 Thariat J, Boudin L, Loria O, Nguyen AM, Kodjikian L, Mathis T. How to Manage a Patient with Ocular Metastases? Biomedicines 2022;10. [PMID: 36551800 DOI: 10.3390/biomedicines10123044] [Reference Citation Analysis]
84 Ma Y, Xin Y, Su D, Zhou Y, Li H, Zou H, Yu X, Yang Q, Cui J, Wang C, Zhang Y. Comparative efficacy and toxicity of immune checkpoint inhibitors in combination with or without chemotherapy treatment for advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.958783] [Reference Citation Analysis]
85 Luo Z, Hao S, Li Y, Cheng L, Zhou X, Gunes EG, Liu S, Chen J. The negative effect of antibiotics on RCC patients with immunotherapy: A systematic review and meta-analysis. Front Immunol 2022;13:1065004. [PMID: 36505435 DOI: 10.3389/fimmu.2022.1065004] [Reference Citation Analysis]
86 Wang Z, Wang G, Lu H, Li H, Tang M, Tong A. Development of therapeutic antibodies for the treatment of diseases. Mol Biomed 2022;3:35. [PMID: 36418786 DOI: 10.1186/s43556-022-00100-4] [Reference Citation Analysis]
87 Rosellini M, Marchetti A, Mollica V, Rizzo A, Santoni M, Massari F. Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma. Nat Rev Urol 2022. [DOI: 10.1038/s41585-022-00676-0] [Reference Citation Analysis]
88 Brown LJ, da Silva IP, Moujaber T, Gao B, Hui R, Gurney H, Carlino M, Nagrial A. Five‐year survival and clinical correlates among patients with advanced non‐small cell lung cancer, melanoma and renal cell carcinoma treated with immune check‐point inhibitors in Australian tertiary oncology centres. Cancer Medicine 2022. [DOI: 10.1002/cam4.5468] [Reference Citation Analysis]
89 Hamano H, Miyata K, Hara T, Sakaguchi S, Oura M, Niimura T, Aizawa F, Yagi K, Okada N, Miki H, Goda M, Ishizawa-izawa Y, Zamami Y, Yanagawa H, Ishizawa K. Multiple Adverse Events of anti-PD1/PDL1 Therapy: A Case- control Study using a Japanese Prescription-diagnostics Database.. [DOI: 10.21203/rs.3.rs-2268880/v1] [Reference Citation Analysis]
90 Al-Danakh A, Safi M, Alradhi M, Chen Q, Baldi S, Zhu X, Yang D. Immune Checkpoint Inhibitor (ICI) Genes and Aging in Clear Cell Renal Cell Carcinoma (ccRCC): Clinical and Genomic Study. Cells 2022;11. [PMID: 36429070 DOI: 10.3390/cells11223641] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Wang Y, Chen W, Li W, Pan X, Cui X. Impact of interaction networks of B cells with other cells on tumorigenesis, progression and response to immunotherapy of renal cell carcinoma: A review. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.995519] [Reference Citation Analysis]
92 Conway JW, Braden J, Wilmott JS, Scolyer RA, Long GV, Pires da Silva I. The effect of organ-specific tumor microenvironments on response patterns to immunotherapy. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1030147] [Reference Citation Analysis]
93 Széles Á, Fazekas T, Váncsa S, Váradi M, Kovács PT, Krafft U, Grünwald V, Hadaschik B, Csizmarik A, Hegyi P, Váradi A, Nyirády P, Szarvas T. Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis. Cancer Immunol Immunother 2022. [DOI: 10.1007/s00262-022-03328-9] [Reference Citation Analysis]
94 Damaskos C, Garmpis N, Dimitroulis D, Garmpi A, Psilopatis I, Sarantis P, Koustas E, Kanavidis P, Prevezanos D, Kouraklis G, Karamouzis MV, Marinos G, Kontzoglou K, Antoniou EA. Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead-A Systematic Review. Int J Mol Sci 2022;23. [PMID: 36430594 DOI: 10.3390/ijms232214117] [Reference Citation Analysis]
95 Mulgaonkar A, Elias R, Woolford L, Guan B, Nham K, Kapur P, Christie A, Tcheuyap VT, Singla N, Bowman IA, Stevens C, Hao G, Brugarolas J, Sun X. ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma. Clin Cancer Res 2022;28:4907-16. [PMID: 36074149 DOI: 10.1158/1078-0432.CCR-22-1547] [Reference Citation Analysis]
96 Fitzgerald KN, Motzer RJ, Lee C. Adjuvant therapy options in renal cell carcinoma — targeting the metastatic cascade. Nat Rev Urol 2022. [DOI: 10.1038/s41585-022-00666-2] [Reference Citation Analysis]
97 Haritsyah Warli M, Prapiska FF, Siregar GP, Sihombing B, Warli SM. PD-L1 expression as predictor of immunotherapy eligibility in penile squamous cell carcinoma patients. F1000Res 2022;11:1281. [DOI: 10.12688/f1000research.126462.1] [Reference Citation Analysis]
98 Doehn C, Bögemann M, Grünwald V, Welslau M, Bedke J, Schostak M, Wolf T, Ehneß R, Degenkolbe E, Witecy S, Goebell PJ. The Non-Interventional PAZOREAL Study to Assess the Effectiveness and Safety of Pazopanib in a Real-Life Setting: Reflecting a Changing mRCC Treatment Landscape. Cancers (Basel) 2022;14. [PMID: 36428579 DOI: 10.3390/cancers14225486] [Reference Citation Analysis]
99 Lang J, Leal AD, Marín-jiménez JA, Hartman SJ, Shulman J, Navarro NM, Lewis MS, Capasso A, Bagby SM, Yacob BW, Macbeth M, Freed BM, Eckhardt SG, Jordan K, Blatchford PJ, Pelanda R, Lieu CH, Messersmith WA, Pitts TM. Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.877635] [Reference Citation Analysis]
100 Xia D, Liu Q, Jiao W, Peng L, Wang Q, Tuo Z, Bi L. Exploration of the role of Cuproptosis genes and their related long non-coding RNA in clear cell renal cell carcinoma: a comprehensive bioinformatics study. BMC Cancer 2022;22:1141. [DOI: 10.1186/s12885-022-10278-z] [Reference Citation Analysis]
101 Iwasa S, Koyama T, Nishino M, Kondo S, Sudo K, Yonemori K, Yoshida T, Tamura K, Shimizu T, Fujiwara Y, Kitano S, Shimomura A, Sato J, Yokoyama F, Iida H, Kondo M, Yamamoto N. First-in-human study of ONO-4578, an antagonist of prostaglandin E(2) receptor 4, alone and with nivolumab in solid tumors. Cancer Sci 2023;114:211-20. [PMID: 36082616 DOI: 10.1111/cas.15574] [Reference Citation Analysis]
102 Choueiri TK, Kluger H, George S, Tykodi SS, Kuzel TM, Perets R, Nair S, Procopio G, Carducci MA, Castonguay V, Folefac E, Lee CH, Hotte SJ, Miller WH Jr, Saggi SS, Lee CW, Desilva H, Bhagavatheeswaran P, Motzer RJ, Escudier B. FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy. J Immunother Cancer 2022;10. [PMID: 36328377 DOI: 10.1136/jitc-2022-005780] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
103 Kenworthy C, Di M, Deshpande H. Hemophagocytic Lymphohistiocytosis as a complication of immune checkpoint inhibitor therapy for sarcoma. Current Problems in Cancer: Case Reports 2022. [DOI: 10.1016/j.cpccr.2022.100202] [Reference Citation Analysis]
104 Khozin S, Stein RM. A novel approach to reducing disparities in health outcomes by enhancing interpretation of cancer clinical trials for underrepresented patient groups. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 2022;1877:188825. [DOI: 10.1016/j.bbcan.2022.188825] [Reference Citation Analysis]
105 Sheng X, Ye D, Zhou A, Yao X, Luo H, He Z, Wang Z, Zhao Y, Ji Z, Zou Q, He C, Guo J, Tu X, Liu Z, Shi B, Liu B, Chen P, Wei Q, Hu Z, Zhang Y, Jiang K, Zhou F, Wu D, Fu C, Li X, Wu B, Wang L, Qin S, Li G, Liu Y, Guo H, Chen K, Zhang D, Wang G, Ding L, Wang Y, Xiaobin Yuan M, Guo J. Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomized, double-blind, multicentre phase III study (CONCEPT). European Journal of Cancer 2022. [DOI: 10.1016/j.ejca.2022.10.025] [Reference Citation Analysis]
106 Sági V, Makra N, Csoszánszki N, Decmann A, Szabó D, Garami M. The Influence of the Gut Microbiome in Paediatric Cancer Origin and Treatment. Antibiotics 2022;11:1521. [DOI: 10.3390/antibiotics11111521] [Reference Citation Analysis]
107 Bigot P, Barthelemy P, Boissier R, Khene Z, Pettenati C, Bernhard J, Correas J, Doumerc N, Gimel P, Ingels A, Nouhaud F, Ouzaïd I, Rioux-leclercq N, Albiges L, Rouprêt M. French AFU Cancer Committee Guidelines - Update 2022-2024: management of kidney cancer. Progrès en Urologie 2022;32:1195-1274. [DOI: 10.1016/j.purol.2022.07.146] [Reference Citation Analysis]
108 Babyshkina NN, Dronova TA, Gervas PA, Popova NO, Dobrodeev AY, Kostromitsky DN, Afanasyev SG, Goldberg VE, Cherdyntseva NV. Nivolumab monotherapy in metastatic colorectal cancer: current approaches to response evaluation. Sib onkol ž 2022;21:135-141. [DOI: 10.21294/1814-4861-2022-21-5-135-141] [Reference Citation Analysis]
109 Parosanu A, Stanciu IM, Pirlog C, Orlov Slavu C, Cotan H, Iaciu C, Popa AM, Olaru M, Moldoveanu O, Catalin B, Nitipir C. Prognostic Models for Renal Cell Carcinoma in the Era of Immune Checkpoint Therapy. Cureus 2022. [DOI: 10.7759/cureus.30821] [Reference Citation Analysis]
110 Pantano F, Tramontana F, Iuliani M, Leanza G, Simonetti S, Piccoli A, Paviglianiti A, Cortellini A, Spinelli GP, Longo UG, Strollo R, Vincenzi B, Tonini G, Napoli N, Santini D. Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis. J Bone Oncol 2022;37:100459. [PMID: 36338920 DOI: 10.1016/j.jbo.2022.100459] [Reference Citation Analysis]
111 Hongo F, Ueda T, Takaha N, Tamada S, Nakatani T, Miki T, Ukimura O. Phase I/ II study of multipeptide cancer vaccine IMA901 after single‐dose cyclophosphamide in Japanese patients with advanced renal cell cancer with long‐term follow up. Int J of Urology 2022. [DOI: 10.1111/iju.15077] [Reference Citation Analysis]
112 Liu D, Zhou J, Wang Y, Li M, Jiang H, Liu Y, Yin X, Ge M, Xiang X, Ying J, Huang J, Zhang YQ, Cheng Y, Huang Z, Yuan X, Han W, Yan D, Wang X, Liu P, Wang L, Zhang X, Luo S, Liu T, Shen L. Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial. BMC Med 2022;20:408. [PMID: 36280870 DOI: 10.1186/s12916-022-02605-9] [Reference Citation Analysis]
113 Grigg CM, Burgess EF, Riggs SB, Zhu J, Raghavan D. Renal Cell Carcinoma. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm097.pub2] [Reference Citation Analysis]
114 Bottiglieri A, Sepe P, Stellato M, Pircher C, Fotia G, Leone AG, Guadalupi V, Claps M, Giannatempo P, Verzoni E, Procopio G. Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy. Cancer Manag Res 2022;14:3071-81. [PMID: 36275783 DOI: 10.2147/CMAR.S360441] [Reference Citation Analysis]
115 Gan K, Zhang K, Li Y, Zhao X, Li H, Xu C, Liu S, Zhang C, Han D, Wen W, Qin W. Establishment and validation of a polygene prognostic model for clear cell renal cell carcinoma. Front Genet 2022;13:1021163. [DOI: 10.3389/fgene.2022.1021163] [Reference Citation Analysis]
116 Zhang X, Qin X, Yu T, Wang K, Chen Y, Xing Q. Chromatin regulators-related lncRNA signature predicting the prognosis of kidney renal clear cell carcinoma and its relationship with immune microenvironment: A study based on bioinformatics and experimental validation. Front Genet 2022;13:974726. [DOI: 10.3389/fgene.2022.974726] [Reference Citation Analysis]
117 Tada K, Daizumoto K, Takahashi M, Uehara H, Tsuda M, Kusuhara Y, Fukawa T, Yamamoto Y, Yamaguchi K, Kanayama HO. Recurrent multiple liver metastases of clear cell renal cell carcinoma with a significant response to sunitinib after nivolumab treatment. IJU Case Rep 2023;6:41-4. [PMID: 36605682 DOI: 10.1002/iju5.12545] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Walton J, Lawson K, Prinos P, Finelli A, Arrowsmith C, Ailles L. PBRM1, SETD2 and BAP1 - the trinity of 3p in clear cell renal cell carcinoma. Nat Rev Urol 2022. [PMID: 36253570 DOI: 10.1038/s41585-022-00659-1] [Reference Citation Analysis]
119 He Y, Zhang S, Zhang X, Zhang Y, Xie B, Zhang J, Long W, Liu Q. A prognostic cuproptosis gene signature predicts immune function and chemotherapy response in gliomas.. [DOI: 10.21203/rs.3.rs-2155356/v1] [Reference Citation Analysis]
120 Pierro M, Baldini C, Auclin E, Vincent H, Varga A, Martin Romano P, Vuagnat P, Besse B, Planchard D, Hollebecque A, Champiat S, Marabelle A, Michot J, Massard C, Mezquita L. Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score. Cancers 2022;14:5078. [DOI: 10.3390/cancers14205078] [Reference Citation Analysis]
121 Vento JA, Rini BI. Treatment of Refractory Metastatic Renal Cell Carcinoma. Cancers 2022;14:5005. [DOI: 10.3390/cancers14205005] [Reference Citation Analysis]
122 Wei Y, Su Y. Using machine learning and RNA to enhance the efficacy of anti-tumor immunotherapy. Evol Intel . [DOI: 10.1007/s12065-022-00781-4] [Reference Citation Analysis]
123 Guo HL, Xie XY, Xu M. Application of nanomaterials in combined thermal ablation and immunotherapy for liver tumors. Shijie Huaren Xiaohua Zazhi 2022; 30(19): 829-837 [DOI: 10.11569/wcjd.v30.i19.829] [Reference Citation Analysis]
124 Chen W, Li D, Bian X, Wu Y, Xu M, Wu M, Tao M. Peripheral Blood Markers Predictive of Progression-Free Survival in Advanced Esophageal Squamous Cell Carcinoma Patients Treated With PD-1 Inhibitors Plus Chemotherapy as First-Line Therapy. Nutr Cancer 2023;75:207-18. [PMID: 36190755 DOI: 10.1080/01635581.2022.2123533] [Reference Citation Analysis]
125 Xia S, Jia H, Qian Z, Xiu Y. Role of copper ionophore–induced death in immune microenvironment and clinical prognosis of ccRCC: An integrated analysis. Front Genet 2022;13:994999. [DOI: 10.3389/fgene.2022.994999] [Reference Citation Analysis]
126 Yukihiro K, Teishima J, Goto K, Aoki G, Sekino Y, Hayashi T, Hasegawa Y, Mita K, Kato M, Kajiwara M, Shigeta M, Maruyama S, Kadonishi Y, Fujiwara S, Hinata N. Impact of modified Glasgow prognostic score on predicting prognosis and modification of risk model for patients with metastatic renal cell carcinoma treated with first line tyrosine kinase inhibitor. Urologic Oncology: Seminars and Original Investigations 2022;40:455.e11-455.e18. [DOI: 10.1016/j.urolonc.2022.06.016] [Reference Citation Analysis]
127 Moradi Tabriz H, Nazar E, Akhlaghi N, Eftekhar Javadi A. Expression of Programmed Death-1 Ligand in Renal Cell Carcinoma and Its Relationship with Pathologic Findings and Disease-Free Survival. Nephro-Urol Mon 2022;14. [DOI: 10.5812/numonthly-127476] [Reference Citation Analysis]
128 Yomo S, Oda K, Oguchi K. Effectiveness of immune checkpoint inhibitors in combination with stereotactic radiosurgery for patients with brain metastases from renal cell carcinoma: inverse probability of treatment weighting using propensity scores. Journal of Neurosurgery 2022. [DOI: 10.3171/2022.9.jns221215] [Reference Citation Analysis]
129 Som A, Rosenboom JG, Chandler A, Sheth RA, Wehrenberg-Klee E. Image-guided intratumoral immunotherapy: Developing a clinically practical technology. Adv Drug Deliv Rev 2022;189:114505. [PMID: 36007674 DOI: 10.1016/j.addr.2022.114505] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
130 Guo T, Wang T, Zhang J, Chen S, Wang X. HIF1A predicts the efficacy of anti-PD-1 therapy in advanced clear cell renal cell carcinoma. Transl Oncol 2022;26:101554. [PMID: 36191462 DOI: 10.1016/j.tranon.2022.101554] [Reference Citation Analysis]
131 Fu L, Bao J, Li J, Li Q, Lin H, Zhou Y, Li J, Yan Y, Langston ME, Sun T, Guo S, Zhou X, Chen Y, Liu Y, Zhao Y, Lu J, Huang Y, Chen W, Chung BI, Luo J. Crosstalk of necroptosis and pyroptosis defines tumor microenvironment characterization and predicts prognosis in clear cell renal carcinoma. Front Immunol 2022;13:1021935. [DOI: 10.3389/fimmu.2022.1021935] [Reference Citation Analysis]
132 Rebuzzi SE, Signori A, Banna GL, Gandini A, Fornarini G, Damassi A, Maruzzo M, De Giorgi U, Basso U, Chiellino S, Galli L, Zucali PA, Fantinel E, Naglieri E, Procopio G, Milella M, Boccardo F, Fratino L, Pipitone S, Ricotta R, Panni S, Mollica V, Sorarù M, Santoni M, Cortellini A, Prati V, Soto Parra HJ, Santini D, Atzori F, Di Napoli M, Caffo O, Messina M, Morelli F, Prati G, Nolè F, Vignani F, Cavo A, Roviello G, Rescigno P, Buti S. The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study. J Transl Med 2022;20:435. [PMID: 36180954 DOI: 10.1186/s12967-022-03601-6] [Reference Citation Analysis]
133 Azuma T, Kano M, Iwata S, Honda S, Miyoshi Y, Nishiguchi J. Utility of periodic medical questionnaires and examinations for immune-related adverse event screening: A prospective observational study. PLoS ONE 2022;17:e0274451. [DOI: 10.1371/journal.pone.0274451] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
134 Haghpanah M, Azimi A, Fadavi P, Bagheri SM, Arefpour AM. The Complete Response of a Renal Cell Carcinoma Metastatic to Brain, Lungs, and Liver to Second-Line Nivolumab: A Case Report. Cureus 2022. [DOI: 10.7759/cureus.29680] [Reference Citation Analysis]
135 Kim JH, Kim GH, Ryu Y, Kim S, Kim H, Yoon SK, Cho Y, Lee JL. Clinical implications of the tumor microenvironment using multiplexed immunohistochemistry in patients with advanced or metastatic renal cell carcinoma treated with nivolumab plus ipilimumab. Front Oncol 2022;12:969569. [DOI: 10.3389/fonc.2022.969569] [Reference Citation Analysis]
136 Dong T, Zhang B, Zhang R, Wang C, Liu X, Wang F, Hao N, Tan K, Chang YZ. Hepcidin is upregulated and is a potential therapeutic target associated with immunity in glioma. Front Oncol 2022;12:963096. [PMID: 36237302 DOI: 10.3389/fonc.2022.963096] [Reference Citation Analysis]
137 Gao Y, Liu M, Li L, Zhang J, Song F, Tian J. Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple-negative breast cancer. Cochrane Database of Systematic Reviews 2022;2022. [DOI: 10.1002/14651858.cd015072] [Reference Citation Analysis]
138 Ged Y, Lee CH. Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma. Expert Rev Anticancer Ther 2022. [PMID: 36154355 DOI: 10.1080/14737140.2022.2128336] [Reference Citation Analysis]
139 . Kidney Cancer. Fundamentals of Cancer Detection, Treatment, and Prevention 2022. [DOI: 10.1002/9783527838561.ch9] [Reference Citation Analysis]
140 Deharo F, Carvelli J, Cautela J, Garcia M, Sarles C, Maues de Paula A, Bourenne J, Gainnier M, Bichon A. Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit. JCM 2022;11:5611. [DOI: 10.3390/jcm11195611] [Reference Citation Analysis]
141 Dubrot J, Du PP, Lane-Reticker SK, Kessler EA, Muscato AJ, Mehta A, Freeman SS, Allen PM, Olander KE, Ockerman KM, Wolfe CH, Wiesmann F, Knudsen NH, Tsao HW, Iracheta-Vellve A, Schneider EM, Rivera-Rosario AN, Kohnle IC, Pope HW, Ayer A, Mishra G, Zimmer MD, Kim SY, Mahapatra A, Ebrahimi-Nik H, Frederick DT, Boland GM, Haining WN, Root DE, Doench JG, Hacohen N, Yates KB, Manguso RT. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. Nat Immunol 2022. [PMID: 36151395 DOI: 10.1038/s41590-022-01315-x] [Reference Citation Analysis]
142 Kim CM, Lee JB, Shin SJ, Ahn JB, Lee M, Kim HS. The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression. ESMO Open 2022;7:100577. [PMID: 36156450 DOI: 10.1016/j.esmoop.2022.100577] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
143 Liu Y, Yu M, Cheng X, Zhang X, Luo Q, Liao S, Chen Z, Zheng J, Long K, Wu X, Qu W, Gong M, Song Y. A novel LUAD prognosis prediction model based on immune checkpoint-related lncRNAs. Front Genet 2022;13:1016449. [DOI: 10.3389/fgene.2022.1016449] [Reference Citation Analysis]
144 Le Guevelou J, Sargos P, Siva S, Ploussard G, Ost P, Gillessen S, Zilli T. The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review. Eur Urol Focus 2022:S2405-4569(22)00205-X. [PMID: 36151031 DOI: 10.1016/j.euf.2022.08.016] [Reference Citation Analysis]
145 Mari R, Guerin M, Vicier C, Walz J, Bonnet N, Pignot G, Gravis G. Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report. Front Immunol 2022;13:984132. [DOI: 10.3389/fimmu.2022.984132] [Reference Citation Analysis]
146 Liao Y, Hou H, Han Z, Liu Y. Systemic therapies for metastatic renal cell carcinoma in the second-line setting: A systematic review and network meta-analysis. Medicine (Baltimore) 2022;101:e30333. [PMID: 36123840 DOI: 10.1097/MD.0000000000030333] [Reference Citation Analysis]
147 Lyou Y, Dorff TB. Chimeric Antigen Receptor (CAR) T-cell Treatment in Renal Cell Carcinoma: Current clinical trials and future directions. KCA 2022. [DOI: 10.3233/kca-220001] [Reference Citation Analysis]
148 Deluce J, Maleki Vareki S, Fernandes R. The role of gut microbiome in immune modulation in metastatic renal cell carcinoma. Ther Adv Med Oncol 2022;14:17588359221122714. [PMID: 36105887 DOI: 10.1177/17588359221122714] [Reference Citation Analysis]
149 Zhang L, Jiang L, Yu L, Li Q, Tian X, He J, Zeng L, Yang Y, Wang C, Wei Y, Jiang X, Li J, Ge X, Gu Q, Li J, Wu D, Sadler AJ, Yu D, Xu D, Gao Y, Yuan X, He B. Inhibition of UBA6 by inosine augments tumour immunogenicity and responses. Nat Commun 2022;13. [DOI: 10.1038/s41467-022-33116-z] [Reference Citation Analysis]
150 Zhou X, Khan S, Huang D, Li L. V-Set and immunoglobulin domain containing (VSIG) proteins as emerging immune checkpoint targets for cancer immunotherapy. Front Immunol 2022;13:938470. [DOI: 10.3389/fimmu.2022.938470] [Reference Citation Analysis]
151 Quigley M, Meyer MJ, Katlinski K. Modeling Resistance to Immune Checkpoint Blockade. Animal Models for the Development of Cancer Immunotherapy 2022. [DOI: 10.1002/9781119535331.ch4] [Reference Citation Analysis]
152 Zhang C, Hu H, Huang R, Huang G, Xi X. ACSL3 is a potential prognostic biomarker for immune infiltration in clear cell renal cell carcinoma. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.909854] [Reference Citation Analysis]
153 Lavoie J, Baichoo P, Chavez E, Nappi L, Khalaf D, Kollmannsberger CK, Chi KN, Weng A, Steidl C, Eigl BJ, Nissen M. Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockade. Front Oncol 2022;12:973402. [DOI: 10.3389/fonc.2022.973402] [Reference Citation Analysis]
154 Li Y, Huang X, Tong D, Jiang C, Zhu X, Wei Z, Gong T, Jin C. Relationships among microbiota, gastric cancer, and immunotherapy. Front Microbiol 2022;13:987763. [DOI: 10.3389/fmicb.2022.987763] [Reference Citation Analysis]
155 Negishi T, Nakagawa T, Nishiyama N, Kitamura H, Okajima E, Furubayashi N, Hori Y, Kuroiwa K, Son Y, Seki N, Tomoda T, Nakamura M. Dissociated response among multiple metastatic lesions in the patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Jpn J Clin Oncol 2022:hyac144. [PMID: 36093731 DOI: 10.1093/jjco/hyac144] [Reference Citation Analysis]
156 Tian Y, Huang A, Tian M, Wang K, Dang Q, Zhang C, Liu H, Zhao J, Yang X, Zhang C, Guo L, Chen F. Incidence risk of peripheral edema in cancer patients treated with PD-1/PD-L1 inhibitors: A PRISMA guideline systematic review and meta-analysis. Medicine (Baltimore) 2022;101:e30151. [PMID: 36086680 DOI: 10.1097/MD.0000000000030151] [Reference Citation Analysis]
157 Massari F, Mollica V. Personalizing immunotherapy for renal cell carcinoma: how far have we come? Expert Opin Biol Ther 2022;:1-5. [PMID: 36083134 DOI: 10.1080/14712598.2022.2122809] [Reference Citation Analysis]
158 Lu L, Zheng D, Qu J, Zhuang Y, Peng J, Lan S, Zhang S, Huang F. METTL16 predicts a favorable outcome and primes antitumor immunity in pancreatic ductal adenocarcinoma. Front Cell Dev Biol 2022;10:759020. [DOI: 10.3389/fcell.2022.759020] [Reference Citation Analysis]
159 Yu L, Sun M, Zhang Q, Zhou Q, Wang Y. Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. Front Immunol 2022;13:982026. [DOI: 10.3389/fimmu.2022.982026] [Reference Citation Analysis]
160 Yuan H, Qin X, Wang J, Yang Q, Fan Y, Xu D. The cuproptosis-associated 13 gene signature as a robust predictor for outcome and response to immune- and targeted-therapies in clear cell renal cell carcinoma. Front Immunol 2022;13:971142. [DOI: 10.3389/fimmu.2022.971142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
161 Lin X, Cui C, Cui Q. Combating pancreatic cancer with ovarian cancer cells.. [DOI: 10.1101/2022.09.01.506158] [Reference Citation Analysis]
162 Shen Y, Cao Y, Zhou L, Wu J, Mao M. Construction of an endoplasmic reticulum stress-related gene model for predicting prognosis and immune features in kidney renal clear cell carcinoma. Front Mol Biosci 2022;9:928006. [DOI: 10.3389/fmolb.2022.928006] [Reference Citation Analysis]
163 Berner F, Bomze D, Lichtensteiger C, Walter V, Niederer R, Hasan Ali O, Wyss N, Bauer J, Freudenmann LK, Marcu A, Wolfschmitt EM, Haen S, Gross T, Abdou MT, Diem S, Knöpfli S, Sinnberg T, Hofmeister K, Cheng HW, Toma M, Klümper N, Purde MT, Pop OT, Jochum AK, Pascolo S, Joerger M, Früh M, Jochum W, Rammensee HG, Läubli H, Hölzel M, Neefjes J, Walz J, Flatz L. Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. Sci Immunol 2022;7:eabn9644. [PMID: 36054337 DOI: 10.1126/sciimmunol.abn9644] [Reference Citation Analysis]
164 Simonetti S, Iuliani M, Stellato M, Cavaliere S, Vincenzi B, Tonini G, Santini D, Pantano F. Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma. J Immunother Cancer 2022;10:e005136. [PMID: 36104102 DOI: 10.1136/jitc-2022-005136] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
165 Grimm MO, Grünwald V, Müller-Huesmann H, Ivanyi P, Schostak M, von der Heyde E, Schultze-Seemann W, Belz H, Bögemann M, Wang M, Herber M, Bedke J; NORA Study Group. Real-World Data on the Use of Nivolumab Monotherapy in the Treatment of Advanced Renal Cell Carcinoma after Prior Therapy: Interim Results from the Noninterventional NORA Study. Eur Urol Focus 2022;8:1289-99. [PMID: 34953677 DOI: 10.1016/j.euf.2021.11.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
166 Nguyen LTH, Zhang J, Rima XY, Wang X, Kwak KJ, Okimoto T, Amann J, Yoon MJ, Shukuya T, Chiang CL, Walters N, Ma Y, Belcher D, Li H, Palmer AF, Carbone DP, Lee LJ, Reátegui E. An immunogold single extracellular vesicular RNA and protein (Au SERP) biochip to predict responses to immunotherapy in non-small cell lung cancer patients. J Extracell Vesicles 2022;11:e12258. [PMID: 36093740 DOI: 10.1002/jev2.12258] [Reference Citation Analysis]
167 Smyth E, Cozens K, Griffiths D, Clark KL, Ewings S, Petty R, Underwood T, Fitzgerald RC, Tanner J, Giger O, Anand S, Griffiths G. ELEVATE - evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial. BMC Cancer 2022;22:946. [PMID: 36050653 DOI: 10.1186/s12885-022-09891-9] [Reference Citation Analysis]
168 Yildirim HC, Guven DC, Aktepe OH, Taban H, Yilmaz F, Yasar S, Aksoy S, Erman M, Kilickap S, Yalcin S. Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease. JCM 2022;11:5171. [DOI: 10.3390/jcm11175171] [Reference Citation Analysis]
169 Yang B, Zhang M, Liu T, Luo T. The necroptosis-related signature and tumor microenvironment immune characteristics associated with clinical prognosis and drug sensitivity analysis in stomach adenocarcinoma.. [DOI: 10.21203/rs.3.rs-1419868/v2] [Reference Citation Analysis]
170 Eisner JR, Beebe KD, Mayhew GM, Shibata Y, Guo Y, Farhangfar C, Farhangfar F, Uronis JM, Mooney J, Milburn MV, Foureau D, White RL, Amin A, Milla ME. Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal Cancer. Cancer Research Communications 2022;2:894-903. [DOI: 10.1158/2767-9764.crc-21-0153] [Reference Citation Analysis]
171 Onal B, Gultekin MH, Simsekoglu MF, Selcuk B, Gurbuz A. Biomarkers in Urological Cancers. Biomarkers in Medicine 2022. [DOI: 10.2174/9789815040463122010005] [Reference Citation Analysis]
172 Füchsl F, Krackhardt AM. Paving the Way to Solid Tumors: Challenges and Strategies for Adoptively Transferred Transgenic T Cells in the Tumor Microenvironment. Cancers 2022;14:4192. [DOI: 10.3390/cancers14174192] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
173 Chandrasekaran J, Elumalai S, Murugesan V, Kunjiappan S, Pavadai P, Theivendren P. Computational design of PD-L1 small molecule inhibitors for cancer therapy. Mol Divers 2022. [PMID: 36006501 DOI: 10.1007/s11030-022-10516-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
174 Shi X, Niu Y, Yang Y, Wang N, Yuan M, Yang C, Dong A, Zhu H, Jia X, Xu Q. Identification of a Prognostic Model Based on Immune Cell Signatures in Clear Cell Renal Cell Carcinoma. Oxidative Medicine and Cellular Longevity 2022;2022:1-16. [DOI: 10.1155/2022/1727575] [Reference Citation Analysis]
175 Rizzo M, Varnier L, Pezzicoli G, Pirovano M, Cosmai L, Porta C. IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinoma. Front Oncol 2022;12:990568. [DOI: 10.3389/fonc.2022.990568] [Reference Citation Analysis]
176 Matsumura S, Kato T, Kujime Y, Kitakaze H, Nakano K, Hongo S, Yoshioka I, Okumi M, Nonomura N, Takada S. Pre-treatment metastatic growth rate predicts clinical outcome of metastatic renal cell carcinoma treated with nivolumab.. [DOI: 10.21203/rs.3.rs-1936031/v1] [Reference Citation Analysis]
177 Peterson C, Denlinger N, Yang Y. Recent Advances and Challenges in Cancer Immunotherapy. Cancers 2022;14:3972. [DOI: 10.3390/cancers14163972] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
178 Hamada K, Tsunoda T, Yoshimura K. Emerging Immune-Monitoring System for Immune Checkpoint Inhibitors. Life (Basel) 2022;12:1229. [PMID: 36013407 DOI: 10.3390/life12081229] [Reference Citation Analysis]
179 Bimbatti D, Dionese M, Lai E, Cavasin N, Basso U, Mattana A, Pierantoni F, Zagonel V, Maruzzo M. Nivolumab drug holiday in patients treated for metastatic renal cell carcinoma: A real-world, single-centre experience. Front Oncol 2022;12:960751. [DOI: 10.3389/fonc.2022.960751] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
180 Zhang Y, Kumar P, Adashek JJ, Skelton WP 4th, Li J, Vosoughi A, Chahoud J, Manley BJ, Spiess PE. Adding Cyclooxygenase Inhibitors to Immune Checkpoint Inhibitors Did Not Improve Outcomes in Metastatic Renal Cell Carcinoma. Cells 2022;11:2505. [PMID: 36010582 DOI: 10.3390/cells11162505] [Reference Citation Analysis]
181 Guven DC, Yekeduz E, Erul E, Yazgan SC, Sahin TK, Karatas G, Aksoy S, Erman M, Yalcin S, Urun Y, Kilickap S. The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study. J Cancer Res Clin Oncol 2022. [PMID: 35960374 DOI: 10.1007/s00432-022-04268-8] [Reference Citation Analysis]
182 Niu D, Chen Y, Mi H, Mo Z, Pang G. The epiphany derived from T-cell–inflamed profiles: Pan-cancer characterization of CD8A as a biomarker spanning clinical relevance, cancer prognosis, immunosuppressive environment, and treatment responses. Front Genet 2022;13:974416. [DOI: 10.3389/fgene.2022.974416] [Reference Citation Analysis]
183 Zou Y, Tan X, Yuan G, Tang Y, Wang Y, Yang C, Luo S, Yao K. SPP1 is expected to be a biomarker for predicting prognosis and immunotherapy efficacy in penile cancer patients.. [DOI: 10.21203/rs.3.rs-1934794/v1] [Reference Citation Analysis]
184 Zhu M, Huang C, Wu X, Gu Y, Hu X, Ma D, Zhong W. Aging-based molecular classification and score system in ccRCC uncovers distinct prognosis, tumor immunogenicity, and treatment sensitivity. Front Immunol 2022;13:877076. [DOI: 10.3389/fimmu.2022.877076] [Reference Citation Analysis]
185 Guan X, Lu N, Zhang J. The combined prognostic model of copper-dependent to predict the prognosis of pancreatic cancer. Front Genet 2022;13:978988. [DOI: 10.3389/fgene.2022.978988] [Reference Citation Analysis]
186 Wesolowski J, Tankiewicz-kwedlo A, Pawlak D. Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer. Cancers 2022;14:3860. [DOI: 10.3390/cancers14163860] [Reference Citation Analysis]
187 Bir Yucel K, Sutcuoglu O, Yazıcı O, Yıldız Y, Şenol E, Uner A. Nivolumab-ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment. J Oncol Pharm Pract 2022;:10781552221118529. [PMID: 35938177 DOI: 10.1177/10781552221118529] [Reference Citation Analysis]
188 Powles T, van den Heuvel R. Exploratory treatment options fail in ccRCC. Medicom Conference Report ASCO 2022 2022. [DOI: 10.55788/215f3bee] [Reference Citation Analysis]
189 Wang X, Xia Z, Li Z, Zhang C. Development of a SETD2-related immune prognostic signature in clear cell renal cell carcinoma. Medicine (Baltimore) 2022;101:e29561. [PMID: 35945780 DOI: 10.1097/MD.0000000000029561] [Reference Citation Analysis]
190 Wang Y, Lai X, Wang J, Xu Y, Zhang X, Zhu X, Liu Y, Shao Y, Zhang L, Fang W. A Joint Model Considering Measurement Errors for Optimally Identifying Tumor Mutation Burden Threshold. Front Genet 2022;13:915839. [DOI: 10.3389/fgene.2022.915839] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
191 Kojima T, Kato R, Sazuka T, Yamamoto H, Fukuda S, Yamana K, Nakaigawa N, Sugino Y, Hamamoto S, Ito H, Murakami H, Obara W. Real-world effectiveness of nivolumab plus ipilimumab and second-line therapy in Japanese untreated patients with metastatic renal cell carcinoma: 2-year analysis from a multicenter retrospective clinical study (J-cardinal study). Jpn J Clin Oncol 2022:hyac124. [PMID: 35920793 DOI: 10.1093/jjco/hyac124] [Reference Citation Analysis]
192 Kern A, Thomas C, Holotiuk O, Drewes S. A rare case of a retrocrural lymph node metastasis from a chromophobe renal cell cancer: complete thoracoscopic resection with a new multi-joint articulating surgical instrument. Interactive CardioVascular and Thoracic Surgery 2022;35. [DOI: 10.1093/icvts/ivac204] [Reference Citation Analysis]
193 Kiss I, Kuhn M, Hrusak K, Buchler B, Boublikova L, Buchler T. Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis. Front Oncol 2022;12:946307. [DOI: 10.3389/fonc.2022.946307] [Reference Citation Analysis]
194 Eggers H, Schünemann C, Grünwald V, Rudolph L, Tiemann ML, Reuter C, Anders-Meyn MF, Ganser A, Ivanyi P. Improving survival in metastatic renal cell carcinoma (mRCC) patients: do elderly patients benefit from expanded targeted therapeutic options? World J Urol 2022. [PMID: 35916904 DOI: 10.1007/s00345-022-04110-3] [Reference Citation Analysis]
195 Mazzotti L, Gaimari A, Bravaccini S, Maltoni R, Cerchione C, Juan M, Navarro EA, Pasetto A, Nascimento Silva D, Ancarani V, Sambri V, Calabrò L, Martinelli G, Mazza M. T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer. IJMS 2022;23:8590. [DOI: 10.3390/ijms23158590] [Reference Citation Analysis]
196 Ishihara H, Ishiyama Y, Nemoto Y, Nakamura K, Tachibana H, Fukuda H, Yoshida K, Kobayashi H, Iizuka J, Shimmura H, Hashimoto Y, Tanabe K, Kondo T, Takagi T. Impact of body mass index on outcomes in an Asian population of advanced renal cell carcinoma and urothelial carcinoma treated with immune checkpoint inhibitors. Clinical Genitourinary Cancer 2022. [DOI: 10.1016/j.clgc.2022.08.001] [Reference Citation Analysis]
197 Dumont C, Flippot R, Bonnet C, Gauthier H, Albigès L, Culine S. Tratamiento del cáncer de riñón metastásico. EMC - Urología 2022;54:1-13. [DOI: 10.1016/s1761-3310(22)46756-9] [Reference Citation Analysis]
198 Sanborn RE, Pishvaian MJ, Callahan MK, Weise A, Sikic BI, Rahma O, Cho DC, Rizvi NA, Sznol M, Lutzky J, Bauman JE, Bitting RL, Starodub A, Jimeno A, Reardon DA, Kaley T, Iwamoto F, Baehring JM, Subramaniam DS, Aragon-Ching JB, Hawthorne TR, Rawls T, Yellin M, Keler T. Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. J Immunother Cancer 2022;10:e005147. [PMID: 35940825 DOI: 10.1136/jitc-2022-005147] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
199 Kankkunen E, Penttilä P, Peltola K, Bono P. C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients. Acta Oncol 2022;:1-8. [PMID: 35905053 DOI: 10.1080/0284186X.2022.2104132] [Reference Citation Analysis]
200 Liu K, Zhao S, Li J, Zheng Y, Wu H, Kong J, Shen Z. Knowledge mapping and research hotspots of immunotherapy in renal cell carcinoma: A text-mining study from 2002 to 2021. Front Immunol 2022;13:969217. [DOI: 10.3389/fimmu.2022.969217] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
201 Fukushima T, Teishima J, Goto K, Takemoto K, Sekino Y, Kobatake K, Ikeda K, Hayashi T, Sentani K, Oue N, Hinoi T, Hinata N. Two case reports of immune checkpoint therapy on chromophobe renal cell carcinoma with sarcomatoid differentiation. Int Canc Conf J 2022;11:286-291. [DOI: 10.1007/s13691-022-00561-y] [Reference Citation Analysis]
202 Gannichida A, Nakazawa Y, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer. World J Clin Oncol 2022; 13(7): 641-651 [DOI: 10.5306/wjco.v13.i7.641] [Reference Citation Analysis]
203 Kim HS, Kim CG, Hong JY, Kim IH, Kang B, Jung S, Kim C, Shin SJ, Choi HJ, Cheon J, Chon HJ, Lim HY. The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma. Ther Adv Med Oncol 2022;14:17588359221113266. [PMID: 35860833 DOI: 10.1177/17588359221113266] [Reference Citation Analysis]
204 Boileau P, Qi NT, van der Laan MJ, Dudoit S, Leng N. A flexible approach for predictive biomarker discovery. Biostatistics 2022:kxac029. [PMID: 35861622 DOI: 10.1093/biostatistics/kxac029] [Reference Citation Analysis]
205 Mukhopadhyay P, Ye J, Anderson KM, Roychoudhury S, Rubin EH, Halabi S, Chappell RJ. Log-Rank Test vs MaxCombo and Difference in Restricted Mean Survival Time Tests for Comparing Survival Under Nonproportional Hazards in Immuno-oncology Trials: A Systematic Review and Meta-analysis. JAMA Oncol 2022. [PMID: 35862037 DOI: 10.1001/jamaoncol.2022.2666] [Reference Citation Analysis]
206 Liu J, Ma J, Xing N, Ji Z, Li J, Zhang S, Guo Z. Interferon-γ predicts the treatment efficiency of immune checkpoint inhibitors in cancer patients. J Cancer Res Clin Oncol. [DOI: 10.1007/s00432-022-04201-z] [Reference Citation Analysis]
207 Hess KJ, Bascoy S, Vadher U, Nawrocki J, Shah D. Neoadjuvant Immunotherapy in the Treatment of Renal Cell Carcinoma: A Case Series. Cureus 2022. [DOI: 10.7759/cureus.27019] [Reference Citation Analysis]
208 Tian Y, Zhang C, Dang Q, Wang K, Liu Q, Liu H, Shang H, Zhao J, Xu Y, Wu T, Liu W, Yang X, Safi M, Wu YS. Risk of Rash in PD-1 or PD-L1-Related Cancer Clinical Trials: A Systematic Review and Meta-Analysis. Journal of Oncology 2022;2022:1-27. [DOI: 10.1155/2022/4976032] [Reference Citation Analysis]
209 Lee JY, Kannan B, Lim BY, Li Z, Lim AH, Loh JW, Ko TK, Ng CC, Chan JY. The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy. Int J Mol Sci 2022;23:7839. [PMID: 35887186 DOI: 10.3390/ijms23147839] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
210 Volkova MI, Turupaev KA, Kalinin SA. Cabozantinib in the treatment of patients with advanced renal cell carcinoma. J Mod Onco 2022;24:184-190. [DOI: 10.26442/18151434.2022.2.201704] [Reference Citation Analysis]
211 Peyraud F, Guegan JP, Bodet D, Nafia I, Fontan L, Auzanneau C, Cousin S, Roubaud G, Cabart M, Chomy F, Le Loarer F, Chaput N, Danlos FX, Planchard D, Even C, Khettab M, Tselikas L, Besse B, Barlesi F, Soria JC, Marabelle A, Bessede A, Italiano A. Circulating L-Arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors. Ann Oncol 2022:S0923-7534(22)01827-0. [PMID: 35850444 DOI: 10.1016/j.annonc.2022.07.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
212 Zukov RA, Chernyaev DV, Zulkaidarova AR. Combination therapy regimens in the treatment of metastatic renal cell carcinoma: A review. J Mod Onco 2022;24:191-198. [DOI: 10.26442/18151434.2022.2.201720] [Reference Citation Analysis]
213 Rodriguez JE, Naigeon M, Goldschmidt V, Roulleaux Dugage M, Seknazi L, Danlos FX, Champiat S, Marabelle A, Michot JM, Massard C, Besse B, Ferrara R, Chaput N, Baldini C. Immunosenescence, inflammaging, and cancer immunotherapy efficacy. Expert Rev Anticancer Ther 2022;:1-12. [PMID: 35815381 DOI: 10.1080/14737140.2022.2098718] [Reference Citation Analysis]
214 Golkaram M, Kuo F, Gupta S, Carlo MI, Salmans ML, Vijayaraghavan R, Tang C, Makarov V, Rappold P, Blum KA, Zhao C, Mehio R, Zhang S, Godsey J, Pawlowski T, Dinatale RG, Morris LG, Durack J, Russo P, Kotecha RR, Coleman J, Chen Y, Reuter VE, Motzer RJ, Voss MH, Liu L, Reznik E, Chan TA, Ari Hakimi A. Spatiotemporal evolution of the ccRCC microenvironment links intra-tumoral heterogeneity to immune escape.. [DOI: 10.1101/2022.07.11.22277322] [Reference Citation Analysis]
215 Zhou L, Fang H, Guo F, Yin M, Long H, Weng G. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma. J Clin Lab Anal 2022;:e24582. [PMID: 35808868 DOI: 10.1002/jcla.24582] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
216 Wei Y, Zhang J, Fan X, Zheng Z, Jiang X, Chen D, Lu Y, Li Y, Wang M, Hu M, Du Q, Yang L, Li H, Xiao Y, Li Y, Jin J, Wang D, Yuan X, Li Q. Immune Profiling in Gastric Cancer Reveals the Dynamic Landscape of Immune Signature Underlying Tumor Progression. Front Immunol 2022;13:935552. [DOI: 10.3389/fimmu.2022.935552] [Reference Citation Analysis]
217 Menshikov KV, Sultanbaev AV, Izmailov AA, Musin SI, Menshikova IA, Chalov VS, Sultanbaeva NI, Lipatov DO. Case report: treatment of metastatic renal cell carcinoma with nivolumab plus cabozantinib in routine clinical practice. Malignant Tumours 2022;12:45-51. [DOI: 10.18027/2224-5057-2022-12-2-45-51] [Reference Citation Analysis]
218 Hong SH, Lee KS, Hwang HJ, Park SY, Han WK, Yoon YE. Synergic Effect of Metformin and Everolimus on Mitochondrial Dynamics of Renal Cell Carcinoma. Genes (Basel) 2022;13:1211. [PMID: 35885994 DOI: 10.3390/genes13071211] [Reference Citation Analysis]
219 Kobayashi M, Numakura K, Hatakeyama S, Muto Y, Sekine Y, Sasagawa H, Kashima S, Yamamoto R, Koizumi A, Nara T, Saito M, Narita S, Ohyama C, Habuchi T. Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism. Genes 2022;13:1204. [DOI: 10.3390/genes13071204] [Reference Citation Analysis]
220 Choucair K, Naqash AR, Nebhan CA, Nipp R, Johnson DB, Saeed A. Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology. Oncologist 2022:oyac119. [PMID: 35781739 DOI: 10.1093/oncolo/oyac119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
221 Morimoto K, Yamada T, Morimoto Y, Ishikawa T, Asai J, Fujihara A, Arai A, Katoh N, Ukimura O, Hirano S, Itoh Y, Takayama K. A real-world study on the safety of the extended dosing schedule for nivolumab and pembrolizumab in patients with solid tumors. International Immunopharmacology 2022;108:108775. [DOI: 10.1016/j.intimp.2022.108775] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
222 Dunn GP, Sherpa N, Manyanga J, Johanns TM. Considerations for personalized neoantigen vaccination in Malignant glioma. Adv Drug Deliv Rev 2022;186:114312. [PMID: 35487282 DOI: 10.1016/j.addr.2022.114312] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
223 Kourtis N, Wang Q, Wang B, Oswald E, Adler C, Cherravuru S, Malahias E, Zhang L, Golubov J, Wei Q, Lemus S, Ni M, Ding Y, Wei Y, Atwal GS, Thurston G, Macdonald LE, Murphy AJ, Dhanik A, Sleeman MA, Tykodi SS, Skokos D. A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma. Nat Cancer 2022;3:885-98. [PMID: 35668194 DOI: 10.1038/s43018-022-00391-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
224 Joly F, Michot J, Dourthe LM, Fléchon A, Mahammedi H, Maillet D, Mouillet G, Pouessel D, Rolland F, Topart D, Albiges L. Cancer du rein métastatique : gestion des toxicités des combinaisons. Bulletin du Cancer 2022;109:844-861. [DOI: 10.1016/j.bulcan.2022.04.019] [Reference Citation Analysis]
225 Pires da Silva I, Zakria D, Ahmed T, Trojanello C, Dimitriou F, Allayous C, Gerard C, Zimmer L, Lo S, Michielin O, Lebbe C, Mangana J, Ascierto PA, Johnson DB, Carlino M, Menzies A, Long G. Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. J Immunother Cancer 2022;10:e004610. [PMID: 35798536 DOI: 10.1136/jitc-2022-004610] [Reference Citation Analysis]
226 Carlisle JW, Jansen CS, Cardenas MA, Sobierajska E, Reyes AM, Greenwald R, Del Balzo L, Prokhnevska N, Kucuk O, Carthon BC, Mullane PC, Osunkoya A, Baumgarten D, Hosseinzadeh F, Wilkinson S, Lake R, Sowalsky AG, Liu Y, Master VA, Bilen MA, Kissick H. Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood. J Immunother Cancer 2022;10:e004803. [PMID: 35863822 DOI: 10.1136/jitc-2022-004803] [Reference Citation Analysis]
227 Rassy E, Dalban C, Colomba E, Derosa L, Silva CAC, Negrier S, Chevreau C, Gravis G, Oudard S, Laguerre B, Barthelemy P, Goupil MG, Geoffrois L, Rolland F, Thiery-vuillemin A, Joly F, Ladoire S, Tantot F, Escudier B, Albiges L. Efficacy and safety of concomitant proton pump inhibitor and nivolumab in renal cell carcinoma: results of the GETUG-AFU 26 NIVOREN multicenter phase II study. Clinical Genitourinary Cancer 2022. [DOI: 10.1016/j.clgc.2022.07.003] [Reference Citation Analysis]
228 Alchahin AM, Mei S, Tsea I, Hirz T, Kfoury Y, Dahl D, Wu C, Subtelny AO, Wu S, Scadden DT, Shin JH, Saylor PJ, Sykes DB, Kharchenko PV, Baryawno N. A new transcriptional metastatic signature predicts survival in clear cell renal cell carcinoma.. [DOI: 10.1101/2022.06.28.497333] [Reference Citation Analysis]
229 Rodger FE, Brennan PT, Nair R, Holroyd DJ. The role of hepatic and pancreatic metastatectomy in the management of metastatic renal cell carcinoma: A systematic review. Surgical Oncology 2022. [DOI: 10.1016/j.suronc.2022.101819] [Reference Citation Analysis]
230 Du K, Zou J, Wang B, Liu C, Khan M, Xie T, Huang X, Shen P, Tian Y, Yuan Y. A Metabolism-Related Gene Prognostic Index Bridging Metabolic Signatures and Antitumor Immune Cycling in Head and Neck Squamous Cell Carcinoma. Front Immunol 2022;13:857934. [DOI: 10.3389/fimmu.2022.857934] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
231 Noel J, Jouinot A, Alexandre J, Ulmann G, Bretagne M, Castel-ajgal Z, De Percin S, Vaquin-villeminey C, Revel M, Peyromaure M, Boudou-rouquette P, Arrondeau J, Gataa I, Durand J, Goldwasser F, Huillard O. Association of Energy Expenditure and Efficacy in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab. Cancers 2022;14:3214. [DOI: 10.3390/cancers14133214] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
232 Ding ZN, Meng GX, Xue JS, Yan LJ, Liu H, Yan YC, Chen ZQ, Hong JG, Wang DX, Dong ZR, Li T. Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis. J Cancer Res Clin Oncol 2022. [PMID: 35767193 DOI: 10.1007/s00432-022-04133-8] [Reference Citation Analysis]
233 Lalani AA, Heng DYC, Basappa NS, Wood L, Iqbal N, Mcleod D, Soulières D, Kollmannsberger C. Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review. Ther Adv Med Oncol 2022;14:175883592211086. [DOI: 10.1177/17588359221108685] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
234 Dong M, Yu T, Zhang Z, Zhang J, Wang R, Tse G, Liu T, Zhong L. ICIs-Related Cardiotoxicity in Different Types of Cancer. JCDD 2022;9:203. [DOI: 10.3390/jcdd9070203] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
235 Manenti S, Orrico M, Masciocchi S, Mandelli A, Finardi A, Furlan R. PD-1/PD-L Axis in Neuroinflammation: New Insights. Front Neurol 2022;13:877936. [PMID: 35756927 DOI: 10.3389/fneur.2022.877936] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
236 Liu R, Qiu K, Wu J, Jiang Y, Wu P, Pang J. Cost-effectiveness analysis of nivolumab plus cabozantinib versus sunitinib as first-line therapy in advanced renal cell carcinoma. Immunotherapy 2022. [PMID: 35754404 DOI: 10.2217/imt-2021-0156] [Reference Citation Analysis]
237 Sagie S, Sarfaty M, Levartovsky M, Gantz Sorotsky H, Berger R, Percik R, Gadot M. RCC Real-World Data: Prognostic Factors and Risk Stratification in the Immunotherapy Era. Cancers 2022;14:3127. [DOI: 10.3390/cancers14133127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
238 Maruzzo M, Pierantoni F, Bortolami A, Palleschi D, Zivi A, Nicodemo M, Sartori D, De Vivo R, Zustovich F, Bimbatti D, Pastorelli D, Vultaggio GD, Soraru' M, Ballestrin M, Modonesi C, Randisi P, Barile C, Perri G, Basso U, Zagonel V. Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study. Target Oncol 2022. [PMID: 35751733 DOI: 10.1007/s11523-022-00892-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
239 Liu YF, Zhang ZC, Wang SY, Fu SQ, Cheng XF, Chen R, Sun T. Immune checkpoint inhibitor-based therapy for advanced clear cell renal cell carcinoma: A narrative review. Int Immunopharmacol 2022;110:108900. [PMID: 35753122 DOI: 10.1016/j.intimp.2022.108900] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
240 Francolini G, Campi R, Di Cataldo V, Detti B, Loi M, Triggiani L, La Mattina S, Borghetti P, Magrini SM, Nicosia L, Alongi F, Ghirardelli P, Vavassori V, Allegra AG, Aquilano M, Scoccimarro E, Peruzzi A, Pastina P, Visani L, Desideri I, Serni S, Meattini I, Livi L. Impact of stereotactic body radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with metastatic kidney cancer concomitantly treated with immune checkpoint inhibitors: a preliminary, multicentre experience. Clin Transl Oncol 2022. [PMID: 35739349 DOI: 10.1007/s12094-022-02844-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
241 Liu WL, Zhang YQ, Li LT, Zhu YY, Ming ZH, Chen WL, Yang RQ, Li RH, Chen M, Zhang GJ. Application of molecular imaging in immune checkpoints therapy: From response assessment to prognosis prediction. Crit Rev Oncol Hematol 2022;176:103746. [PMID: 35752425 DOI: 10.1016/j.critrevonc.2022.103746] [Reference Citation Analysis]
242 Xia D, Liu Q, Yan S, Bi L. Construction of a Prognostic Model for KIRC and Identification of Drugs Sensitive to Therapies - A Comprehensive Biological Analysis Based on m6A-Related LncRNAs. Front Oncol 2022;12:895315. [PMID: 35719976 DOI: 10.3389/fonc.2022.895315] [Reference Citation Analysis]
243 Hamada K, Fujiwara R, Takemura K, Komai Y, Oguchi T, Numao N, Yamamoto S, Yonese J, Yuasa T. Tumor shrinkage patterns of nivolumab monotherapy in metastatic renal cell carcinoma. Int J Urol 2022. [PMID: 35717138 DOI: 10.1111/iju.14964] [Reference Citation Analysis]
244 Yu M, Liu X, Xu H, Shen S, Wang F, Chen D, Li G, Wang Z, Zuo Z, Zhao A. Comprehensive Evaluation of the m6A Regulator Prognostic Risk Score in the Prediction of Immunotherapy Response in Clear Cell Renal Cell Carcinoma. Front Immunol 2022;13:818120. [DOI: 10.3389/fimmu.2022.818120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
245 Viray H, McDermott DF, Einstein DJ. Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval. Expert Rev Anticancer Ther 2022;:1-8. [PMID: 35698870 DOI: 10.1080/14737140.2022.2088515] [Reference Citation Analysis]
246 Hasanov E, Yeboa DN, Tucker MD, Swanson TA, Beckham TH, Rini B, Ene CI, Hasanov M, Derks S, Smits M, Dudani S, Heng DYC, Brastianos PK, Bex A, Hanalioglu S, Weinberg JS, Hirsch L, Carlo MI, Aizer A, Brown PD, Bilen MA, Chang EL, Jaboin J, Brugarolas J, Choueiri TK, Atkins MB, McGregor BA, Halasz LM, Patel TR, Soltys SG, McDermott DF, Elder JB, Baskaya MK, Yu JB, Timmerman R, Kim MM, Mut M, Markert J, Beal K, Tannir NM, Samandouras G, Lang FF, Giles R, Jonasch E. An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma. CA Cancer J Clin 2022. [PMID: 35708940 DOI: 10.3322/caac.21729] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
247 Park BC, Jung S, Chen ST, Dewan AK, Johnson DB. Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors. Am J Clin Dermatol 2022. [PMID: 35708849 DOI: 10.1007/s40257-022-00706-y] [Reference Citation Analysis]
248 Halima A, Vuong W, Chan TA. Next-generation sequencing: unraveling genetic mechanisms that shape cancer immunotherapy efficacy. J Clin Invest 2022;132:e154945. [PMID: 35703181 DOI: 10.1172/JCI154945] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
249 Wang Q, Tang H, Luo X, Chen J, Zhang X, Li X, Li Y, Chen Y, Xu Y, Han S. Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma. Front Immunol 2022;13:890150. [PMID: 35686121 DOI: 10.3389/fimmu.2022.890150] [Reference Citation Analysis]
250 Mohsenzadegan M, Nowroozi MR, Fotovvat A, Bavandpour Baghshahi P, Bokaie S, Inanloo SH, Sharifi L. The prospect of targeting T cell immunoglobulin and mucin-domain containing-3 in renal cell carcinoma immunotherapy. Scand J Immunol 2022;:e13197. [PMID: 35700044 DOI: 10.1111/sji.13197] [Reference Citation Analysis]
251 Saygin D, Ghosh N, Reid P. Immune Checkpoint Inhibitor-Associated Myositis: A Distinct Form of Inflammatory Myopathy. J Clin Rheumatol 2022. [PMID: 35696731 DOI: 10.1097/RHU.0000000000001874] [Reference Citation Analysis]
252 Gill S, Nowak AK, Bowyer S, Endersby R, Ebert MA, Cook A. Clinical evidence for synergy between immunotherapy and radiotherapy (SITAR). J Med Imaging Radiat Oncol 2022. [PMID: 35699321 DOI: 10.1111/1754-9485.13441] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
253 Tullemans BME, Brouns SLN, Swieringa F, Sabrkhany S, van den Berkmortel FWPJ, Peters NAJB, de Bruijn P, Koolen SLW, Heemskerk JWM, Aarts MJB, Kuijpers MJE. Quantitative and qualitative changes in platelet traits of sunitinib-treated patients with renal cell carcinoma in relation to circulating sunitinib levels: a proof-of-concept study. BMC Cancer 2022;22:653. [PMID: 35698081 DOI: 10.1186/s12885-022-09676-0] [Reference Citation Analysis]
254 Long Y, Yu X, Chen R, Tong Y, Gong L. Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy. Front Immunol 2022;13:910704. [PMID: 35663968 DOI: 10.3389/fimmu.2022.910704] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
255 Wu Q, Luo S, Xie X. Lack of Efficacy of Immune Checkpoint Inhibitors in Cancer Patients Older Than 75? J Immunother 2022. [PMID: 35674663 DOI: 10.1097/CJI.0000000000000426] [Reference Citation Analysis]
256 Voss MH. Up-front Nivolumab With or Without Salvage Ipilimumab Across International Metastatic Database Consortium Risk Groups in Metastatic Clear Cell Renal Cell Carcinoma. J Clin Oncol 2022;:JCO2200834. [PMID: 35679526 DOI: 10.1200/JCO.22.00834] [Reference Citation Analysis]
257 Iikura Y, Aoyama T, Hiraide M, Wakatsuki T, Nakayama I, Ogura M, Ooki A, Takahari D, Chin K, Yamaguchi K, Hama T. Safety evaluation of fixed-dose nivolumab in patients with gastric cancer. Health Sci Rep 2022;5:e673. [PMID: 35662976 DOI: 10.1002/hsr2.673] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
258 Waddell T, Fife K, Griffiths R, Sharma A, Dhokia P, Groves L, Hurst M, Tsang C, Sugrue D, McKenna S, Houghton J, Carroll R. Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study. BMC Cancer 2022;22:617. [PMID: 35668384 DOI: 10.1186/s12885-022-09694-y] [Reference Citation Analysis]
259 Habashy KJ, Mansour R, Moussalem C, Sawaya R, Massaad MJ. Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them. Br J Cancer. [DOI: 10.1038/s41416-022-01864-w] [Reference Citation Analysis]
260 Tsuruta A, Shiiba Y, Matsunaga N, Fujimoto M, Yoshida Y, Koyanagi S, Ohdo S. Diurnal Expression of PD-1 on Tumor-Associated Macrophages Underlies the Dosing Time-Dependent Antitumor Effects of the PD-1/PD-L1 Inhibitor BMS-1 in B16/BL6 Melanoma-Bearing Mice. Mol Cancer Res 2022;20:972-82. [PMID: 35190830 DOI: 10.1158/1541-7786.MCR-21-0786] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
261 Storm BN, Abedian Kalkhoran H, Wilms EB, Brocken P, Codrington H, Houtsma D, Portielje JEA, de Glas N, van der Ziel D, van den Bos F, Visser LE. Real-life safety of PD-1 and PD-L1 inhibitors in older patients with cancer: An observational study. J Geriatr Oncol 2022:S1879-4068(22)00134-5. [PMID: 35668012 DOI: 10.1016/j.jgo.2022.05.013] [Reference Citation Analysis]
262 Motzer RJ, Powles T, Burotto M, Escudier B, Bourlon MT, Shah AY, Suárez C, Hamzaj A, Porta C, Hocking CM, Kessler ER, Gurney H, Tomita Y, Bedke J, Zhang J, Simsek B, Scheffold C, Apolo AB, Choueiri TK. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. The Lancet Oncology 2022. [DOI: 10.1016/s1470-2045(22)00290-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
263 Higgs EF, Bao R, Hatogai K, Gajewski TF. Wilms tumor reveals DNA repair gene hyperexpression is linked to lack of tumor immune infiltration. J Immunother Cancer 2022;10:e004797. [PMID: 35705315 DOI: 10.1136/jitc-2022-004797] [Reference Citation Analysis]
264 Kiss I, Kuhn M, Hrusak K, Buchler T. Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis. ESMO Open 2022;7:100474. [DOI: 10.1016/j.esmoop.2022.100474] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
265 Liu Y, Huang T, Shen L, Wu Y, Chen S, Fan W. Research progress on anti-tumor immune effect of cryoablation. Chin J Acad Radiol 2022;5:74-81. [DOI: 10.1007/s42058-022-00092-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
266 Saerens M, Kruse V, Lybaert W. Strategies to overcome relapse of immunotherapy-related hepatitis: dose reduction is not the key. Acta Clin Belg 2022;77:546-51. [PMID: 33754957 DOI: 10.1080/17843286.2021.1903662] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
267 Guha A, Sayegh N, Agarwal N. Targeting Cardiovascular Adverse Events of Metastatic Renal Cell Carcinoma Therapies. JACC: CardioOncology 2022;4:235-237. [DOI: 10.1016/j.jaccao.2022.05.007] [Reference Citation Analysis]
268 Nazzaro G, Buffon S, Giacalone S, Maronese CA, Marzano AV. Skin manifestations associated with checkpoint inhibitors. JEADV Clinical Practice 2022;1:73-87. [DOI: 10.1002/jvc2.27] [Reference Citation Analysis]
269 Nong C, Guan P, Li L, Zhang H, Hu H. Tumor immunotherapy: Mechanisms and clinical applications. MedComm – Oncology 2022;1. [DOI: 10.1002/mog2.8] [Reference Citation Analysis]
270 Lindskog M, Laurell A, Kjellman A, Melichar B, Rey PM, Zieliński H, Villacampa F, Bigot P, Zoltan B, Parikh O, Alba DV, Jellvert Å, Flaskó T, Gallardo E, Caparrós MJR, Purkalne G, Suenaert P, Karlsson-parra A, Ljungberg B. Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study. European Urology Open Science 2022;40:38-45. [DOI: 10.1016/j.euros.2022.03.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
271 Ganini C, Montanaro M, Scimeca M, Palmieri G, Anemona L, Concetti L, Melino G, Bove P, Amelio I, Candi E, Mauriello A. No Time to Die: How Kidney Cancer Evades Cell Death. IJMS 2022;23:6198. [DOI: 10.3390/ijms23116198] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
272 Chen C, Zhang C, Wu B, Xu T. Immune-related adverse events in older adults: Data mining of the FDA Adverse Event Reporting System. J Geriatr Oncol 2022:S1879-4068(22)00130-8. [PMID: 35660091 DOI: 10.1016/j.jgo.2022.05.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
273 Bessede A, Marabelle A, Guégan JP, Danlos FX, Cousin S, Peyraud F, Chaput N, Spalato M, Roubaud G, Cabart M, Khettab M, Chaibi A, Rey C, Nafia I, Mahon FX, Soria JC, Italiano A. Impact of acetaminophen on the efficacy of immunotherapy in cancer patients. Ann Oncol 2022:S0923-7534(22)01208-X. [PMID: 35654248 DOI: 10.1016/j.annonc.2022.05.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
274 Feng C, Lyu Y, Gong L, Wang J. Therapeutic Potential of Natural Products in the Treatment of Renal Cell Carcinoma: A Review. Nutrients 2022;14:2274. [DOI: 10.3390/nu14112274] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
275 Bootsma M, McKay RR, Emamekhoo H, Bade RM, Schehr JL, Mannino MC, Singh A, Wolfe SK, Schultz ZD, Sperger J, Xie W, Signoretti S, Kyriakopoulos CE, Kosoff D, Abel EJ, Helzer KT, Rydzewski N, Bakhtiar H, Shi Y, Blitzer G, Bassetti M, Floberg J, Yu M, Sethakorn N, Sharifi M, Harari PM, Choueiri TK, Lang JM, Zhao SG. Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma. J Clin Oncol 2022;:JCO2200219. [PMID: 35617646 DOI: 10.1200/JCO.22.00219] [Reference Citation Analysis]
276 Yekedüz E, Tural D, Ertürk İ, Karakaya S, Erol C, Ercelep Ö, Arslan Ç, Sever ÖN, Kılıçkap S, Şentürk Öztaş N, Küçükarda A, Can O, Öksüzoğlu B, Şendur MA, Karadurmuş N, Ürün Y. The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study. J Cancer Res Clin Oncol 2022. [PMID: 35616728 DOI: 10.1007/s00432-022-04055-5] [Reference Citation Analysis]
277 Xiang Z, Li J, Zhang Z, Cen C, Chen W, Jiang B, Meng Y, Wang Y, Berglund B, Zhai G, Wu J. Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis. Front Pharmacol 2022;13:883655. [DOI: 10.3389/fphar.2022.883655] [Reference Citation Analysis]
278 Zhong J, Liao X, Peng S, Cao J, Liu Y, Liu C, Qiu J, Guan X, Zhang Y, Liu X, Peng S. A Visualized Dynamic Prediction Model for Overall Survival in Elderly Patients With Pancreatic Cancer for Smart Medical Services. Front Public Health 2022;10:885624. [DOI: 10.3389/fpubh.2022.885624] [Reference Citation Analysis]
279 Jajodia A, Goel V, Patnaik N, Pasricha S, Gupta G, Batra U, Talwar V. Analysis of Spatial Heterogeneity of Responses in Metastatic Sites in Renal Cell Carcinoma Patients Treated with Nivolumab. Tomography 2022;8:1363-73. [DOI: 10.3390/tomography8030110] [Reference Citation Analysis]
280 Xie M, Dang Z, Sun X, Zhang B, Zhang Q, Tian Q, Cai J, Rao W. An analysis report on the application of immune checkpoint inhibitors after liver transplantation. Therapeutic Advances in Chronic Disease 2022;13:204062232210993. [DOI: 10.1177/20406223221099334] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
281 Liu Y, Ni M, Li L, Wang J, Tu Z, Zhou H, Zhang S. A novel four-gene signature predicts immunotherapy response of patients with different cancers. J Clin Lab Anal 2022;:e24494. [PMID: 35588138 DOI: 10.1002/jcla.24494] [Reference Citation Analysis]
282 Long AH, Morgenstern DA, Leruste A, Bourdeaut F, Davis KL. Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again. Am Soc Clin Oncol Educ Book 2022;42:1-14. [PMID: 35580293 DOI: 10.1200/EDBK_349799] [Reference Citation Analysis]
283 Li H, Sahu KK, Maughan BL. Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers. Cancers (Basel) 2022;14:2460. [PMID: 35626064 DOI: 10.3390/cancers14102460] [Reference Citation Analysis]
284 Tang L, Zhang M, Liu C. Advances in Nanotechnology-Based Immunotherapy for Glioblastoma. Front Immunol 2022;13:882257. [DOI: 10.3389/fimmu.2022.882257] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
285 Provencio M, Serna-Blasco R, Nadal E, Insa A, García-Campelo MR, Casal Rubio J, Dómine M, Majem M, Rodríguez-Abreu D, Martínez-Martí A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé Caro R, Viñolas N, Barneto Aranda I, Viteri S, Pereira E, Royuela A, Calvo V, Martín-López J, García-García F, Casarrubios M, Franco F, Sánchez-Herrero E, Massuti B, Cruz-Bermúdez A, Romero A. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial). J Clin Oncol 2022;:JCO2102660. [PMID: 35576508 DOI: 10.1200/JCO.21.02660] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
286 Chen X, Wu W, Wei W, Zou L. Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma. Front Pharmacol 2022;13:869488. [PMID: 35559250 DOI: 10.3389/fphar.2022.869488] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
287 Qu G, Wang D, Xu W, Guo W. Comprehensive Analysis of the Correlation Between Pyroptosis-Related LncRNAs and Tumor Microenvironment, Prognosis, and Immune Infiltration in Hepatocellular Carcinoma. Front Genet 2022;13:867627. [PMID: 35559014 DOI: 10.3389/fgene.2022.867627] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
288 Provencio M, Calvo V, Romero A, Spicer JD, Cruz-Bermúdez A. Treatment Sequencing in Resectable Lung Cancer: The Good and the Bad of Adjuvant Versus Neoadjuvant Therapy. Am Soc Clin Oncol Educ Book 2022;42:1-18. [PMID: 35561296 DOI: 10.1200/EDBK_358995] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
289 Lu K, Chiu KY, Cheng CL. Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution. Cancer Treat Res 2022;183:201-23. [PMID: 35551661 DOI: 10.1007/978-3-030-96376-7_7] [Reference Citation Analysis]
290 Minichsdorfer C, Gleiss A, Aretin MB, Schmidinger M, Fuereder T. Serum parameters as prognostic biomarkers in a real world cancer patient population treated with anti PD-1/PD-L1 therapy. Ann Med 2022;54:1339-49. [PMID: 35535695 DOI: 10.1080/07853890.2022.2070660] [Reference Citation Analysis]
291 Ingels A, Campi R, Capitanio U, Amparore D, Bertolo R, Carbonara U, Erdem S, Kara Ö, Klatte T, Kriegmair MC, Marchioni M, Mir MC, Ouzaïd I, Pavan N, Pecoraro A, Roussel E, de la Taille A. Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma. Nat Rev Urol 2022. [PMID: 35546184 DOI: 10.1038/s41585-022-00592-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
292 Wang H, Li C, Yang R, Jin J, Liu D, Li W. Prognostic value of the platelet-to-lymphocyte ratio in lung cancer patients receiving immunotherapy: A systematic review and meta-analysis. PLoS One 2022;17:e0268288. [PMID: 35522679 DOI: 10.1371/journal.pone.0268288] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
293 Whooley J, Alazzawi M, Donlon NE, Bolger JC, Robb WB. PD-1 inhibitors in esophageal cancer: a systematic review of the oncological outcomes associated with PD-1 blockade and the evolving therapeutic paradigm. Dis Esophagus 2022;35:doab063. [PMID: 34553222 DOI: 10.1093/dote/doab063] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
294 Jee B, Seo E, Park K, Kim YR, Byeon SJ, Lee SM, Chung JH, Song W, Sung HH, Jeon HG, Jeong BC, Seo SI, Jeon SS, Lee HM, Park SH, Park WY, Kang M. Molecular Subtypes Based on Genomic and Transcriptomic Features Correlate with the Responsiveness to Immune Checkpoint Inhibitors in Metastatic Clear Cell Renal Cell Carcinoma. Cancers (Basel) 2022;14:2354. [PMID: 35625960 DOI: 10.3390/cancers14102354] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
295 Bai Y, Pei Y, Xia L, Ma L, Deng S. A Novel Immune-Prognosis Index Predicts the Benefit of Lung Adenocarcinoma Patients. Front Pharmacol 2022;13:818170. [DOI: 10.3389/fphar.2022.818170] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
296 Pham NB, Abraham N, Velankar KY, Schueller NR, Philip EJ, Jaber Y, Gawalt ES, Fan Y, Pal SK, Meng WS. Localized PD-1 Blockade in a Mouse Model of Renal Cell Carcinoma. Front Drug Deliv 2022;2. [DOI: 10.3389/fddev.2022.838458] [Reference Citation Analysis]
297 Dong H, Qi Y, Kong X, Wang Z, Fang Y, Wang J. PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism. Front Pharmacol 2022;13:835510. [PMID: 35517794 DOI: 10.3389/fphar.2022.835510] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
298 Yang J, Zhou Y, Li Y, Hu W, Yuan C, Chen S, Ye G, Chen Y, Wu Y, Liu J, Wang Y, Du J, Tong X. Functional deficiency of succinate dehydrogenase promotes tumorigenesis and development of clear cell renal cell carcinoma through weakening of ferroptosis. Bioengineered 2022;13:11187-207. [PMID: 35510387 DOI: 10.1080/21655979.2022.2062537] [Reference Citation Analysis]
299 Glass EB, Hoover AA, Bullock KK, Madden MZ, Reinfeld BI, Harris W, Parker D, Hufnagel DH, Crispens MA, Khabele D, Rathmell WK, Rathmell JC, Wilson AJ, Giorgio TD, Yull FE. Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer. BMC Cancer 2022;22:497. [PMID: 35513776 DOI: 10.1186/s12885-022-09612-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
300 Guven DC, Stephen B, Sahin TK, Cakir IY, Erul E, Aksoy S. The Efficacy of Immune Checkpoint Inhibitors in Rare Tumors: A Systematic Review of Published Clinical Trials. Crit Rev Oncol Hematol 2022;:103700. [PMID: 35533815 DOI: 10.1016/j.critrevonc.2022.103700] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
301 Basso U, Paolieri F, Rizzo M, De Giorgi U, Bracarda S, Antonuzzo L, Atzori F, Cartenì G, Procopio G, Fratino L, D’arcangelo M, Fornarini G, Zucali P, Cusmai A, Santoni M, Pipitone S, Carella C, Panni S, Deppieri FM, Zagonel V, Tortora G. Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study. Cancers 2022;14:2293. [DOI: 10.3390/cancers14092293] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
302 De Biasi S, Guida A, Lo Tartaro D, Fanelli M, Depenni R, Dominici M, Finak G, Porta C, Paolini A, Borella R, Bertoldi C, Cossarizza A, Sabbatini R, Gibellini L. Redistribution of CD8+ T cell subsets in metastatic renal cell carcinoma patients treated with anti-PD-1 therapy. Cytometry A 2022. [PMID: 35507402 DOI: 10.1002/cyto.a.24562] [Reference Citation Analysis]
303 Kuusisalo S, Koivunen JP, Iivanainen S. Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study. Cancers (Basel) 2022;14:2276. [PMID: 35565405 DOI: 10.3390/cancers14092276] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
304 Jiang Q, Huang J, Zhang B, Li X, Chen X, Cui B, Li S, Guo G. Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis. Front Immunol 2022;13:801909. [PMID: 35309350 DOI: 10.3389/fimmu.2022.801909] [Reference Citation Analysis]
305 Shao J, Liu Q, Shen J, Qian X, Yan J, Zhu Y, Qiu X, Lu C, Cen L, Tian M, Du J, Liu B. Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report. Front Immunol 2022;13:799026. [PMID: 35273594 DOI: 10.3389/fimmu.2022.799026] [Reference Citation Analysis]
306 Xavier CB, Lopes CDH, Harada G, Peres EDB, Katz A, Jardim DL. Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis. Translational Oncology 2022;19:101383. [DOI: 10.1016/j.tranon.2022.101383] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
307 Bian Y, Liu YF, Li J, Liu F, Fang X, Lu J, Shao C. Machine Learning for Computed Tomography Radiomics: Prediction of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma. Pancreas 2022;51:549-58. [PMID: 35877153 DOI: 10.1097/MPA.0000000000002069] [Reference Citation Analysis]
308 Flippot R, Gorgeu V, Pujalte M, Colomba E, Alves C, Cerbone L, Carril L, Derosa L, Escudier B, Albigès L. Therapeutic sequencing in the era of first-line immune checkpoint inhibitor combinations, a novel challenge in patients with metastatic clear-cell renal cell carcinoma. Bulletin du Cancer 2022;109:2S31-2S38. [DOI: 10.1016/s0007-4551(22)00236-3] [Reference Citation Analysis]
309 Jiang X, Wang J, Zheng X, Liu Z, Zhang X, Li Y, Wilhelm J, Cao J, Huang G, Zhang J, Sumer B, Lea J, Lu Z, Gao J, Luo M. Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy. J Immunother Cancer 2022;10:e003960. [PMID: 35623658 DOI: 10.1136/jitc-2021-003960] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
310 Xiao M, Xie L, Cao G, Lei S, Wang P, Wei Z, Luo Y, Fang J, Yang X, Huang Q, Xu L, Guo J, Wen S, Wang Z, Wu Q, Tang J, Wang L, Chen X, Chen C, Zhang Y, Yao W, Ye J, He R, Huang J, Ye L. CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy. J Immunother Cancer 2022;10:e004022. [PMID: 35580929 DOI: 10.1136/jitc-2021-004022] [Reference Citation Analysis]
311 Neuenschwander B, Roychoudhury S, Wandel S, Natarajan K, Zuber E. The Predictive Individual Effect for Survival Data. Ther Innov Regul Sci 2022;56:492-500. [PMID: 35294767 DOI: 10.1007/s43441-022-00386-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
312 Zapała Ł, Kunc M, Sharma S, Pęksa R, Popęda M, Biernat W, Radziszewski P. Evaluation of PD-L1 (E1L3N, 22C3) expression in venous tumor thrombus is superior to its assessment in renal tumor in predicting overall survival in renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 2022;40:200.e1-200.e10. [DOI: 10.1016/j.urolonc.2022.02.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
313 Fattizzo B, Rampi N, Barcellini W. Hematological and Extra-Hematological Autoimmune Complications after Checkpoint Inhibitors. Pharmaceuticals 2022;15:557. [DOI: 10.3390/ph15050557] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
314 Song L, Liu S, Zhao S. Everolimus (RAD001) combined with programmed death-1 (PD-1) blockade enhances radiosensitivity of cervical cancer and programmed death-ligand 1 (PD-L1) expression by blocking the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) pathway. Bioengineered 2022;13:11240-57. [PMID: 35485300 DOI: 10.1080/21655979.2022.2064205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
315 Cascallar M, Alijas S, Pensado-lópez A, Vázquez-ríos AJ, Sánchez L, Piñeiro R, de la Fuente M. What Zebrafish and Nanotechnology Can Offer for Cancer Treatments in the Age of Personalized Medicine. Cancers 2022;14:2238. [DOI: 10.3390/cancers14092238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
316 Aragon-Ching JB. Rapidly evolving first-line therapy using checkpoint inhibitors in metastatic renal cell cancer. Future Med Chem 2022. [PMID: 35481395 DOI: 10.4155/fmc-2021-0301] [Reference Citation Analysis]
317 Serzan M, Atkins MB. Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab. Expert Rev Anticancer Ther 2022. [PMID: 35483033 DOI: 10.1080/14737140.2022.2072300] [Reference Citation Analysis]
318 Mudassar F, Shen H, Cook KM, Hau E. Improving the synergistic combination of programmed death‐1/programmed death ligand‐1 blockade and radiotherapy by targeting the hypoxic tumour microenvironment. J Med Imag Rad Onc. [DOI: 10.1111/1754-9485.13416] [Reference Citation Analysis]
319 Zhanghuang C, Wang J, Yao Z, Li L, Xie Y, Tang H, Zhang K, Wu C, Yang Z, Yan B. Development and Validation of a Nomogram to Predict Cancer-Specific Survival in Elderly Patients With Papillary Renal Cell Carcinoma. Front Public Health 2022;10:874427. [PMID: 35444972 DOI: 10.3389/fpubh.2022.874427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
320 de Joode K, van de Geer W, van Leenders G, Hamberg P, Westgeest H, Beeker A, Oosting S, van Rooijen J, Beerepoot L, Labots M, Mathijssen R, Lolkema M, Cuppen E, Sleijfer S, van de Werken H, van der Veldt A. Genomic and transcriptomic landscape of advanced renal cell cancer to individualize treatment strategy.. [DOI: 10.1101/2022.04.22.488773] [Reference Citation Analysis]
321 Msaouel P, Goswami S, Thall PF, Wang X, Yuan Y, Jonasch E, Gao J, Campbell MT, Shah AY, Corn PG, Tam AL, Ahrar K, Rao P, Sircar K, Cohen L, Basu S, Duan F, Jindal S, Zhang Y, Chen H, Yadav SS, Shazer R, Der-Torossian H, Allison JP, Sharma P, Tannir NM. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med 2022;14:eabm6420. [PMID: 35442707 DOI: 10.1126/scitranslmed.abm6420] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
322 Uemura H, Tomita Y, Nonomura N, Yoshizaki K, Nakao T, Shinohara N. Real-world safety and effectiveness of nivolumab for advanced renal cell carcinoma in Japan: a post-marketing surveillance. Int J Clin Oncol 2022. [PMID: 35441907 DOI: 10.1007/s10147-022-02155-3] [Reference Citation Analysis]
323 Sebastian M, Divita Dean B, T. Flores C. Immunotherapy against Gliomas. Brain Tumors 2022. [DOI: 10.5772/intechopen.101386] [Reference Citation Analysis]
324 Atkins MB, Jegede OA, Haas NB, McDermott DF, Bilen MA, Stein M, Sosman JA, Alter R, Plimack ER, Ornstein M, Hurwitz M, Peace DJ, Signoretti S, Denize T, Cimadamore A, Wu CJ, Braun D, Einstein D, Catalano PJ, Hammers H. Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). J Clin Oncol 2022;:JCO2102938. [PMID: 35442713 DOI: 10.1200/JCO.21.02938] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
325 Nakano R, Shiomi H, Fujiwara A, Yoshihara K, Yoshioka R, Kawata S, Ota S, Yuri Y, Takashima T, Aizawa N, Ikeda N, Nishimura T, Enomoto H, Iijima H. Clinical Characteristics of ICI-Related Pancreatitis and Cholangitis Including Radiographic and Endoscopic Findings. Healthcare 2022;10:763. [DOI: 10.3390/healthcare10050763] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
326 Zeng X, Li L, Hu Z, Peng D. Integrated Multi-Omics Analysis Identified PTPRG and CHL1 as Key Regulators of Immunophenotypes in Clear Cell Renal Cell Carcinoma(ccRCC). Front Oncol 2022;12:832027. [PMID: 35433461 DOI: 10.3389/fonc.2022.832027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
327 Kato K, Mizuno T, Koseki T, Ito Y, Takahashi K, Tsuboi N, Yamada S. Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database. Front Pharmacol 2022;13:803706. [PMID: 35401222 DOI: 10.3389/fphar.2022.803706] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
328 van Laar SA, Gombert-Handoko KB, Groenwold RHH, van der Hulle T, Visser LE, Houtsma D, Guchelaar HJ, Zwaveling J. Real-World Metastatic Renal Cell Carcinoma Treatment Patterns and Clinical Outcomes in The Netherlands. Front Pharmacol 2022;13:803935. [PMID: 35401238 DOI: 10.3389/fphar.2022.803935] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
329 Fusco R, Simonetti I, Ianniello S, Villanacci A, Grassi F, Dell’aversana F, Grassi R, Cozzi D, Bicci E, Palumbo P, Borgheresi A, Giovagnoni A, Miele V, Barile A, Granata V. Pulmonary Lymphangitis Poses a Major Challenge for Radiologists in an Oncological Setting during the COVID-19 Pandemic. JPM 2022;12:624. [DOI: 10.3390/jpm12040624] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
330 Chen C, Chen Y, Jin X, Ding Y, Jiang J, Wang H, Yang Y, Lin W, Chen X, Huang Y, Teng L. Identification of Tumor Mutation Burden, Microsatellite Instability, and Somatic Copy Number Alteration Derived Nine Gene Signatures to Predict Clinical Outcomes in STAD. Front Mol Biosci 2022;9:793403. [DOI: 10.3389/fmolb.2022.793403] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
331 Liu Y, Xu Y, Cheng X, Lin Y, Jiang S, Yu H, Zhang Z, Lu L, Zhang X. Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis. Front Immunol 2022;13:862084. [DOI: 10.3389/fimmu.2022.862084] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
332 Holm JS, Funt SA, Borch A, Munk KK, Bjerregaard A, Reading JL, Maher C, Regazzi A, Wong P, Al-ahmadie H, Iyer G, Tamhane T, Bentzen AK, Herschend NO, De Wolf S, Snyder A, Merghoub T, Wolchok JD, Nielsen M, Rosenberg JE, Bajorin DF, Hadrup SR. Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma. Nat Commun 2022;13. [DOI: 10.1038/s41467-022-29342-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
333 Numakura K, Nakai Y, Kojima T, Osawa T, Narita S, Nakayama M, Kitamura H, Nishiyama H, Shinohara N. Overview of clinical management for older patients with renal cell carcinoma. Jpn J Clin Oncol 2022:hyac047. [PMID: 35397166 DOI: 10.1093/jjco/hyac047] [Reference Citation Analysis]
334 Kim JH, Ryu M, Park YS, Ma J, Lee SY, Kim D, Kang Y. Predictive biomarkers for the efficacy of nivolumab as ≥ 3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09488-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
335 Moser K, Soto M, Geba D, Allen P, Lindpaintner K. Clinicians’ perspective on use of immune checkpoint inhibitors and related biomarkers for solid tumors.. [DOI: 10.1101/2022.04.01.22269254] [Reference Citation Analysis]
336 Yuasa T, Urasaki T, Oki R. Recent Advances in Medical Therapy for Urological Cancers. Front Oncol 2022;12:746922. [DOI: 10.3389/fonc.2022.746922] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
337 Ishihara H, Nemoto Y, Tachibana H, Fukuda H, Yoshida K, Kobayashi H, Iizuka J, Hashimoto Y, Takagi T, Ishida H, Kondo T, Tanabe K. Outcomes of nivolumab monotherapy for previously treated metastatic renal cell carcinoma: a real-world multi-institution data with a minimum of 2 years of follow-up. Jpn J Clin Oncol 2022:hyac044. [PMID: 35373823 DOI: 10.1093/jjco/hyac044] [Reference Citation Analysis]
338 Obinata D. Update on Treatment of Renal Cell Carcinoma. Nichidai Igaku Zasshi 2022;81:77-81. [DOI: 10.4264/numa.81.2_77] [Reference Citation Analysis]
339 Vano Y, Elaidi R, Bennamoun M, Chevreau C, Borchiellini D, Pannier D, Maillet D, Gross-goupil M, Tournigand C, Laguerre B, Barthélémy P, Coquan E, Gravis G, Houede N, Cancel M, Huillard O, Beuzeboc P, Fournier L, Méjean A, Cathelineau X, Doumerc N, Paparel P, Bernhard J, de la Taille A, Bensalah K, Tricard T, Waeckel T, Pignot G, Braychenko E, Caruso S, Sun C, Verkarre V, Lacroix G, Moreira M, Meylan M, Bougouïn A, Phan L, Thibault-carpentier C, Zucman-rossi J, Fridman WH, Sautès-fridman C, Oudard S. Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. The Lancet Oncology 2022. [DOI: 10.1016/s1470-2045(22)00128-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 12.0] [Reference Citation Analysis]
340 Tosello J, Borcoman E, Sedlik C, Piaggio E. Le rôle des ganglions lymphatiques drainant la tumeur à l’ère des immunothérapies. Bulletin de l'Académie Nationale de Médecine 2022;206:485-495. [DOI: 10.1016/j.banm.2021.11.025] [Reference Citation Analysis]
341 Tannir NM, Cho DC, Diab A, Sznol M, Bilen MA, Balar AV, Grignani G, Puente E, Tang L, Chien D, Hoch U, Choudhury A, Yu D, Currie SL, Tagliaferri MA, Zalevsky J, Siefker-Radtke AO, Hurwitz ME. Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study. J Immunother Cancer 2022;10:e004419. [PMID: 35444058 DOI: 10.1136/jitc-2021-004419] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
342 Cherny N, Dafni U, Pentheroudakis G, Piccart M, Zygoura P, Gyawali B, de Vries E. “The first ones now, will later be last”: understanding the importance of historical context when reading ESMO-MCBS scores. ESMO Open 2022;7:100413. [DOI: 10.1016/j.esmoop.2022.100413] [Reference Citation Analysis]
343 Farooq MZ, Aqeel SB, Lingamaneni P, Pichardo RC, Jawed A, Khalid S, Banskota SU, Fu P, Mangla A. Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events: A Systematic Review and Meta-analysis. JAMA Netw Open 2022;5:e227722. [PMID: 35438755 DOI: 10.1001/jamanetworkopen.2022.7722] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
344 Mar N, Uchio E, Kalebasty AR. Use of Immunotherapy in Clinical Management of Genitourinary Cancers – a Review. Cancer Treatment and Research Communications 2022. [DOI: 10.1016/j.ctarc.2022.100564] [Reference Citation Analysis]
345 Pan Z, Chen J, Xiao X, Xie Y, Jiang H, Zhang B, Lu H, Yuan Y, Han L, Zhou Y, Zong H, Wang L, Sun R, Zhu J. Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement. Acta Pharmaceutica Sinica B 2022;12:1928-42. [DOI: 10.1016/j.apsb.2021.10.028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
346 Shi Y, Zhang Q, Bi H, Lu M, Tan Y, Zou D, Ge L, Chen Z, Liu C, Ci W, Ma L. Decoding the multicellular ecosystem of vena caval tumor thrombus in clear cell renal cell carcinoma by single-cell RNA sequencing. Genome Biol 2022;23:87. [PMID: 35361264 DOI: 10.1186/s13059-022-02651-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
347 Vilaça M, Braga F, Mesquita A. Cutaneous Metastases and Long-Term Survival of a Patient With Clear Cell Renal Carcinoma. Cureus 2022. [DOI: 10.7759/cureus.23598] [Reference Citation Analysis]
348 Yuan B, Wang G, Tang X, Tong A, Zhou L. Immunotherapy of glioblastoma: recent advances and future prospects. Hum Vaccin Immunother 2022;:1-16. [PMID: 35344682 DOI: 10.1080/21645515.2022.2055417] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
349 Starzer AM, Heller G, Tomasich E, Melchardt T, Feldmann K, Hatziioannou T, Traint S, Minichsdorfer C, Schwarz-Nemec U, Nackenhorst M, Müllauer L, Preusser M, Berghoff AS, Fuereder T. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma. J Immunother Cancer 2022;10:e003420. [PMID: 35338086 DOI: 10.1136/jitc-2021-003420] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
350 Naito S, Kato T, Tsuchiya N. Surgical and focal treatment for metastatic renal cell carcinoma: A literature review. Int J Urol 2022. [PMID: 35340081 DOI: 10.1111/iju.14841] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
351 Zhang S, Xu X, Chen J, Zhang Z, Liu F, Zhong WL. Efficacy and Safety of Nivolumab for Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Journal of Oncology 2022;2022:1-5. [DOI: 10.1155/2022/5430525] [Reference Citation Analysis]
352 Grumberg V, Roze S, Chevalier J, Borrill J, Gaudin AF, Branchoux S. A Review of Overall Survival Extrapolations of Immune-Checkpoint Inhibitors Used in Health Technology Assessments by the French Health Authorities. Int J Technol Assess Health Care 2022;38:e28. [PMID: 35331347 DOI: 10.1017/S0266462322000125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
353 Zhang J, Wang H, Yuan C, Wu J, Xu J, Chen S, Zhang C, He Y. ITGAL as a Prognostic Biomarker Correlated With Immune Infiltrates in Gastric Cancer. Front Cell Dev Biol 2022;10:808212. [DOI: 10.3389/fcell.2022.808212] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
354 Deng J, Zhou M, Liao T, Kuang W, Xia H, Yin Z, Tan Q, Li Y, Song S, Zhou E, Jin Y. Targeting Cancer Cell Ferroptosis to Reverse Immune Checkpoint Inhibitor Therapy Resistance. Front Cell Dev Biol 2022;10:818453. [DOI: 10.3389/fcell.2022.818453] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
355 Masuda T, Tanaka N, Takamatsu K, Hakozaki K, Takahashi R, Anno T, Kufukihara R, Shojo K, Mikami S, Shinojima T, Kakimi K, Tsunoda T, Aimono E, Nishihara H, Mizuno R, Oya M. Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer. J Immunother Cancer 2022;10:e003883. [PMID: 35314433 DOI: 10.1136/jitc-2021-003883] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
356 Han B, Zhen F, Zheng XS, Hu J, Chen XS. Systematic analysis of the expression and prognostic value of ITPR1 and correlation with tumor infiltrating immune cells in breast cancer. BMC Cancer 2022;22:297. [PMID: 35313846 DOI: 10.1186/s12885-022-09410-w] [Reference Citation Analysis]
357 Roviello G, Gambale E, Giorgione R, Santini D, Stellato M, Fornarini G, Rebuzzi SE, Basso U, Bimbatti D, Doni L, Nesi G, Bersanelli M, Buti S, De Giorgi U, Galli L, Sbrana A, Conca R, Carella C, Naglieri E, Pignata S, Procopio G, Antonuzzo L. Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study. Cancer Med 2022. [PMID: 35312175 DOI: 10.1002/cam4.4681] [Reference Citation Analysis]
358 Motzer RJ, Choueiri TK, McDermott DF, Powles T, Vano YA, Gupta S, Yao J, Han C, Ammar R, Papillon-Cavanagh S, Saggi SS, McHenry MB, Ross-Macdonald P, Wind-Rotolo M. Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. J Immunother Cancer 2022;10:e004316. [PMID: 35304405 DOI: 10.1136/jitc-2021-004316] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
359 Yang Y, Psutka SP, Parikh AB, Li M, Collier K, Miah A, Mori SV, Hinkley M, Tykodi SS, Hall E, Thompson JA, Yin M. Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma. Cancer Med 2022. [PMID: 35304832 DOI: 10.1002/cam4.4679] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
360 Ciraolo E, Althoff S, Ruß J, Rosnev S, Butze M, Pühl M, Frentsch M, Bullinger L, Na IK. Simultaneous Genetic Ablation of PD-1, LAG-3, and TIM-3 in CD8 T Cells Delays Tumor Growth and Improves Survival Outcome. Int J Mol Sci 2022;23:3207. [PMID: 35328630 DOI: 10.3390/ijms23063207] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
361 Yaseen MM, Abuharfeil NM, Darmani H. CMTM6 as a master regulator of PD-L1. Cancer Immunol Immunother 2022. [PMID: 35294592 DOI: 10.1007/s00262-022-03171-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
362 Fang C, Zhong R, Qiu C, Zou BB. The Prognostic Value of GNG7 in Colorectal Cancer and Its Relationship With Immune Infiltration. Front Genet 2022;13:833013. [PMID: 35281820 DOI: 10.3389/fgene.2022.833013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
363 Alimohammadi A, Fajkovic H, Remzi M, Shariat S, Schmidinger M. Recent pharmacological approaches for the treatment of renal cell carcinoma. Expert Rev Clin Pharmacol 2022. [PMID: 35285369 DOI: 10.1080/17512433.2022.2053521] [Reference Citation Analysis]
364 Yaseen MM, Abuharfeil NM, Darmani H. The clinical and prognostic significance of CMTM6/PD-L1 in oncology. Clin Transl Oncol 2022. [PMID: 35278198 DOI: 10.1007/s12094-022-02811-0] [Reference Citation Analysis]
365 Sager RA, Backe SJ, Ahanin E, Smith G, Nsouli I, Woodford MR, Bratslavsky G, Bourboulia D, Mollapour M. Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma. Nat Rev Urol 2022. [PMID: 35264774 DOI: 10.1038/s41585-022-00571-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
366 Kasherman L, Siu DHW, Woodford R, Harris CA. Angiogenesis Inhibitors and Immunomodulation in Renal Cell Cancers: The Past, Present, and Future. Cancers (Basel) 2022;14:1406. [PMID: 35326557 DOI: 10.3390/cancers14061406] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
367 Alban TJ, Grabowski MM, Otvos B, Bayik D, Zalavadia A, Makarov V, Troike K, Mcgraw M, Rabljenovic A, Lauko A, Neumann C, Roversi G, Waite KA, Cioffi G, Patil N, Tran TT, Mccortney K, Steffens A, Diaz CM, Brown JM, Egan KM, Horbinski CM, Barnholtz-sloan JS, Vogelbaum MA, Bucala R, Chan TA, Ahluwalia MS, Lathia JD. The MIF SNP rs755622 is a germline determinant of tumor immune activation in Glioblastoma.. [DOI: 10.1101/2022.03.07.483365] [Reference Citation Analysis]
368 Hasegawa H, Shitara K, Takiguchi S, Takiguchi N, Ito S, Kochi M, Horinouchi H, Kinoshita T, Yoshikawa T, Muro K, Nishikawa H, Suna H, Kodera Y. A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer. Gastric Cancer 2022. [PMID: 35254550 DOI: 10.1007/s10120-022-01286-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
369 Chen YW, Rini BI. Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma. Curr Oncol Rep 2022. [PMID: 35247142 DOI: 10.1007/s11912-022-01196-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
370 Yang X, Ma L, Zhang X, Huang L, Wei J. Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia. Exp Hematol Oncol 2022;11:11. [PMID: 35236415 DOI: 10.1186/s40164-022-00263-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
371 Sun X, Song Z, Jiang H, Ma Y, Chen M. Image classification of immune checkpoint inhibitor–related pneumonia in lung cancer patients. Clinical Imaging 2022. [DOI: 10.1016/j.clinimag.2022.03.012] [Reference Citation Analysis]
372 Rodrigues S, Figueiredo C. Recent insights into the use of immune checkpoint inhibitors in gastric cancer. Porto Biomedical Journal 2022;7:e162. [DOI: 10.1097/j.pbj.0000000000000162] [Reference Citation Analysis]
373 Fontes-Sousa M, Magalhães H, Oliveira A, Carneiro F, Dos Reis FP, Madeira PS, Meireles S. Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor (TKI) Monotherapy? Adv Ther 2022;39:1107-25. [PMID: 35025061 DOI: 10.1007/s12325-021-02007-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
374 Zhao L, Li T, Song Y, Yang Y, Ma B, Zhang Y, Shang Y, Xu B, Guo J, Qin P, Han L, Fu X, Lin H, Liu L, Ren X, Wang Z, Gao Q. High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study. Front Immunol 2021;12:779248. [PMID: 35058923 DOI: 10.3389/fimmu.2021.779248] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
375 Jin S, Liu C, Shi G, Mu Y, Zhang H, Zhu Y, Su H, Ye D. IL-1A is associated with postoperative survival and immune contexture in clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 2022;40:111.e1-111.e9. [DOI: 10.1016/j.urolonc.2021.11.029] [Reference Citation Analysis]
376 Wang H, Rong X, Zhao G, Zhou Y, Xiao Y, Ma D, Jin X, Wu Y, Yan Y, Yang H, Zhou Y, Qian M, Niu C, Hu X, Li D, Liu Q, Wen Y, Jiang Y, Zhao C, Shao Z. The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer. Cell Metabolism 2022. [DOI: 10.1016/j.cmet.2022.02.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
377 Luo Q, Zhang Y, Wang Z, Sun Y, Shi L, Yu Y, Shi J, Hu Z, Wang F. A novel peptide-based probe 99mTc-PEG6-RD-PDP2 for the molecular imaging of tumor PD-L2 expression. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.02.068] [Reference Citation Analysis]
378 Wei B, Feng H, Wu H. Reduced CCR2 Can Improve the Prognosis of Sarcoma by Remodeling the Tumor Microenvironment. IJGM 2022;Volume 15:3043-53. [DOI: 10.2147/ijgm.s349295] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
379 Maisel F, Smolle MA, Mollnar S, Riedl JM, Barth DA, Seles M, Terbuch A, Rossmann CH, Eisner F, Mannweiler S, Hutterer G, Zigeuner R, Pummer K, Smolle-jüttner F, Lindenmann J, Stotz M, Gerger A, Jost PJ, Bauernhofer T, Pichler M, Posch F. Benefit of metastasectomy in renal cell carcinoma: A propensity score analysis. Clinical Genitourinary Cancer 2022. [DOI: 10.1016/j.clgc.2022.03.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
380 Walia HK, Sharma P, Singh N, Sharma S. Immunotherapy in Small Cell Lung Cancer Treatment: a Promising Headway for Future Perspective. Curr Treat Options Oncol 2022. [PMID: 35226309 DOI: 10.1007/s11864-022-00949-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
381 Bai S, Chen L, Yan Y, Wang X, Jiang A, Li R, Kang H, Feng Z, Li G, Ma W, Zhang J, Ren J. Identification of Hypoxia-Immune-Related Gene Signatures and Construction of a Prognostic Model in Kidney Renal Clear Cell Carcinoma. Front Cell Dev Biol 2021;9:796156. [PMID: 35211477 DOI: 10.3389/fcell.2021.796156] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
382 Zhai D, An D, Wan C, Yang K. Radiotherapy: Brightness and darkness in the era of immunotherapy. Transl Oncol 2022;19:101366. [PMID: 35219093 DOI: 10.1016/j.tranon.2022.101366] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
383 Studentova H, Zemankova A, Spisarova M, Skanderova D, Tudos Z, Melichar B, Student V. A Pathological Complete Response to the Combination of Ipilimumab and Nivolumab in a Patient with Metastatic Renal Cell Carcinoma. Medicina 2022;58:336. [DOI: 10.3390/medicina58030336] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
384 An Y, Li X, Yao F, Duan J, Yang XD. Novel Complex of PD-L1 Aptamer and Albumin Enhances Antitumor Efficacy In Vivo. Molecules 2022;27:1482. [PMID: 35268583 DOI: 10.3390/molecules27051482] [Reference Citation Analysis]
385 Kopecký J, Kubeček O, Kyllarová A, Priester P. Adverse effects of combination immunotherapy in renal cancer, lung cancer, and melanoma. Onkologie 2022;16:10-15. [DOI: 10.36290/xon.2022.002] [Reference Citation Analysis]
386 dos Reis AFP, Simão D, Odeny T, Rodrigues C, Fontes-sousa M, Luz RD, Chowdry RP, Welsh SJ, Paller C, Barata PC. A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer. KCA 2022. [DOI: 10.3233/kca-210012] [Reference Citation Analysis]
387 Pal SK, Puente J, Heng DYC, Glen H, Koralewski P, Stroyakovskiy D, Alekseev B, Parnis F, Castellano D, Ciuleanu T, Lee JL, Sunela K, O'Hara K, Binder TA, Peng L, Smith AD, Rha SY. Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial. Eur Urol 2022:S0302-2838(21)02272-7. [PMID: 35210132 DOI: 10.1016/j.eururo.2021.12.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
388 Zhang H, Chen J, Zhang X, Zhu X, Wang Z, Sun G, Liang J, Chen Y, Shen Y, Liu J, Li X, Wei Q, Liu Z, Zeng H, Shen P. Efficacy of second-line ICIs combined with TKIs among patients with metastatic renal cell carcinoma: a real-world study. Immunotherapy 2022. [PMID: 35187953 DOI: 10.2217/imt-2021-0108] [Reference Citation Analysis]
389 Yoshida T, Tanaka T, Shindo T, Kyoda Y, Hashimoto K, Kobayashi K, Hasegawa T, Masumori N. A case of metastatic Xp11.2 translocation renal cell carcinoma showing a prolonged response to nivolumab as 6th-line treatment. Int Canc Conf J. [DOI: 10.1007/s13691-022-00536-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
390 Saiga K, Ohe C, Yoshida T, Ohsugi H, Ikeda J, Atsumi N, Noda Y, Yasukochi Y, Higasa K, Taniguchi H, Kinoshita H, Tsuta K. PBRM1 Immunohistochemical Expression Profile Correlates with Histomorphological Features and Endothelial Expression of Tumor Vasculature for Clear Cell Renal Cell Carcinoma. Cancers (Basel) 2022;14:1062. [PMID: 35205810 DOI: 10.3390/cancers14041062] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
391 Vauchier C, Auclin E, Barthélémy P, Carril-ajuria L, Ryckewaert T, Borchiellini D, Castel-ajgal Z, Bennamoun M, Campedel L, Thiery-vuillemin A, Coquan E, Crouzet L, Berdah J, Chevreau C, Ratta R, Fléchon A, Lefort F, Albiges L, Gross-goupil M, Vano Y, Thibault C, Oudard S, Silvestris N. REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study. Journal of Oncology 2022;2022:1-12. [DOI: 10.1155/2022/3449660] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
392 Takei S, Kawazoe A, Shitara K. The New Era of Immunotherapy in Gastric Cancer. Cancers (Basel) 2022;14:1054. [PMID: 35205802 DOI: 10.3390/cancers14041054] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
393 Markham A. Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma. Target Oncol 2022. [PMID: 35175500 DOI: 10.1007/s11523-022-00866-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
394 Adashek JJ, Breunig JJ, Posadas E, Bhowmick NA, Ellis L, Freedland SJ, Kim H, Figlin R, Gong J. First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been? Drugs 2022. [PMID: 35175588 DOI: 10.1007/s40265-022-01683-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
395 Maniar A, Haslam A, Prasad V. Evaluating management of progressive disease for control arm patients in trials of first line PD-1 or PD-L1 inhibitor-based treatment for metastatic solid tumours. Eur J Cancer 2022;164:95-104. [PMID: 35182927 DOI: 10.1016/j.ejca.2022.01.006] [Reference Citation Analysis]
396 Robatel S, Schenk M. Current Limitations and Novel Perspectives in Pancreatic Cancer Treatment. Cancers 2022;14:985. [DOI: 10.3390/cancers14040985] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
397 Wang J, Tang J, Chen T, Yue S, Fu W, Xie Z, Liu X. A web-based prediction model for overall survival of elderly patients with early renal cell carcinoma: a population-based study. J Transl Med 2022;20. [DOI: 10.1186/s12967-022-03287-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
398 Allouchery M, Beuvon C, Pérault-Pochat MC, Roblot P, Puyade M, Martin M. Safety of Immune Checkpoint Inhibitor Resumption after Interruption for Immune-Related Adverse Events, a Narrative Review. Cancers (Basel) 2022;14:955. [PMID: 35205703 DOI: 10.3390/cancers14040955] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
399 Redwood AJ, Dick IM, Creaney J, Robinson BWS. What’s next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination. OncoImmunology 2022;11:2038403. [DOI: 10.1080/2162402x.2022.2038403] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
400 Rauthan A, Murthy NY, Patil P, Nigade G, Somashekhar SP, Zaveri SS. Real-World Experience with Nivolumab in Metastatic Renal Cell Carcinoma Patients Who Have Progressed on Prior Therapies: A Single-Center Study from India. South Asian J Cancer. [DOI: 10.1055/s-0041-1740373] [Reference Citation Analysis]
401 Konwar M, Bose D, Maurya M, Ravi R. A comprehensive evaluation of the safety of ipilimumab, nivolumab and their combination therapy: A systematic review and network meta-analysis. J Oncol Pharm Pract 2022;:10781552221074315. [PMID: 35147454 DOI: 10.1177/10781552221074315] [Reference Citation Analysis]
402 Ueda K, Suekane S, Kurose H, Ito N, Ogasawara N, Hiroshige T, Chikui K, Ejima K, Uemura K, Nakiri M, Nishihara K, Igawa T. Immune-related adverse events are clinical biomarkers to predict favorable outcomes in advanced renal cell carcinoma treated with nivolumab plus ipilimumab. Jpn J Clin Oncol 2022:hyac009. [PMID: 35141749 DOI: 10.1093/jjco/hyac009] [Reference Citation Analysis]
403 Yang Y, Mori SV, Li M, Hinkley M, Parikh AB, Collier KA, Miah A, Yin M. Salvage nivolumab and ipilimumab after prior anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma: A meta-analysis. Cancer Med 2022. [PMID: 35138046 DOI: 10.1002/cam4.4587] [Reference Citation Analysis]
404 Tan H, Wang L, Liu Z. Role of Suprabasin in the Dedifferentiation of Follicular Epithelial Cell-Derived Thyroid Cancer and Identification of Related Immune Markers. Front Genet 2022;13:810681. [DOI: 10.3389/fgene.2022.810681] [Reference Citation Analysis]
405 Zhang Y, Hu J, Yang J, Xie Y, Chen Z, Shangguan W, Han J, He W, Yang J, Zheng Z, Zhong Q, Zhu D, Xie W. Selection of Optimal Candidates for Cytoreductive Nephrectomy in Patients with Metastatic Clear Cell Renal Cell Carcinoma: A Predictive Model Based on SEER Database. Front Oncol 2022;12:814512. [PMID: 35127544 DOI: 10.3389/fonc.2022.814512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
406 O'sullivan H, Conroy M, Power D, Bambury R, O’mahony D, Collins D, O’leary M, O’reilly S. Immune Checkpoint Inhibitors and Palliative Care at the End of Life: An Irish Multicentre Retrospective Study. J Palliat Care. [DOI: 10.1177/08258597221078391] [Reference Citation Analysis]
407 Taboada RG, Riechelmann RP, Mauro C, Barros M, Hubner RA, Mcnamara MG, Lamarca A, Valle JW. Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and Outcomes. The Oncologist 2022. [DOI: 10.1093/oncolo/oyab024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
408 Qian Y, Li Y, Chen K, Liu N, Hong X, Wu D, Xu Z, Zhou L, Xu L, Jia R, Ge Y. Pan-Cancer Transcriptomic Analysis Identifies PLK1 Crucial for the Tumorigenesis of Clear Cell Renal Cell Carcinoma. JIR 2022;Volume 15:1099-116. [DOI: 10.2147/jir.s347732] [Reference Citation Analysis]
409 Chatzkel J, Schell MJ, Chahoud J, Jain R, Zhang J, Swank J, Ludlow S, Lombardi K, Lucas Y, Croft C, Rembisz J, Jameel G, Fishman M. Coordinated pembrolizumab and high dose IL-2 (5-in-a-row schedule) for therapy of metastatic clear cell renal cancer. Clinical Genitourinary Cancer 2022. [DOI: 10.1016/j.clgc.2022.01.010] [Reference Citation Analysis]
410 Hao Y, Xiao Y, Yan J, Yang R, Huang R, Zheng C, Huang C, Chen X, Xiao W, Lei J, Liu J. The total flavonoids of Hippophae rhamnoides stimulate recruitment of CD8+ T cells into the tumor microenvironment promoting cancer immune control. Phytomedicine Plus 2022;2:100204. [DOI: 10.1016/j.phyplu.2021.100204] [Reference Citation Analysis]
411 Mcgregor B, Mortazavi A, Cordes L, Salabao C, Vandlik S, Apolo AB. Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review. Cancer Treatment Reviews 2022;103:102333. [DOI: 10.1016/j.ctrv.2021.102333] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
412 Ljubimov VA, Ramesh A, Davani S, Danielpour M, Breunig JJ, Black KL. Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic. Adv Drug Deliv Rev 2022;181:114033. [PMID: 34808227 DOI: 10.1016/j.addr.2021.114033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
413 Cai Y, Liang X, Zhan Z, Zeng Y, Lin J, Xu A, Xue S, Xu W, Chai P, Mao Y, Song Z, Han L, Xiao J, Song Y, Zhang X. A Ferroptosis-Related Gene Prognostic Index to Predict Temozolomide Sensitivity and Immune Checkpoint Inhibitor Response for Glioma. Front Cell Dev Biol 2022;9:812422. [DOI: 10.3389/fcell.2021.812422] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
414 Iivanainen S, Ekström J, Virtanen H, Kataja VV, Koivunen JP. Predicting Objective Response Rate (ORR) in Immune Checkpoint Inhibitor (ICI) Therapies with Machine Learning (ML) by Combining Clinical and Patient-Reported Data. Applied Sciences 2022;12:1563. [DOI: 10.3390/app12031563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
415 Dormuth I, Liu T, Xu J, Yu M, Pauly M, Ditzhaus M. Which test for crossing survival curves? A user’s guideline. BMC Med Res Methodol 2022;22. [DOI: 10.1186/s12874-022-01520-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
416 Li J, Cao J, Liang C, Deng R, Li P, Tian J. The analysis of N6-methyladenosine regulators impacting the immune infiltration in clear cell renal cell carcinoma. Med Oncol 2022;39:41. [PMID: 35092501 DOI: 10.1007/s12032-021-01645-0] [Reference Citation Analysis]
417 Wu Z, Chen Q, Qu L, Li M, Wang L, Mir MC, Carbonara U, Pandolfo SD, Black PC, Paul AK, Di Lorenzo G, Porpiglia F, Mari A, Necchi A, Rouprêt M, Psutka SP, Autorino R. Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis. Eur Urol 2022:S0302-2838(22)00065-3. [PMID: 35101302 DOI: 10.1016/j.eururo.2022.01.028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
418 Jonasch E, Atkins MB, Chowdhury S, Mainwaring P. Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts? Cancers (Basel) 2022;14:644. [PMID: 35158916 DOI: 10.3390/cancers14030644] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
419 Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol 2022. [PMID: 35082367 DOI: 10.1038/s41571-022-00600-w] [Cited by in Crossref: 39] [Cited by in F6Publishing: 54] [Article Influence: 39.0] [Reference Citation Analysis]
420 Teishima J, Murata D, Inoue S, Hayashi T, Mita K, Hasegawa Y, Kato M, Kajiwara M, Shigeta M, Maruyama S, Moriyama H, Fujiwara S, Matsubara A. Prediction of early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitor. Curr Urol 2021;15:187-92. [PMID: 35069080 DOI: 10.1097/CU9.0000000000000042] [Reference Citation Analysis]
421 Saleh K, Kordahi M, Felefly T, Kourie HR, Khalife N. Pembrolizumab: first adjuvant immunotherapy in renal cell carcinoma? Future Oncology. [DOI: 10.2217/fon-2021-1309] [Reference Citation Analysis]
422 Medina López RA, Rivero Belenchon I, Mazuecos-Quirós J, Congregado-Ruíz CB, Couñago F. Update on the treatment of metastatic renal cell carcinoma. World J Clin Oncol 2022; 13(1): 1-8 [DOI: 10.5306/wjco.v13.i1.1] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
423 Hori H, Fujita K, Nishio A, Nishijima M, Inaba M, Anami T, Matsui S, Kitamura Y, Matsuoka R, Watanabe A. Pembrolizumab-related cholangitis with multiple fatal liver abscesses after endoscopic biliary drainage: a case report and review of the literature. Clin J Gastroenterol 2022. [PMID: 35072901 DOI: 10.1007/s12328-022-01593-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
424 Thompson NA, Stewart GD, Welsh SJ, Doherty GJ, Robinson MJ, Neville BA, Vervier K, Harris SR, Adams DJ, Dalchau K, Bruce D, Demiris N, Lawley TD, Corrie PG. The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy. BMC Cancer 2022;22. [DOI: 10.1186/s12885-021-09156-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
425 Popovic M, Matovina-Brko G, Jovic M, Popovic LS. Immunotherapy: A new standard in the treatment of metastatic clear cell renal cell carcinoma. World J Clin Oncol 2022; 13(1): 28-38 [DOI: 10.5306/wjco.v13.i1.28] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
426 Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer 2022;21. [DOI: 10.1186/s12943-021-01489-2] [Cited by in Crossref: 47] [Cited by in F6Publishing: 56] [Article Influence: 47.0] [Reference Citation Analysis]
427 Jia Q, Liao X, Zhang Y, Xu B, Song Y, Bian G, Fu X. Anti-Tumor Role of CAMK2B in Remodeling the Stromal Microenvironment and Inhibiting Proliferation in Papillary Renal Cell Carcinoma. Front Oncol 2022;12:740051. [DOI: 10.3389/fonc.2022.740051] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
428 Rizzo A, Mollica V, Santoni M, Ricci AD, Gadaleta-Caldarola G, Montironi R, Massari F. Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis. Future Oncol 2022. [PMID: 35048736 DOI: 10.2217/fon-2021-0841] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
429 Li J, Cao J, Li P, Deng R, Yao Z, Ying L, Tian J. A Bioinformatic Analysis of Immune-Related Prognostic Genes in Clear Cell Renal Cell Carcinoma Based on TCGA and GEO Databases. Int J Gen Med 2022;15:325-42. [PMID: 35035230 DOI: 10.2147/IJGM.S341801] [Reference Citation Analysis]
430 Martori C, Sanchez-Moral L, Paul T, Pardo JC, Font A, Ruiz de Porras V, Sarrias MR. Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance? Cancers (Basel) 2022;14:440. [PMID: 35053602 DOI: 10.3390/cancers14020440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
431 Khan E, Shrestha AK, Elkhooly M, Wilson H, Ebbert M, Srivastava S, Wen S, Rollins S, Sriwastava S. CNS and PNS manifestation in immune checkpoint inhibitors: A systematic review. J Neurol Sci 2022;432:120089. [PMID: 34942546 DOI: 10.1016/j.jns.2021.120089] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
432 Liu P, Chen R, Zhang X, Fu R, Tao L, Jia W. Combined PD-1/PD-L1 and tumor-infiltrating immune cells redefined a unique molecular subtype of high-grade serous ovarian carcinoma. BMC Genomics 2022;23. [DOI: 10.1186/s12864-021-08265-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
433 Santoni M, Rizzo A, Mollica V, Matrana MR, Rosellini M, Faloppi L, Marchetti A, Battelli N, Massari F. The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: The MOUSEION-01 study. Crit Rev Oncol Hematol 2022;170:103596. [PMID: 35031442 DOI: 10.1016/j.critrevonc.2022.103596] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
434 Shi X, Feng D, Li D, Zhang F, Wei W. The Role of Lymph Node Dissection for Non-Metastatic Renal Cell Carcinoma: An Updated Systematic Review and Meta-Analysis. Front Oncol 2021;11:790381. [PMID: 35096589 DOI: 10.3389/fonc.2021.790381] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
435 Korkmaz Yilmaz M, Gulturk I, Tacar SY, Yilmaz M. Nivolumab induced hypophysitis in an advanced RCC patient. J Oncol Pharm Pract 2022;:10781552211072212. [PMID: 35006033 DOI: 10.1177/10781552211072212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
436 Hwang GE, Lee JW, Jeon S, Cho IH, Kim HD. Vogt-Koyanagi-Harada syndrome-like uveitis after nivolumab administration as a treatment for ovarian cancer. Doc Ophthalmol 2022. [PMID: 34997406 DOI: 10.1007/s10633-021-09862-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
437 Schlauch D, Fu X, Jones SF, Burris HA 3rd, Spigel DR, Reeves J, McKenzie AJ. Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors. JCO Precis Oncol 2021;5:1625-38. [PMID: 34994650 DOI: 10.1200/PO.21.00008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
438 Saad OA, Li WT, Krishnan AR, Nguyen GC, Lopez JP, McKay RR, Wang-Rodriguez J, Ongkeko WM. The renal clear cell carcinoma immune landscape. Neoplasia 2022;24:145-54. [PMID: 34991061 DOI: 10.1016/j.neo.2021.12.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
439 Okuno-Ito R, Yamamoto M, Sato Y, Serizawa T, Kawagishi J, Shuto T, Yomo S, Akabane A, Aoyagi K, Kawabe T, Kikuchi Y, Nakasaki K, Gondo M, Higuchi Y, Takebayashi T. Stereotactic radiosurgery results for brain metastasis patients with renal cancer: A validity study of Renal Graded Prognostic Assessment and proposal of a new grading index (JLGK2101 Study). Clin Transl Radiat Oncol 2022;32:69-75. [PMID: 34984241 DOI: 10.1016/j.ctro.2021.11.002] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
440 Karpova N, Ivanov MV, Mileiko VA, Rumyantsev A, Titova TA, Arakelyan GA, Oganesyan AP, Kanygina AV, Sharova E, Gafanov RA, Kalpinsky AS, Alekseev BY, Semenova AI, Protsenko SA, Moiseenko FV, Matveev VB, Nosov DA. Experience of the nivolumab use in patients with metastatic renal cell carcinoma provided under the expanded access program in Russia. Subgroup analysis of the correlation between expression markers and the effectiveness of nivolumab therapy. Malignant Tumours 2022;11:23-35. [DOI: 10.18027/2224-5057-2021-11-3-23-35] [Reference Citation Analysis]
441 Bakouny Z, Sadagopan A, Ravi P, Metaferia NY, Li J, AbuHammad S, Tang S, Denize T, Garner ER, Gao X, Braun DA, Hirsch L, Steinharter JA, Bouchard G, Walton E, West D, Labaki C, Dudani S, Gan CL, Sethunath V, Carvalho FLF, Imamovic A, Ricker C, Vokes NI, Nyman J, Berchuck JE, Park J, Hirsch MS, Haq R, Mary Lee GS, McGregor BA, Chang SL, Feldman AS, Wu CJ, McDermott DF, Heng DYC, Signoretti S, Van Allen EM, Choueiri TK, Viswanathan SR. Integrative clinical and molecular characterization of translocation renal cell carcinoma. Cell Rep 2022;38:110190. [PMID: 34986355 DOI: 10.1016/j.celrep.2021.110190] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
442 Rosellini M, Marchetti A, Tassinari E, Nuvola G, Rizzo A, Santoni M, Mollica V, Massari F. Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer. Expert Review of Precision Medicine and Drug Development 2022;7:131-149. [DOI: 10.1080/23808993.2022.2156786] [Reference Citation Analysis]
443 Ravindranathan D, Alhalabi O, Rafei H, Shah AY, Bilen MA. Landscape of Immunotherapy in Genitourinary Malignancies. Adv Exp Med Biol 2021;1342:143-92. [PMID: 34972965 DOI: 10.1007/978-3-030-79308-1_5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
444 Abdelrahim M, Abudayyeh A. Renal Toxicity. Adv Exp Med Biol 2021;1342:389-97. [PMID: 34972976 DOI: 10.1007/978-3-030-79308-1_16] [Reference Citation Analysis]
445 Merseburger AS, Grünwald V. Medikamentöse Therapie des metastasierten Nierenzellkarzinoms. Die Urologie 2022. [DOI: 10.1007/978-3-642-41168-7_60-2] [Reference Citation Analysis]
446 Yu Y, Wang W, Qin Z, Li H, Liu Q, Ma H, Sun H, Bauer TL, Pimiento JM, Gabriel E, Birdas T, Li Y, Xing W. A clinical nomogram for predicting tumor regression grade in esophageal squamous-cell carcinoma treated with immune neoadjuvant immunotherapy. Ann Transl Med 2022;10:102. [PMID: 35282099 DOI: 10.21037/atm-22-78] [Reference Citation Analysis]
447 Martini A, Larcher A. The Future of Artificial Intelligence Applied to Perioperative Immunotherapy Trials: Renal Cell Carcinoma. Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers 2022. [DOI: 10.1007/978-3-030-80546-3_23] [Reference Citation Analysis]
448 Karachaliou GS, Hirshman N, Zhang T. Immunotherapy. Urologic Oncology 2022. [DOI: 10.1007/978-3-030-89891-5_15] [Reference Citation Analysis]
449 Orhan A. The Tumor Microenvironment in Pancreatic Cancer and Challenges to Immunotherapy. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_65] [Reference Citation Analysis]
450 Naranbhai V, Viard M, Dean M, Groha S, Braun DA, Labaki C, Shukla SA, Yuki Y, Shah P, Chin K, Wind-Rotolo M, Mu XJ, Robbins PB, Gusev A, Choueiri TK, Gulley JL, Carrington M. HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. Lancet Oncol 2022;23:172-84. [PMID: 34895481 DOI: 10.1016/S1470-2045(21)00582-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 26.0] [Reference Citation Analysis]
451 Slovin SF. Biomarkers of Immunotherapy Response and the Future Role of Targeted Therapies in Non-metastatic Prostate Cancer. Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers 2022. [DOI: 10.1007/978-3-030-80546-3_13] [Reference Citation Analysis]
452 Zhou J, Zeng Y, Wang H, Jin S, Wang Y, He S, Frey B, Fietkau R, Hecht M, Ma H, Zhang W, Gaipl US. Identification of an endogenous retroviral signature to predict anti-PD1 response in advanced clear cell renal cell carcinoma: an integrated analysis of three clinical trials. Ther Adv Med Oncol 2022;14:175883592211261. [DOI: 10.1177/17588359221126154] [Reference Citation Analysis]
453 Bhagat S, Jadhav A, Patil S, Barkate H. Axitinib in management of renal cell carcinoma: Indian perspective. Oncol J India 2022;6:14. [DOI: 10.4103/oji.oji_42_21] [Reference Citation Analysis]
454 Goto T. Immunoediting and cancer priming. Cancer Immunology and Immunotherapy 2022. [DOI: 10.1016/b978-0-12-823397-9.00005-3] [Reference Citation Analysis]
455 Zhai L, Ladomersky E, Lauing KL, Bollu L, Bell A, Kim M, Rabin E, Wainwright DA. Indoleamine 2,3-dioxygenase 1 (IDO): A mediator of immunoresistance in adults with brain cancer treated with immunomodulatory therapy. Immunotherapeutic Strategies for the Treatment of Glioma 2022. [DOI: 10.1016/b978-0-12-819755-4.00006-0] [Reference Citation Analysis]
456 Keshavarz-fathi M, Keshavarz-fathi M, Rezaei N. Cancer Immunology. Encyclopedia of Infection and Immunity 2022. [DOI: 10.1016/b978-0-12-818731-9.00083-5] [Reference Citation Analysis]
457 Jain M, Mishra A, Singh MK, Shyam H, Kumar S, Shankar P, Singh S. Immunotherapeutic and their immunological aspects: Current treatment strategies and agents. Natl J Maxillofac Surg 2022;13:322-9. [PMID: 36683928 DOI: 10.4103/njms.njms_62_22] [Reference Citation Analysis]
458 Twardowski P. Immuno-Oncologic Treatment of Genitourinary Malignancies. Cancer Metastasis Through the Lymphovascular System 2022. [DOI: 10.1007/978-3-030-93084-4_69] [Reference Citation Analysis]
459 Abad Vivas-pérez JI, Barrabino Martín R, Urda Romacho J. Cáncer renal avanzado, perfiles para los nuevos tratamientos. Medicina Clínica Práctica 2022;5:100277. [DOI: 10.1016/j.mcpsp.2021.100277] [Reference Citation Analysis]
460 Orhan A. Cancer Immunodiagnosis in Upper Gastrointestinal Cancers. Handbook of Cancer and Immunology 2022. [DOI: 10.1007/978-3-030-80962-1_147-1] [Reference Citation Analysis]
461 Fluhrer H, Hutterer GC, Golbeck S, Stidl M, Niedrist T, Pichler R, Mischinger J, Seles M, Mannweiler S, Spiegelberg J, Bauernhofer T, Jost PJ, Ahyai S, Zigeuner R, Pichler M, Barth DA. Improved overall survival of metastatic renal cell carcinoma patients in the era of modern tyrosine kinase inhibitors and immune checkpoint inhibitors: results from a real-life, population-based Austrian study comprising three decades of follow-up. Ther Adv Med Oncol 2022;14:175883592211340. [DOI: 10.1177/17588359221134065] [Reference Citation Analysis]
462 Lee CH, Jung SJ, Seo WI, Chung JI, Lee DS, Jeong DH, Jeon Y, Choi I. Coexpression of lymphocyte-activation gene 3 and programmed death ligand-1 in tumor infiltrating immune cells predicts worse outcome in renal cell carcinoma. Int J Immunopathol Pharmacol 2022;36:3946320221125588. [PMID: 36083857 DOI: 10.1177/03946320221125588] [Reference Citation Analysis]
463 Montemagno C, Luciano F, Pagès G. Opposing Roles of Vascular Endothelial Growth Factor C in Metastatic Dissemination and Resistance to Radio/Chemotherapy: Discussion of Mechanisms and Therapeutic Strategies. Methods in Molecular Biology 2022. [DOI: 10.1007/978-1-0716-2217-9_1] [Reference Citation Analysis]
464 Strobl J, Mischinger J, Golbeck SV, Pichler M, Zigeuner R. Nierenparenchymtumoren. Die Urologie 2022. [DOI: 10.1007/978-3-642-41168-7_63-2] [Reference Citation Analysis]
465 Pierrard J, Tison T, Grisay G, Seront E. Global management of brain metastasis from renal cell carcinoma. Critical Reviews in Oncology/Hematology 2022. [DOI: 10.1016/j.critrevonc.2022.103600] [Reference Citation Analysis]
466 Rajasekaran T, Chowdhury AR, Kanesvaran R. Renal Cell Carcinoma in Older Adults with Frailty. Frailty in Older Adults with Cancer 2022. [DOI: 10.1007/978-3-030-89162-6_21] [Reference Citation Analysis]
467 Demasure S, Spriet I, Debruyne PR, Laenen A, Wynendaele W, Baldewijns M, Dumez H, Clement PM, Wildiers H, Schöffski P, Roussel E, Kinget L, Albersen M, Beuselinck B. Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study. Acta Oncol 2022;61:22-9. [PMID: 34711121 DOI: 10.1080/0284186X.2021.1989720] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
468 Li S, Li J, Peng L, Li Y, Wan X. Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States. Front Pharmacol 2021;12:736860. [PMID: 34966275 DOI: 10.3389/fphar.2021.736860] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
469 Lv Z, Cui B, Huang X, Feng HY, Wang T, Wang HF, Xuan YD, Li HZ, Ma X, Huang Y, Zhang X. FGL1 as a Novel Mediator and Biomarker of Malignant Progression in Clear Cell Renal Cell Carcinoma. Front Oncol 2021;11:756843. [PMID: 34956878 DOI: 10.3389/fonc.2021.756843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
470 Yang F, Wang JF, Wang Y, Liu B, Molina JR. Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges. Cancers (Basel) 2021;14:109. [PMID: 35008273 DOI: 10.3390/cancers14010109] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
471 Huang A, Yang Y, Shi JY, Li YK, Xu JX, Cheng Y, Gu J. Mucinous adenocarcinoma: A unique clinicopathological subtype in colorectal cancer. World J Gastrointest Surg 2021; 13(12): 1567-1583 [DOI: 10.4240/wjgs.v13.i12.1567] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
472 Xu S, Lai R, Zhao Q, Zhao P, Zhao R, Guo Z. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors. Front Immunol 2021;12:794099. [PMID: 34950153 DOI: 10.3389/fimmu.2021.794099] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
473 Seront E, Lhommel R, Tombal B. Case Report: Early 68Ga-PSMA-PET Metabolic Assessment and Response to Systemic Treatment for First-Line Metastatic Clear Cell Renal Cell Carcinoma; About Two Clinical Cases. Front Oncol 2021;11:782166. [PMID: 34950588 DOI: 10.3389/fonc.2021.782166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
474 Korman AJ, Garrett-Thomson SC, Lonberg N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat Rev Drug Discov 2021. [PMID: 34937915 DOI: 10.1038/s41573-021-00345-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
475 Roulleaux Dugage M, Nassif EF, Italiano A, Bahleda R. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review. Front Immunol 2021;12:775761. [PMID: 34925348 DOI: 10.3389/fimmu.2021.775761] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
476 Shen S, Wu Q, Liu J, Wu L, Zhang R, Uemura Y, Yu X, Chen L, Liu T. Analysis of human glioma-associated co-inhibitory immune checkpoints in glioma microenvironment and peripheral blood. Int J Immunopathol Pharmacol 2021;35:20587384211056505. [PMID: 34923867 DOI: 10.1177/20587384211056505] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
477 Blank CU, Wong DJ, Ho TH, Bauer TM, Lee CB, Bene-Tchaleu F, Zhu J, Zhang X, Cha E, Sznol M. Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors. Curr Oncol 2021;28:5466-79. [PMID: 34940094 DOI: 10.3390/curroncol28060455] [Reference Citation Analysis]
478 Guven DC, Aktepe OH, Aksun MS, Sahin TK, Kavgaci G, Ucgul E, Cakir IY, Yildirim HC, Guner G, Akin S, Kertmen N, Dizdar O, Aksoy S, Erman M, Yalcin S, Kilickap S. The association between albumin-globulin ratio (AGR) and survival in patients treated with immune checkpoint inhibitors. Cancer Biomark 2021. [PMID: 34958005 DOI: 10.3233/CBM-210349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
479 Wang H, Xu H, Cheng Q, Liang C. Identification of a Novel Stem Cell Subtype for Clear Cell Renal Cell Carcinoma Based on Stem Cell Gene Profiling. Front Oncol 2021;11:758989. [PMID: 34912710 DOI: 10.3389/fonc.2021.758989] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
480 Yoshida T, Miki H, Satake H, Kobayashi T, Matsumi Y, Hamada M, Boku S, Shibata N, Ishida M, Sekimoto M. Pathological Complete Response of Clinical T4b Ascending Colon Cancer after Preoperative Chemotherapy Using Pembrolizumab. Case Rep Oncol 2021;14:1497-504. [PMID: 34899242 DOI: 10.1159/000519470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
481 Calvo V, Fernández MA, Collazo-Lorduy A, Franco F, Núñez B, Provencio M. Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data. Lung Cancer Manag 2021;10:LMT51. [PMID: 34899991 DOI: 10.2217/lmt-2021-0003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
482 Jin X, Chen L, Zhou N, Ni H, Zu L, He J, Yang L, Zhu Y, Sun X, Li X, Xu S. LRMP Associates With Immune Infiltrates and Acts as a Prognostic Biomarker in Lung Adenocarcinoma. Front Mol Biosci 2021;8:711928. [PMID: 34901148 DOI: 10.3389/fmolb.2021.711928] [Reference Citation Analysis]
483 Gulati S, Previtera M, Lara PN. BRCA1-Associated Protein 1 (BAP-1) as a Prognostic and Predictive Biomarker in Clear Cell Renal Cell Carcinoma: A Systematic Review. KCA 2021. [DOI: 10.3233/kca-210006] [Reference Citation Analysis]
484 Zhang Y, Chen X, Fu Q, Wang F, Zhou X, Xiang J, He N, Hu Z, Jin X. Comprehensive analysis of pyroptosis regulators and tumor immune microenvironment in clear cell renal cell carcinoma. Cancer Cell Int 2021;21:667. [PMID: 34906145 DOI: 10.1186/s12935-021-02384-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
485 Mollica V, Santoni M, Matrana MR, Basso U, De Giorgi U, Rizzo A, Maruzzo M, Marchetti A, Rosellini M, Bleve S, Maslov D, Tawagi K, Philon E, Blake Z, Massari F. Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma. Target Oncol 2021. [PMID: 34894318 DOI: 10.1007/s11523-021-00861-y] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
486 Alemohammad H, Najafzadeh B, Asadzadeh Z, Baghbanzadeh A, Ghorbaninezhad F, Najafzadeh A, Safarpour H, Bernardini R, Brunetti O, Sonnessa M, Fasano R, Silvestris N, Baradaran B. The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer. Biomed Pharmacother 2021;146:112516. [PMID: 34906767 DOI: 10.1016/j.biopha.2021.112516] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
487 Ito T, Mizutani K, Takahara K, Ando R, Yasui T, Shiroki R, Koie T, Miyake H. Assessment of prognostic factors in previously treated Japanese patients with metastatic renal cell carcinoma who received nivolumab: An observational multi-institute study. Mol Clin Oncol 2022;16:17. [PMID: 34881037 DOI: 10.3892/mco.2021.2446] [Reference Citation Analysis]
488 Liu C, Wang M, Xu C, Li B, Chen J, Chen J, Wang Z. Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation. J Immunol Res 2021;2021:8970173. [PMID: 34877360 DOI: 10.1155/2021/8970173] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
489 Ged Y, Voss MH. Novel emerging biomarkers to immunotherapy in kidney cancer. Ther Adv Med Oncol 2021;13:17588359211059367. [PMID: 34868351 DOI: 10.1177/17588359211059367] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
490 Janisch F, Kienapfel C, Fühner C, Klotzbücher T, Marks P, Hillemacher T, Meyer CP, Iwata T, Parizi MK, Sauter G, Fisch M, Shariat SF, Dahlem R, Rink M. Treatment and Outcome of Metastatic Renal Cell Carcinoma With Sarcomatoid Differentiation: A Single-Center, Real-World Analysis of Retrospective Data. Front Surg 2021;8:763271. [PMID: 34869564 DOI: 10.3389/fsurg.2021.763271] [Reference Citation Analysis]
491 Kanesvaran R, Porta C, Wong A, Powles T, Ng QS, Schmidinger M, Ye D, Malhotra H, Miura Y, Lee JL, Chong FLT, Pu YS, Yen CC, Saad M, Lee HJ, Kitamura H, Bhattacharyya GS, Curigliano G, Poon E, Choo SP, Peters S, Lim E, Yoshino T, Pentheroudakis G. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma. ESMO Open 2021;6:100304. [PMID: 34864348 DOI: 10.1016/j.esmoop.2021.100304] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
492 Wang J, Huang M, Huang P, Zhao J, Tan J, Huang F, Ma R, Xiao Y, Deng G, Wei L, Wei Q, Wang Z, He S, Shen J, Sooranna S, Meng L, Song J. The Identification of a Tumor Infiltration CD8+ T-Cell Gene Signature That Can Potentially Improve the Prognosis and Prediction of Immunization Responses in Papillary Renal Cell Carcinoma. Front Oncol 2021;11:757641. [PMID: 34858833 DOI: 10.3389/fonc.2021.757641] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
493 Hahn AW, Shah AY, Campbell MT. First-Line Immuno-Oncology Combinations for Metastatic Clear Cell Renal Cell Carcinoma (mRCC): A Systematic Review of Phase III Clinical Trials. KCA 2021;5:207-17. [DOI: 10.3233/kca-210123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
494 Parikh M, Tenold ME, Qi L, Lara F, Robles D, Meyers FJ, Lara PN. Phase Ib/II trial of Ibrutinib and Nivolumab in Patients with Advanced Refractory Renal Cell Carcinoma1. KCA 2021;5:181-7. [DOI: 10.3233/kca-210128] [Reference Citation Analysis]
495 An R, Zhao F, Wang L, Shan J, Wang X. Predictive effect of molecular and clinical characteristics for the OS and PFS efficacy of anti-PD-1/PD-L1 immunotherapy in patients with NSCLC: a meta-analysis and systematic review. BMJ Open 2021;11:e047663. [DOI: 10.1136/bmjopen-2020-047663] [Reference Citation Analysis]
496 Sun L, Lai TJ, Prins RM. Is there a role for neoadjuvant anti-PD-1 therapies in glioma? Curr Opin Neurol 2021;34:834-9. [PMID: 34608074 DOI: 10.1097/WCO.0000000000000992] [Reference Citation Analysis]
497 Liao W, Lei W, Feng M, Yang Y, Wu Q, Zhou K, Bai L, Wen F, Li Q. Cost-Effectiveness Analysis of First-Line Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma in the United States. Adv Ther 2021;38:5662-70. [PMID: 34664194 DOI: 10.1007/s12325-021-01926-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
498 Kim JH, Lee KS, Kim C, Choi YD, Kim TH. Subcutaneous Interleukin-2 Monotherapy for Metastatic Renal Cell Carcinoma in Korean Patients. Korean J Urol Oncol 2021;19:252-260. [DOI: 10.22465/kjuo.2021.19.4.252] [Reference Citation Analysis]
499 Dawsey SJ, Ornstein MC. Addition of Salvage Immunotherapy to Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma. Curr Oncol 2021;28:5019-24. [PMID: 34940060 DOI: 10.3390/curroncol28060421] [Reference Citation Analysis]
500 Ballesteros PÁ, Chamorro J, Román-Gil MS, Pozas J, Gómez Dos Santos V, Granados ÁR, Grande E, Alonso-Gordoa T, Molina-Cerrillo J. Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma. Cancers (Basel) 2021;13:5981. [PMID: 34885091 DOI: 10.3390/cancers13235981] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
501 Lu Y, Wu F, Cao Q, Sun Y, Huang M, Xiao J, Zhou B, Zhang L. B7-H4 is increased in lung adenocarcinoma harboring EGFR-activating mutations and contributes to immunosuppression. Oncogene 2021. [PMID: 34839353 DOI: 10.1038/s41388-021-02124-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
502 Jacquelot N, Ghaedi M, Warner K, Chung DC, Crome SQ, Ohashi PS. Immune Checkpoints and Innate Lymphoid Cells-New Avenues for Cancer Immunotherapy. Cancers (Basel) 2021;13:5967. [PMID: 34885076 DOI: 10.3390/cancers13235967] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
503 Comandone A, Vana F, Comandone T, Tucci M. Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results. Cancers (Basel) 2021;13:5896. [PMID: 34885006 DOI: 10.3390/cancers13235896] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
504 Al-rabayah AA, Sawalha R, Fawzi Al Froukh R, Al-bawab R, Jaddoua SM. Pazopanib or Sunitinib? cost-utility analysis of pazopanib versus sunitinib in the first-line treatment of metastatic renal cell carcinoma in Jordan. Journal of Pharmaceutical Health Services Research 2021;12:566-73. [DOI: 10.1093/jphsr/rmab061] [Reference Citation Analysis]
505 Hakozaki K, Tanaka N, Takamatsu K, Takahashi R, Yasumizu Y, Mikami S, Shinojima T, Kakimi K, Kamatani T, Miya F, Tsunoda T, Aimono E, Nishihara H, Mizuno R, Oya M. Landscape of prognostic signatures and immunogenomics of the AXL/GAS6 axis in renal cell carcinoma. Br J Cancer 2021;125:1533-43. [PMID: 34611307 DOI: 10.1038/s41416-021-01559-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
506 Wang Z, Chen Z, Zhao H, Lin H, Wang J, Wang N, Li X, Ding D. ISPRF: a machine learning model to predict the immune subtype of kidney cancer samples by four genes. Transl Androl Urol 2021;10:3773-86. [PMID: 34804821 DOI: 10.21037/tau-21-650] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
507 Boegemann M, Goebell PJ, Woike M, Buncke J, Schlack K, Schrader AJ. Assessment of prognosis by established prognosis scores and physicians' judgement in mRCC patients: an analysis of the STAR-TOR registry. Transl Androl Urol 2021;10:4062-74. [PMID: 34804848 DOI: 10.21037/tau-20-938] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
508 Kim MC, Jin Z, Kolb R, Borcherding N, Chatzkel JA, Falzarano SM, Zhang W. Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma. Cancers (Basel) 2021;13:5856. [PMID: 34831009 DOI: 10.3390/cancers13225856] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
509 Kandalaft LE, Harari A. Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers. Cancers (Basel) 2021;13:5819. [PMID: 34830973 DOI: 10.3390/cancers13225819] [Reference Citation Analysis]
510 Wang J, Hong J, Yang F, Liu F, Wang X, Shen Z, Wu D. A deficient MIF-CD74 signaling pathway may play an important role in immunotherapy-induced hyper-progressive disease. Cell Biol Toxicol 2021. [PMID: 34797429 DOI: 10.1007/s10565-021-09672-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
511 Huntoon K, Damante M, Wang J, Olencki T, Elder JB. Survival benefit with resection of brain metastases from renal cell carcinoma in the setting of molecular targeted therapy and/or immune therapy. Curr Probl Cancer 2021;:100805. [PMID: 34836657 DOI: 10.1016/j.currproblcancer.2021.100805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
512 Ursprung S, Mossop H, Gallagher FA, Sala E, Skells R, Sipple JAN, Mitchell TJ, Chhabra A, Fife K, Matakidou A, Young G, Walker A, Thomas MG, Ortuzar MC, Sullivan M, Protheroe A, Oades G, Venugopal B, Warren AY, Stone J, Eisen T, Wason J, Welsh SJ, Stewart GD. The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol. BMC Cancer 2021;21:1238. [PMID: 34794412 DOI: 10.1186/s12885-021-08965-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
513 Navani V, Heng DYC. Treatment Selection in First-line Metastatic Renal Cell Carcinoma-The Contemporary Treatment Paradigm in the Age of Combination Therapy: A Review. JAMA Oncol 2021. [PMID: 34792538 DOI: 10.1001/jamaoncol.2021.4337] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
514 Storkus WJ, Maurer D, Lin Y, Ding F, Bose A, Lowe D, Rose A, DeMark M, Karapetyan L, Taylor JL, Chelvanambi M, Fecek RJ, Filderman JN, Looney TJ, Miller L, Linch E, Lowman GM, Kalinski P, Butterfield LH, Tarhini A, Tawbi H, Kirkwood JM. Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma. J Immunother Cancer 2021;9:e003675. [PMID: 34782430 DOI: 10.1136/jitc-2021-003675] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
515 Iinuma K, Enomoto T, Kawada K, Fujimoto S, Ishida T, Takagi K, Nagai S, Ito H, Kawase M, Nakai C, Kawase K, Kato D, Takai M, Nakane K, Kameyama K, Koie T. Utility of Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune Inflammation Index as Prognostic, Predictive Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab and Ipilimumab. J Clin Med 2021;10:5325. [PMID: 34830607 DOI: 10.3390/jcm10225325] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
516 Emamekhoo H, Olsen MR, Carthon BC, Drakaki A, Percent IJ, Molina AM, Cho DC, Bendell JC, Gordan LN, Rezazadeh Kalebasty A, George DJ, Hutson TE, Arrowsmith ER, Zhang J, Zoco J, Johansen JL, Leung DK, Tykodi SS. Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920. Cancer 2021. [PMID: 34784056 DOI: 10.1002/cncr.34016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
517 Yu X, Li W, Young KH, Li Y. Posttranslational Modifications in PD-L1 Turnover and Function: From Cradle to Grave. Biomedicines 2021;9:1702. [PMID: 34829931 DOI: 10.3390/biomedicines9111702] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
518 Sato Y, Fu Y, Liu H, Lee MY, Shaw MH. Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response. BMC Cancer 2021;21:1222. [PMID: 34774008 DOI: 10.1186/s12885-021-08974-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
519 Gulati S, Vogelzang NJ. Biomarkers in renal cell carcinoma: Are we there yet? Asian J Urol 2021;8:362-75. [PMID: 34765444 DOI: 10.1016/j.ajur.2021.05.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
520 Basile D, Simionato F, Cappetta A, Garattini SK, Roviello G, Aprile G. State-of-the-Art of Monoclonal Antibodies for the Treatment of Gastric Cancer. Biologics 2021;15:451-62. [PMID: 34764633 DOI: 10.2147/BTT.S290323] [Reference Citation Analysis]
521 Wang A, Chu H, Jin Z, Jia Q, Zhu B. Programmed Cell Death Protein Ligand 2 Is a Potential Biomarker That Predicts the Efficacy of Immunotherapy. Dis Markers 2021;2021:9453692. [PMID: 34754345 DOI: 10.1155/2021/9453692] [Reference Citation Analysis]
522 Saevets VV, Shamanova AY, Rostovcev DM. Antitumor effect on immune control points (PD-1/PD-L1) in malignant neoplasms. jour 2021;20:78-84. [DOI: 10.52420/2071-5943-2021-20-4-78-84] [Reference Citation Analysis]
523 Zhang ZY, Zhang SL, Chen HL, Mao YQ, Kong CY, Li ZM, Wang LS, Ma M, Han B. Low EGR1 expression predicts poor prognosis in clear cell renal cell carcinoma. Pathol Res Pract 2021;228:153666. [PMID: 34749216 DOI: 10.1016/j.prp.2021.153666] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
524 Brozovich A, Garmezy B, Pan T, Wang L, Farach-Carson MC, Satcher RL. All bone metastases are not created equal: Revisiting treatment resistance in renal cell carcinoma. J Bone Oncol 2021;31:100399. [PMID: 34745857 DOI: 10.1016/j.jbo.2021.100399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
525 Au L, Hatipoglu E, Robert de Massy M, Litchfield K, Beattie G, Rowan A, Schnidrig D, Thompson R, Byrne F, Horswell S, Fotiadis N, Hazell S, Nicol D, Shepherd STC, Fendler A, Mason R, Del Rosario L, Edmonds K, Lingard K, Sarker S, Mangwende M, Carlyle E, Attig J, Joshi K, Uddin I, Becker PD, Sunderland MW, Akarca A, Puccio I, Yang WW, Lund T, Dhillon K, Vasquez MD, Ghorani E, Xu H, Spencer C, López JI, Green A, Mahadeva U, Borg E, Mitchison M, Moore DA, Proctor I, Falzon M, Pickering L, Furness AJS, Reading JL, Salgado R, Marafioti T, Jamal-Hanjani M, Kassiotis G, Chain B, Larkin J, Swanton C, Quezada SA, Turajlic S; PEACE Consortium., TRACERx Renal Consortium. Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell 2021;39:1497-1518.e11. [PMID: 34715028 DOI: 10.1016/j.ccell.2021.10.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 13.5] [Reference Citation Analysis]
526 Mao Z, Jiang P, Zhang Y, Li Y, Jia X, Wang Q, Jiao M, Jiang L, Shen Y, Guo H. First-line immune-based combination therapies for advanced non-small cell lung cancer: A Bayesian network meta-analysis. Cancer Med 2021. [PMID: 34747149 DOI: 10.1002/cam4.4405] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
527 Wang L, Liu XX, Yang YM, Wang Y, Song YY, Gao S, Li LY, Zhang ZS. RHBDF2 gene functions are correlated to facilitated renal clear cell carcinoma progression. Cancer Cell Int 2021;21:590. [PMID: 34736454 DOI: 10.1186/s12935-021-02277-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
528 Kamran SC, Gao X. Solving the Stereotactic Body Radiotherapy and Checkpoint Inhibitor Puzzle in Metastatic Renal Cell Carcinoma. Eur Urol 2021:S0302-2838(21)02115-1. [PMID: 34742587 DOI: 10.1016/j.eururo.2021.10.014] [Reference Citation Analysis]
529 Ren Z, Qin S, Meng Z, Chen Z, Chai X, Xiong J, Bai Y, Yang L, Zhu H, Fang W, Lin X, Chen X, Li E, Wang L, Yan P, Zou J. A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression. Liver Cancer 2021;10:500-9. [PMID: 34721511 DOI: 10.1159/000516470] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
530 Lin J, Zhang Y, Hou W, Qin Q, Galsky MD, Oh WK, Tsao CK. Evolving Patterns of Metastasis in Renal Cell Carcinoma: Do We Need to Perform Routine Bone Imaging? J Kidney Cancer VHL 2021;8:13-9. [PMID: 34722126 DOI: 10.15586/jkcvhl.v8i4.202] [Reference Citation Analysis]
531 Liu Y, Zhang Z, Liu R, Wei W, Zhang Z, Mai L, Guo S, Han H, Zhou F, He L, Dong P. Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma. Radiat Oncol 2021;16:211. [PMID: 34727963 DOI: 10.1186/s13014-021-01937-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
532 Nguyen LTH, Wang X, Kwak KJ, Zhang J, Okimoto T, Amann J, Rima XY, Yoon MJ, Shukuya T, Walters N, Ma Y, Belcher D, Li H, Palmer AF, Carbone DP, Lee LJ, Reátegui E. An Immunogold Single Extracellular Vesicular RNA and Protein (AuSERP) Biochip to Predict Responses to Immunotherapy in Non-Small Cell Lung Cancer Patients.. [DOI: 10.1101/2021.10.30.466609] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
533 Feng T, Zhao J, Wei D, Guo P, Yang X, Li Q, Fang Z, Wei Z, Li M, Jiang Y, Luo Y. Immunogenomic Analyses of the Prognostic Predictive Model for Patients With Renal Cancer. Front Immunol 2021;12:762120. [PMID: 34712244 DOI: 10.3389/fimmu.2021.762120] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
534 Xu J, Zheng Q, Cheng X, Hu S, Zhang C, Zhou X, Sun P, Wang W, Su Z, Zou T, Song Z, Xia Y, Yi X, Gao Y. Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma. J Nanobiotechnology 2021;19:355. [PMID: 34717654 DOI: 10.1186/s12951-021-01101-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
535 Masoumi E, Tahaghoghi-Hajghorbani S, Jafarzadeh L, Sanaei MJ, Pourbagheri-Sigaroodi A, Bashash D. The application of immune checkpoint blockade in breast cancer and the emerging role of nanoparticle. J Control Release 2021;340:168-87. [PMID: 34743998 DOI: 10.1016/j.jconrel.2021.10.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
536 Labadie BW, Balar AV, Luke JJ. Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers. Cancers (Basel) 2021;13:5415. [PMID: 34771578 DOI: 10.3390/cancers13215415] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
537 Yuan M, Zhu Z, Mao W, Wang H, Qian H, Wu J, Guo X, Xu Q. Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study. Front Oncol 2021;11:683502. [PMID: 34692475 DOI: 10.3389/fonc.2021.683502] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
538 Gangaev A, Rozeman EA, Rohaan MW, Isaeva OI, Philips D, Patiwael S, van den Berg JH, Ribas A, Schadendorf D, Schilling B, Schumacher TN, Blank CU, Haanen JBAG, Kvistborg P. Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response. Proc Natl Acad Sci U S A 2021;118:e2102849118. [PMID: 34670835 DOI: 10.1073/pnas.2102849118] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
539 Nemoto Y, Ishihara H, Nakamura K, Tachibana H, Fukuda H, Yoshida K, Kobayashi H, Iizuka J, Shimmura H, Hashimoto Y, Tanabe K, Kondo T, Takagi T. Efficacy and safety of immune checkpoint inhibitors in elderly patients with metastatic renal cell carcinoma. Int Urol Nephrol 2021. [PMID: 34704214 DOI: 10.1007/s11255-021-03042-y] [Reference Citation Analysis]
540 Ruhland MK, Alspach E. Senescence and Immunoregulation in the Tumor Microenvironment. Front Cell Dev Biol 2021;9:754069. [PMID: 34692707 DOI: 10.3389/fcell.2021.754069] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
541 Wang X, Su W, Tang D, Jing J, Xiong J, Deng Y, Liu H, Ma W, Liu Z, Zhang Q. An Immune-Related Gene Prognostic Index for Triple-Negative Breast Cancer Integrates Multiple Aspects of Tumor-Immune Microenvironment. Cancers (Basel) 2021;13:5342. [PMID: 34771505 DOI: 10.3390/cancers13215342] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
542 Akhbariyoon H, Azizpour Y, Esfahani MF, Firoozabad MSM, Rad MR, Esfahani KS, Khoshavi N, Karimi N, Shirinisaz A, Abedi F, Rad MR, Sharifi P. Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials. Clin Immunol 2021;232:108873. [PMID: 34688855 DOI: 10.1016/j.clim.2021.108873] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
543 Rapoport BL, Shannon VR, Cooksley T, Johnson DB, Anderson L, Blidner AG, Tintinger GR, Anderson R. Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer. Front Pharmacol 2021;12:743582. [PMID: 34675810 DOI: 10.3389/fphar.2021.743582] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
544 Mandal S, Ray B, Baniya Sharma S, Poulose J, Kasireddy V. Hyperprogression: A Unique Phenomenon of Progression of Existing Tumor Secondary to Immunotherapy. Cureus 2021;13:e17992. [PMID: 34667669 DOI: 10.7759/cureus.17992] [Reference Citation Analysis]
545 Allegra A, Gioacchino MD, Tonacci A, Petrarca C, Gangemi S. Nanomedicine for Immunotherapy Targeting Hematological Malignancies: Current Approaches and Perspective. Nanomaterials (Basel) 2021;11:2792. [PMID: 34835555 DOI: 10.3390/nano11112792] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
546 Chanez B, Caillol F, Ratone JP, Pesenti C, Rochigneux P, Pignot G, Thomassin J, Brunelle S, Walz J, Salem N, Giovannini M, Gravis G. Endoscopic Ultrasound-Guided Radiofrequency Ablation as an Future Alternative to Pancreatectomy for Pancreatic Metastases from Renal Cell Carcinoma: A Prospective Study. Cancers (Basel) 2021;13:5267. [PMID: 34771431 DOI: 10.3390/cancers13215267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
547 Ito T, Yamamoto K, Furukawa J, Harada K, Fujisawa M, Omura T, Yano I. Association of sunitinib concentration and clinical outcome in patients with metastatic renal cell carcinoma treated with a 2-week-on and 1-week-off schedule. J Clin Pharm Ther 2021. [PMID: 34669974 DOI: 10.1111/jcpt.13517] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
548 Pinto Á, Reig O, Iglesias C, Gallardo E, García-Del Muro X, Alonso T, Anguera G, Suárez C, Muñoz-Langa J, Villalobos-León L, Rodríguez-Sánchez Á, Lainez N, Martínez-Ortega E, Campayo M, Velastegui A, Rodriguez-Vida A, Villa-Guzmán JC, Méndez-Vidal MJ, Rubio G, García I, Capdevila L, Lambea J, Vázquez S, Fernández O, Hernando-Polo S, Cerezo S, Santander C, García-Marrero R, Zambrana F, González-Del Alba A, Lazaro-Quintela M, Castellano D, Chirivella I, Anido U, Viana A, García A, Sotelo M, Arévalo MG, García-Donas J, Hernández C, Bolós MV, Llinares J, Climent MA. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study. Clin Genitourin Cancer 2021:S1558-7673(21)00189-0. [PMID: 34789409 DOI: 10.1016/j.clgc.2021.09.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
549 Kitadai R, Okuma Y. Future Perspective of Chemotherapy and Pharmacotherapy in Thymic Carcinoma. Cancers (Basel) 2021;13:5239. [PMID: 34680386 DOI: 10.3390/cancers13205239] [Reference Citation Analysis]
550 Youssef M, Ahmed HY, Zongo A, Korin A, Zhan F, Hady E, Umair M, Shahid Riaz Rajoka M, Xiong Y, Li B. Probiotic Supplements: Their Strategies in the Therapeutic and Prophylactic of Human Life-Threatening Diseases. Int J Mol Sci 2021;22:11290. [PMID: 34681948 DOI: 10.3390/ijms222011290] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
551 Takahashi M, Watanabe S, Suzuki R, Arita M, Sato K, Sato M, Sekiya Y, Abe Y, Fujisaki T, Ohtsubo A, Shoji S, Nozaki K, Ichikawa K, Kondo R, Saida Y, Hokari S, Aoki N, Hayashi M, Ohshima Y, Koya T, Kikuchi T. PD-1 blockade therapy augments the antitumor effects of lymphodepletion and adoptive T cell transfer. Cancer Immunol Immunother 2021. [PMID: 34657194 DOI: 10.1007/s00262-021-03078-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
552 Zhang C, Guo L, Su Z, Luo N, Tan Y, Xu P, Ye L, Tong S, Liu H, Li X, Chen Q, Tian D. Tumor Immune Microenvironment Landscape in Glioma Identifies a Prognostic and Immunotherapeutic Signature. Front Cell Dev Biol 2021;9:717601. [PMID: 34650972 DOI: 10.3389/fcell.2021.717601] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
553 Liu M, Gao Y, Yuan Y, Shi S, Wu J, Tian J, Zhang J. An evidence mapping and scientometric analysis of the top-100 most cited clinical trials of anti-PD-1/PD-L1 drugs to treat cancers. Biomed Pharmacother 2021;143:112238. [PMID: 34649362 DOI: 10.1016/j.biopha.2021.112238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
554 Bronger H. Immunology and Immune Checkpoint Inhibition in Ovarian Cancer - Current Aspects. Geburtshilfe Frauenheilkd 2021;81:1128-44. [PMID: 34629492 DOI: 10.1055/a-1475-4335] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
555 Das S, Idate R, Regan DP, Fowles JS, Lana SE, Thamm DH, Gustafson DL, Duval DL. Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma. Commun Biol 2021;4:1178. [PMID: 34635775 DOI: 10.1038/s42003-021-02683-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
556 Jang A, Adler DM, Rauterkus GP, Bilen MA, Barata PC. Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going? Cancers (Basel) 2021;13:5065. [PMID: 34680214 DOI: 10.3390/cancers13205065] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
557 Ueda K, Suekane S, Kurose H, Ogasawara N, Hiroshige T, Chikui K, Uemura K, Nakiri M, Nishihara K, Matsuo M, Igawa T. Absolute lymphocyte count is an independent predictor of survival in patients with metastatic renal cell carcinoma treated with nivolumab. Jpn J Clin Oncol 2021:hyab157. [PMID: 34607361 DOI: 10.1093/jjco/hyab157] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
558 Nie Y, Li J, Wu W, Guo D, Lei X, Zhang T, Wang Y, Mao Z, Zhang X, Song W. A Novel Nine-lncRNA Risk Signature Correlates With Immunotherapy in Hepatocellular Carcinoma. Front Oncol 2021;11:706915. [PMID: 34604045 DOI: 10.3389/fonc.2021.706915] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
559 Miyashita K, Karayama M, Inoue Y, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Kono M, Matsui T, Niwa M, Koda K, Toyoshima M, Matsushima S, Matsuura S, Asada K, Fujii M, Kusagaya H, Matsuda H, Inui N, Suda T. Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis. BMC Pulm Med 2021;21:309. [PMID: 34600514 DOI: 10.1186/s12890-021-01681-6] [Reference Citation Analysis]
560 Powles T, Albiges L, Bex A, Grünwald V, Porta C, Procopio G, Schmidinger M, Suárez C, de Velasco G; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma. Ann Oncol 2021;32:1511-9. [PMID: 34597799 DOI: 10.1016/j.annonc.2021.09.014] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 19.0] [Reference Citation Analysis]
561 Bian Y, Liu YF, Jiang H, Meng Y, Liu F, Cao K, Zhang H, Fang X, Li J, Yu J, Feng X, Li Q, Wang L, Lu J, Shao C. Machine learning for MRI radiomics: a study predicting tumor-infiltrating lymphocytes in patients with pancreatic ductal adenocarcinoma. Abdom Radiol (NY) 2021;46:4800-16. [PMID: 34189612 DOI: 10.1007/s00261-021-03159-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
562 Wang Y, Zhang X, Wang Y, Zhao W, Li H, Zhang L, Li X, Zhang T, Zhang H, Huang H, Liu C. Application of immune checkpoint targets in the anti-tumor novel drugs and traditional Chinese medicine development. Acta Pharm Sin B 2021;11:2957-72. [PMID: 34729298 DOI: 10.1016/j.apsb.2021.03.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
563 Chmielewska I, Dudzińska M, Szczyrek M, Świrska J, Wojas-Krawczyk K, Zwolak A. Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab? PLoS One 2021;16:e0257484. [PMID: 34587185 DOI: 10.1371/journal.pone.0257484] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
564 Kinoshita T, Terai H, Yaguchi T. Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer. Life (Basel) 2021;11:1029. [PMID: 34685400 DOI: 10.3390/life11101029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
565 Sejima T, Masago T, Yoshida M, Nishi T, Kawabata Y, Tajima Y, Yumioka T, Honda M, Takenaka A. Pathological eradication of recurrent metastatic renal cell carcinoma with sarcomatoid component by nivolumab plus ipilimumab combination therapy. Int Cancer Conf J 2021;10:285-9. [PMID: 34567939 DOI: 10.1007/s13691-021-00501-2] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
566 Li S, Li J, Peng L, Li Y, Wan X. Cost-Effectiveness of Frontline Treatment for Advanced Renal Cell Carcinoma in the Era of Immunotherapies. Front Pharmacol 2021;12:718014. [PMID: 34566643 DOI: 10.3389/fphar.2021.718014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
567 Hao J, Cao Y, Yu H, Zong L, An R, Xue Y. Effect of MAP3K8 on Prognosis and Tumor-Related Inflammation in Renal Clear Cell Carcinoma. Front Genet 2021;12:674613. [PMID: 34567061 DOI: 10.3389/fgene.2021.674613] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
568 Xiao Y, Chen P, Luo C, Xu Z, Li X, Liu L, Zhao L. Discovery of a novel anti PD-L1 X TIGIT bispecific antibody for the treatment of solid tumors. Cancer Treat Res Commun 2021;29:100467. [PMID: 34598062 DOI: 10.1016/j.ctarc.2021.100467] [Reference Citation Analysis]
569 Śledzińska P, Bebyn MG, Furtak J, Kowalewski J, Lewandowska MA. Prognostic and Predictive Biomarkers in Gliomas. Int J Mol Sci 2021;22:10373. [PMID: 34638714 DOI: 10.3390/ijms221910373] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 11.0] [Reference Citation Analysis]
570 Yuan J, Khilnani A, Brody J, Andtbacka RHI, Hu-Lieskovan S, Luke JJ, Diab A, Marabelle A, Snyder A, Cao ZA, Hodi FS. Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition. Eur J Cancer 2021;157:493-510. [PMID: 34561127 DOI: 10.1016/j.ejca.2021.08.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
571 Dou S, Li R, He N, Zhang M, Jiang W, Ye L, Yang Y, Zhao G, Yang Y, Li J, Chen D, Zhu G. The Immune Landscape of Chinese Head and Neck Adenoid Cystic Carcinoma and Clinical Implication. Front Immunol 2021;12:618367. [PMID: 34552580 DOI: 10.3389/fimmu.2021.618367] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
572 Cerbone L, Nunno VD, Carril Ajuria L, Alves Costa Silva C, Colomba E, Guida A, Salviat F, Hirsch L, Benchimol-Zouari A, Flippot R, Escudier B, Albiges L. Activity of Systemic Treatments After Cabozantinib Failure in Advanced Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer 2021:S1558-7673(21)00178-6. [PMID: 34688544 DOI: 10.1016/j.clgc.2021.09.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
573 Movassaghi M, Chung R, Anderson CB, Stein M, Saenger Y, Faiena I. Overcoming Immune Resistance in Prostate Cancer: Challenges and Advances. Cancers (Basel) 2021;13:4757. [PMID: 34638243 DOI: 10.3390/cancers13194757] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
574 Oza B, Frangou E, Smith B, Bryant H, Kaplan R, Choodari-Oskooei B, Powles T, Stewart GD, Albiges L, Bex A, Choueiri TK, Davis ID, Eisen T, Fielding A, Harrison D, McWhirter A, Mulhere S, Nathan P, Rini B, Ritchie A, Scovell S, Shakeshaft C, Stockler MR, Thorogood N, Parmar MKB, Larkin J, Meade A. RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse. Contemp Clin Trials 2021;108:106482. [PMID: 34538402 DOI: 10.1016/j.cct.2021.106482] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
575 Dizman N, Lyou Y, Salgia N, Bergerot PG, Hsu J, Enriquez D, Izatt T, Trent JM, Byron S, Pal S. Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis. J Immunother Cancer 2020;8:e000953. [PMID: 32661119 DOI: 10.1136/jitc-2020-000953] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
576 Takamatsu K, Tanaka N, Hakozaki K, Takahashi R, Teranishi Y, Murakami T, Kufukihara R, Niwa N, Mikami S, Shinojima T, Sasaki T, Sato Y, Kume H, Ogawa S, Kakimi K, Kamatani T, Miya F, Tsunoda T, Aimono E, Nishihara H, Sawada K, Imamura T, Mizuno R, Oya M. Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy. Nat Commun 2021;12:5547. [PMID: 34545095 DOI: 10.1038/s41467-021-25865-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
577 Zhang D, Li Y, Li H, Tang T, Zheng Y, Guo X, Xu X. A Preliminary Study of the Complement Component 1q Levels in Predicting the Efficacy of Combined Immunotherapy in Patients with Lung Cancer. Cancer Manag Res 2021;13:7131-7. [PMID: 34531687 DOI: 10.2147/CMAR.S314369] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
578 Wei B, Yu M, Yao J, Jiang M, An J, Yang J, Lin J, Zhao Y, Zhu Y. Multidimensional Analyses of Tumor Immune Microenvironment Reveal the Possible Rationality of Immunotherapy and Identify High Immunotherapy Response Subtypes for Renal Papillary Cell Carcinoma. Front Immunol 2021;12:657951. [PMID: 34531849 DOI: 10.3389/fimmu.2021.657951] [Reference Citation Analysis]
579 Tung I, Sahu A. Immune Checkpoint Inhibitor in First-Line Treatment of Metastatic Renal Cell Carcinoma: A Review of Current Evidence and Future Directions. Front Oncol 2021;11:707214. [PMID: 34527581 DOI: 10.3389/fonc.2021.707214] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
580 Gao L, Chen Y. Autophagy controls programmed death-ligand 1 expression on cancer cells (Review). Biomed Rep 2021;15:84. [PMID: 34512972 DOI: 10.3892/br.2021.1460] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
581 Sun JX, Xia QD, Liu CQ, Xu JZ, Xun Y, Lu JL, Hu J, Wang SG. Construction of a Novel Immune-Related lncRNA Pair Signature with Prognostic Significance for Kidney Clear Cell Renal Cell Carcinoma. Dis Markers 2021;2021:8800358. [PMID: 34512816 DOI: 10.1155/2021/8800358] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
582 Kim H, Ahn S, Kim H, Hong JY, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim KM, Kim ST. The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors. J Cancer Res Clin Oncol 2021. [PMID: 34510272 DOI: 10.1007/s00432-021-03781-6] [Reference Citation Analysis]
583 Zhou L, Wei X. Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer. Front Immunol 2021;12:701951. [PMID: 34504488 DOI: 10.3389/fimmu.2021.701951] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
584 Nakai Y, Otsuka T, Inoue T, Nawa T, Hatano K, Yamamoto Y, Nagahara A, Nakayama M, Kakimoto KI, Nishimura K. Two cases of delayed onset of immune-related adverse events after discontinuation of nivolumab in patients with metastatic renal cell cancer. IJU Case Rep 2021;4:326-9. [PMID: 34497995 DOI: 10.1002/iju5.12338] [Reference Citation Analysis]
585 Kim H, Shim BY, Lee SJ, Lee JY, Lee HJ, Kim IH. Loss of Von Hippel-Lindau (VHL) Tumor Suppressor Gene Function: VHL-HIF Pathway and Advances in Treatments for Metastatic Renal Cell Carcinoma (RCC). Int J Mol Sci 2021;22:9795. [PMID: 34575959 DOI: 10.3390/ijms22189795] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
586 Koh SA. An update on immunotherapy with PD-1 and PD-L1 blockade. Yeungnam Univ J Med 2021. [PMID: 34496466 DOI: 10.12701/yujm.2021.01312] [Reference Citation Analysis]
587 Ren X, Ma L, Wang N, Zhou R, Wu J, Xie X, Zhang H, Liu D, Ma X, Dang C, Kang H, Zhou Z. Antioxidant Gene Signature Impacts the Immune Infiltration and Predicts the Prognosis of Kidney Renal Clear Cell Carcinoma. Front Genet 2021;12:721252. [PMID: 34490047 DOI: 10.3389/fgene.2021.721252] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
588 Stenzel PJ, Hörner N, Foersch S, Wagner DC, Tsaur I, Thomas A, Haferkamp A, Macher-Goeppinger S, Roth W, Porubsky S, Tagscherer KE. Nivolumab Reduces PD1 Expression and Alters Density and Proliferation of Tumor Infiltrating Immune Cells in a Tissue Slice Culture Model of Renal Cell Carcinoma. Cancers (Basel) 2021;13:4511. [PMID: 34572738 DOI: 10.3390/cancers13184511] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
589 Wang Z, He L, Li W, Xu C, Zhang J, Wang D, Dou K, Zhuang R, Jin B, Zhang W, Hao Q, Zhang K, Zhang W, Wang S, Gao Y, Gu J, Shang L, Tan Z, Su H, Zhang Y, Zhang C, Li M. GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma. J Immunother Cancer 2021;9:e002787. [PMID: 34489334 DOI: 10.1136/jitc-2021-002787] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
590 Ueno S, Uenomachi M, Kusaba H, Ito M, Suzuki K, Ohmura H, Tsuchihashi K, Ariyama H, Akashi K, Baba E. Improvement in recurring nivolumab-induced pneumonitis with repetitive administration of infliximab in a patient with head and neck cancer: A case report. Mol Clin Oncol 2021;15:221. [PMID: 34476105 DOI: 10.3892/mco.2021.2379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
591 Li E, Huang X, Zhang G, Liang T. Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy. J Exp Clin Cancer Res 2021;40:279. [PMID: 34479614 DOI: 10.1186/s13046-021-02055-w] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
592 Lennartz S, Persigehl T. [Radiological monitoring of immunotherapy in renal cell carcinoma]. Aktuelle Urol 2021;52:474-80. [PMID: 34428827 DOI: 10.1055/a-1489-2163] [Reference Citation Analysis]
593 Mezheyeuski A, Strell C. Multiplexed Imaging for Immune Profiling on Human FFPE Material. Methods Mol Biol 2021;2350:125-44. [PMID: 34331283 DOI: 10.1007/978-1-0716-1593-5_9] [Reference Citation Analysis]
594 Xiong W, Zhang B, Yu H, Zhu L, Yi L, Jin X. RRM2 Regulates Sensitivity to Sunitinib and PD-1 Blockade in Renal Cancer by Stabilizing ANXA1 and Activating the AKT Pathway. Adv Sci (Weinh) 2021;8:e2100881. [PMID: 34319001 DOI: 10.1002/advs.202100881] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
595 Sharp J, Khaki AR, Prasad V. Use of Second-line Immunotherapy in Control Arms of Randomized Clinical Trials in Kidney Cancer: A Systematic Review. JAMA Netw Open 2021;4:e2124728. [PMID: 34570209 DOI: 10.1001/jamanetworkopen.2021.24728] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
596 Dapash M, Hou D, Castro B, Lee-Chang C, Lesniak MS. The Interplay between Glioblastoma and Its Microenvironment. Cells 2021;10:2257. [PMID: 34571905 DOI: 10.3390/cells10092257] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
597 Lecuelle J, Boidot R, Mananet H, Derangère V, Albuisson J, Goussot V, Arnould L, Tharin Z, Ray Coquard I, Ghiringhelli F, Truntzer C, Fumet JD. TCR Clonality and Genomic Instability Signatures as Prognostic Biomarkers in High Grade Serous Ovarian Cancer. Cancers (Basel) 2021;13:4394. [PMID: 34503204 DOI: 10.3390/cancers13174394] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
598 DiNatale RG, Hakimi AA, Chan TA. Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology. Hum Mol Genet 2020;29:R214-25. [PMID: 33029628 DOI: 10.1093/hmg/ddaa203] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
599 Ge Y, Zhang H, Weygant N, Yao J. Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials. Front Pharmacol 2021;12:640099. [PMID: 34447305 DOI: 10.3389/fphar.2021.640099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
600 Bhindi B, Bearrick EN, Cheville JC, Lohse CM, Mason RJ, Shah P, Harrington S, Zhang H, Dong H, Boorjian SA, Thompson RH, Leibovich BC. Bim Expression in Peritumoral Lymphocytes is Associated with Survival in Patients with Metastatic Clear Cell Renal Cell Carcinoma. KCA 2021;5:129-35. [DOI: 10.3233/kca-210116] [Reference Citation Analysis]
601 Shpilsky J, Catalano PJ, Mcdermott DF. First-Line Immunotherapy Combinations in Advanced Renal Cell Carcinoma: A Rapid Review and Meta-Analysis. KCA 2021;5:153-63. [DOI: 10.3233/kca-210120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
602 Paderi A, Fancelli S, Caliman E, Pillozzi S, Gambale E, Mela MM, Doni L, Mazzoni F, Antonuzzo L. Safety of Immune Checkpoint Inhibitors in Elderly Patients: An Observational Study. Curr Oncol 2021;28:3259-67. [PMID: 34449588 DOI: 10.3390/curroncol28050283] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
603 Laria A, Lurati A, Castelnovo L, Tamburello A, Faggioli PM, Mazzone A. Rheumatic immune-related adverse events from checkpoint inhibitor therapy: a case series. Beyond Rheumatol 2021;3. [DOI: 10.4081/br.2021.65] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
604 Kinget L, Bechter O, Punie K, Debruyne PR, Brems H, Clement P, Roussel E, Van Herck Y, Albersen M, Baldewijns M, Schöffski P, Beuselinck B. Multitumor Case Series of Germline BRCA1, BRCA2 and CHEK2-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors. Curr Oncol 2021;28:3227-39. [PMID: 34449592 DOI: 10.3390/curroncol28050280] [Reference Citation Analysis]
605 Zhou Q, Li K, Lai Y, Yao K, Wang Q, Zhan X, Peng S, Cai W, Yao W, Zang X, Xu K, Huang J, Huang H. B7 score and T cell infiltration stratify immune status in prostate cancer. J Immunother Cancer 2021;9:e002455. [PMID: 34417325 DOI: 10.1136/jitc-2021-002455] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
606 Kato K, Mizuno T, Koseki T, Ito Y, Hatano M, Takahashi K, Yamada S, Tsuboi N. Concomitant Proton Pump Inhibitors and Immune Checkpoint Inhibitors Increase Nephritis Frequency. In Vivo 2021;35:2831-40. [PMID: 34410975 DOI: 10.21873/invivo.12570] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
607 Yoshino M, Ishihara H, Ishiyama Y, Tachibana H, Toki D, Yamashita K, Kobayashi H, Fukuda H, Yoshida K, Takagi T, Iizuka J, Ishida H, Kondo T, Tanabe K. Albumin-to-Alkaline Phosphatase Ratio as a Novel Prognostic Marker of Nivolumab Monotherapy for Previously Treated Metastatic Renal Cell Carcinoma. In Vivo 2021;35:2855-62. [PMID: 34410978 DOI: 10.21873/invivo.12573] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
608 Kopecky J, Kubecek O, Buchler T, Melichar B, Poprach A, Zemanova M, Katolicka J, Kiss I, Hajek J, Studentova H, Spisarova M. Administration of Nivolumab in Metastatic Renal Cell Cancer Following Treatment With mTOR Inhibitors. In Vivo 2021;35:2981-90. [PMID: 34410998 DOI: 10.21873/invivo.12593] [Reference Citation Analysis]
609 Koide H, Noda S, Yoshida T, Kageyama S, Teramura K, Kato T, Kawauchi A, Fujimoto N, Terada T. Severe Skin Disorders Due to Sorafenib Use After Nivolumab Treatment in Renal Cell Carcinoma Patients. In Vivo 2021;35:2969-74. [PMID: 34410996 DOI: 10.21873/invivo.12591] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
610 Kim YJ, Kim K, Seo SY, Yu J, Kim IH, Kim HJ, Park CK, Lee KH, Choi J, Song MS, Kim JH. Time-sequential change in immune-related gene expression after irradiation in glioblastoma: next-generation sequencing analysis. Anim Cells Syst (Seoul) 2021;25:245-54. [PMID: 34408813 DOI: 10.1080/19768354.2021.1954550] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
611 Labriola MK, Zhu J, Gupta RT, McCall S, Jackson J, Kong EF, White JR, Cerqueira G, Gerding K, Simmons JK, George D, Zhang T. Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma. J Immunother Cancer 2020;8:e000319. [PMID: 32221016 DOI: 10.1136/jitc-2019-000319] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 17.5] [Reference Citation Analysis]
612 Herrmann T, Ginzac A, Molnar I, Bailly S, Durando X, Mahammedi H. Eosinophil counts as a relevant prognostic marker for response to nivolumab in the management of renal cell carcinoma: a retrospective study. Cancer Med 2021;10:6705-13. [PMID: 34405573 DOI: 10.1002/cam4.4208] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
613 Yu ZK, Xie RL, You R, Liu YP, Chen XY, Chen MY, Huang PY. The role of the bacterial microbiome in the treatment of cancer. BMC Cancer 2021;21:934. [PMID: 34412621 DOI: 10.1186/s12885-021-08664-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
614 Marchetti A, Rosellini M, Rizzo A, Mollica V, Battelli N, Massari F, Santoni M. An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma. Expert Opin Pharmacother 2021;22:2323-36. [PMID: 34405738 DOI: 10.1080/14656566.2021.1959548] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
615 Zhou QH, Li KW, Chen X, He HX, Peng SM, Peng SR, Wang Q, Li ZA, Tao YR, Cai WL, Liu RY, Huang H. HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma. J Immunother Cancer 2020;8:e000157. [PMID: 31959726 DOI: 10.1136/jitc-2019-000157] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 17.5] [Reference Citation Analysis]
616 Yu EM, Linville L, Rosenthal M, Aragon-Ching JB. A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma. Vaccines (Basel) 2021;9:919. [PMID: 34452045 DOI: 10.3390/vaccines9080919] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
617 Timmer FEF, Geboers B, Nieuwenhuizen S, Dijkstra M, Schouten EAC, Puijk RS, de Vries JJJ, van den Tol MP, Bruynzeel AME, Streppel MM, Wilmink JW, van der Vliet HJ, Meijerink MR, Scheffer HJ, de Gruijl TD. Pancreatic Cancer and Immunotherapy: A Clinical Overview. Cancers (Basel) 2021;13:4138. [PMID: 34439292 DOI: 10.3390/cancers13164138] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
618 Doppalapudi SK, Leopold ZR, Thaper A, Kaldany A, Chua K, Patel HV, Srivastava A, Singer EA. Clearing up Clear Cell: Clarifying the Immuno-Oncology Treatment Landscape for Metastatic Clear Cell RCC. Cancers (Basel) 2021;13:4140. [PMID: 34439293 DOI: 10.3390/cancers13164140] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
619 Lyadova MA, Lyadov VK. Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review. J Mod Onco 2021;23:319-326. [DOI: 10.26442/18151434.2021.2.200502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
620 Ollivier L, Guimas V, Rio E, Vaugier L, Masson I, Libois V, Labbé M, Fradin D, Potiron V, Supiot S. [Combination radiotherapy-immunotherapy in genitourinary cancer]. Cancer Radiother 2021;25:565-9. [PMID: 34391648 DOI: 10.1016/j.canrad.2021.06.033] [Reference Citation Analysis]
621 Yamaguchi T, Shimizu J, Hasegawa T, Horio Y, Inaba Y, Hanai N, Muro K, Hida T. Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis. BMC Cancer 2021;21:924. [PMID: 34399710 DOI: 10.1186/s12885-021-08661-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
622 Shan Q, Lu H. Immune Checkpoint Inhibitors in Special Populations. Technol Cancer Res Treat 2021;20:15330338211036526. [PMID: 34384286 DOI: 10.1177/15330338211036526] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
623 Rocconi RP, Stanbery L, Madeira da Silva L, Barrington RA, Aaron P, Manning L, Horvath S, Wallraven G, Bognar E, Walter A, Nemunaitis J. Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer. Vaccines (Basel) 2021;9:894. [PMID: 34452019 DOI: 10.3390/vaccines9080894] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
624 Desai K, Brown L, Wei W, Tucker M, Kao C, Kinsey E, Rini B, Beckermann K, Zhang T, Ornstein MC. A Multi-institutional, Retrospective Analysis of Patients with Metastatic Renal Cell Carcinoma to Bone Treated with Combination Ipilimumab and Nivolumab. Target Oncol 2021. [PMID: 34379283 DOI: 10.1007/s11523-021-00832-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
625 Tannock IF, Patel A. Pharmacoeconomics. Indian J Med Paediatr Oncol 2021;42:218-20. [DOI: 10.1055/s-0041-1733826] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
626 Kouri M, Vadalouca A, Kouloulias V, Papadopoulou E, Vardas E, Kyrodimos E, Trichas M, Galitis E, Zygogianni A, Liakouli Z, Nicolatou-galitis O, Psyrri A. Oral Complications of Head and Neck Cancer Therapy. Forum of Clinical Oncology 2021;12:52-66. [DOI: 10.2478/fco-2019-0016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
627 Vladimirova LY, Storozhakova AE, Popova IL, Kabanov SN, Abramova NA, Teplyakova MA, Tikhanovskaya NM, Novoselova KA, Lyanova AA, Ryadinskaya LA, Myagkova VS, Alieva FV, Kalabanova EA, Svetitskaya YV, Samaneva NY, Tishina AV. Some aspects of nivolumab administration in treatment for metastatic melanoma (clinical cases). Medicinskij sovet 2021. [DOI: 10.21518/2079-701x-2021-9-64-74] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
628 Kumar A. COMPREHENSIVE REVIEW ON ETIOPATHOGENESIS, TREATMENT AND EMERGING THERAPIES OF BREAST CANCER. Asian J Pharm Clin Res 2021. [DOI: 10.22159/ajpcr.2021.v14i8.41974] [Reference Citation Analysis]
629 Stellato M, Procopio G, De Giorgi U, Maruzzo M, Bimbatti D, Mennitto A, Sbrana A, Roviello G, Casadei C, Sepe P, Pignata S, Santini D. Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators. J Transl Med 2021;19:328. [PMID: 34344414 DOI: 10.1186/s12967-021-03008-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
630 Rhyner Agocs G, Assarzadegan N, Kirsch R, Dawson H, Galván JA, Lugli A, Zlobec I, Berger MD. LAG-3 Expression Predicts Outcome in Stage II Colon Cancer. J Pers Med 2021;11:749. [PMID: 34442393 DOI: 10.3390/jpm11080749] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
631 Caruso M, Romeo V, Stanzione A, Buonerba C, Di Lorenzo G, Maurea S. Current Imaging Evaluation of Tumor Response to Advanced Medical Treatment in Metastatic Renal-Cell Carcinoma: Clinical Implications. Applied Sciences 2021;11:6930. [DOI: 10.3390/app11156930] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
632 Sepe P, Ottini A, Pircher CC, Franza A, Claps M, Guadalupi V, Verzoni E, Procopio G. Characteristics and Treatment Challenges of Non-Clear Cell Renal Cell Carcinoma. Cancers (Basel) 2021;13:3807. [PMID: 34359706 DOI: 10.3390/cancers13153807] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
633 Desbaillets N, Hottinger AF. Immunotherapy in Glioblastoma: A Clinical Perspective. Cancers (Basel) 2021;13:3721. [PMID: 34359621 DOI: 10.3390/cancers13153721] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
634 Wang M, Zhai X, Li J, Guan J, Xu S, Li Y, Zhu H. The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors. Front Immunol 2021;12:670391. [PMID: 34367136 DOI: 10.3389/fimmu.2021.670391] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
635 Zimmermannova O, Caiado I, Ferreira AG, Pereira CF. Cell Fate Reprogramming in the Era of Cancer Immunotherapy. Front Immunol 2021;12:714822. [PMID: 34367185 DOI: 10.3389/fimmu.2021.714822] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
636 Zarrabi K, Walzer E, Zibelman M. Immune Checkpoint Inhibition in Advanced Non-Clear Cell Renal Cell Carcinoma: Leveraging Success from Clear Cell Histology into New Opportunities. Cancers (Basel) 2021;13:3652. [PMID: 34359554 DOI: 10.3390/cancers13153652] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
637 Sasaki A, Kawazoe A, Eto T, Okunaka M, Mishima S, Sawada K, Nakamura Y, Kotani D, Kuboki Y, Taniguchi H, Kojima T, Doi T, Yoshino T, Akimoto T, Shitara K. Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer. ESMO Open 2020;4:e000775. [PMID: 32719002 DOI: 10.1136/esmoopen-2020-000775] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
638 Petrazzuolo A, Perez-Lanzon M, Martins I, Liu P, Kepp O, Minard-Colin V, Maiuri MC, Kroemer G. Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects. Cell Death Dis 2021;12:713. [PMID: 34272360 DOI: 10.1038/s41419-021-03997-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
639 Mollica V, Brocchi S, Dall'Olio FG, Marcolin L, Paccapelo A, Santoni M, Rizzo A, Montironi R, Golfieri R, Massari F, Ardizzoni A. Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough. Cancers (Basel) 2021;13:3492. [PMID: 34298702 DOI: 10.3390/cancers13143492] [Reference Citation Analysis]
640 Romano A, Storti P, Marchica V, Scandura G, Notarfranchi L, Craviotto L, Di Raimondo F, Giuliani N. Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma. Front Oncol 2021;11:684561. [PMID: 34307150 DOI: 10.3389/fonc.2021.684561] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
641 Wojtukiewicz MZ, Rek MM, Karpowicz K, Górska M, Polityńska B, Wojtukiewicz AM, Moniuszko M, Radziwon P, Tucker SC, Honn KV. Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev 2021. [PMID: 34236546 DOI: 10.1007/s10555-021-09976-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
642 Zhao Y, Liu L, Weng L. Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives. Front Pharmacol 2021;12:714483. [PMID: 34305619 DOI: 10.3389/fphar.2021.714483] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
643 Alexander JL, Ibraheim H, Sheth B, Little J, Khan MS, Richards C, Hunter N, Chauhan D, Ratnakumaran R, McHugh K, Pinato DJ, Nathan P, Choy J, Crusz SM, Furness A, Turajlic S, Pickering L, Larkin J, Teare JP, Papa S, Speight A, Sharma A, Powell N. Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximab. J Immunother Cancer 2021;9:e002742. [PMID: 34233964 DOI: 10.1136/jitc-2021-002742] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
644 Tsimafeyeu IV. Nivolumab: 5 years from the day of international registration of immunotherapy of metastatic kidney cancer. Malignant Tumours 2021;10:21-29. [DOI: 10.18027/2224-5057-2020-10-4-21-29] [Reference Citation Analysis]
645 Tse BCY, Welham Z, Engel AF, Molloy MP. Genomic, Microbial and Immunological Microenvironment of Colorectal Polyps. Cancers (Basel) 2021;13:3382. [PMID: 34298598 DOI: 10.3390/cancers13143382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
646 Kubo T, Shinkawa T, Kikuchi Y, Murata K, Kanaseki T, Tsukahara T, Hirohashi Y, Torigoe T. Fundamental and Essential Knowledge for Pathologists Engaged in the Research and Practice of Immune Checkpoint Inhibitor-Based Cancer Immunotherapy. Front Oncol 2021;11:679095. [PMID: 34290982 DOI: 10.3389/fonc.2021.679095] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
647 Wang S, Chen S, Ying Y, Ma X, Shen H, Li J, Wang X, Lin Y, Liu B, Zheng X, Xie L. Comprehensive Analysis of Ferroptosis Regulators With Regard to PD-L1 and Immune Infiltration in Clear Cell Renal Cell Carcinoma. Front Cell Dev Biol 2021;9:676142. [PMID: 34291048 DOI: 10.3389/fcell.2021.676142] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
648 Kodama Y, Tanaka I, Sato T, Hori K, Gen S, Morise M, Matsubara D, Sato M, Sekido Y, Hashimoto N. Oxytocin receptor is a promising therapeutic target of malignant mesothelioma. Cancer Sci 2021;112:3520-32. [PMID: 34115916 DOI: 10.1111/cas.15025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
649 Wang S, Ma X, Ying Y, Sun J, Yang Z, Li J, Jin K, Wang X, Xie B, Zheng X, Liu B, Xie L. Upregulation of ARNTL2 is associated with poor survival and immune infiltration in clear cell renal cell carcinoma. Cancer Cell Int 2021;21:341. [PMID: 34217271 DOI: 10.1186/s12935-021-02046-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
650 Presley CJ, Gomes F, Burd CE, Kanesvaran R, Wong ML. Immunotherapy in Older Adults With Cancer. J Clin Oncol 2021;39:2115-27. [PMID: 34043444 DOI: 10.1200/JCO.21.00138] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
651 Naito S, Kato T, Numakura K, Hatakeyama S, Koguchi T, Kandori S, Kawasaki Y, Adachi H, Kato R, Narita S, Yamamoto H, Ogawa S, Kawamura S, Obara W, Ito A, Nishiyama H, Kojima Y, Ohyama C, Habuchi T, Tsuchiya N. Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era. Int J Clin Oncol 2021. [PMID: 34191191 DOI: 10.1007/s10147-021-01979-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
652 Yin X, Wang Z, Wang J, Xu Y, Kong W, Zhang J. Development of a novel gene signature to predict prognosis and response to PD-1 blockade in clear cell renal cell carcinoma. Oncoimmunology 2021;10:1933332. [PMID: 34262797 DOI: 10.1080/2162402X.2021.1933332] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
653 Iivanainen S, Ekstrom J, Virtanen H, Kataja VV, Koivunen JP. Electronic patient-reported outcomes and machine learning in predicting immune-related adverse events of immune checkpoint inhibitor therapies. BMC Med Inform Decis Mak 2021;21:205. [PMID: 34193140 DOI: 10.1186/s12911-021-01564-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
654 Yokota C, Nakata J, Takano K, Nakajima H, Hayashibara H, Minagawa H, Chiba Y, Hirayama R, Kijima N, Kinoshita M, Hashii Y, Tsuboi A, Oka Y, Oji Y, Kumanogoh A, Sugiyama H, Kagawa N, Kishima H. Distinct difference in tumor-infiltrating immune cells between Wilms' tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies. Neurooncol Adv 2021;3:vdab091. [PMID: 34355173 DOI: 10.1093/noajnl/vdab091] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
655 Liu Q, Qi Y, Zhai J, Kong X, Wang X, Wang Z, Fang Y, Wang J. Molecular and Clinical Characterization of LAG3 in Breast Cancer Through 2994 Samples. Front Immunol 2021;12:599207. [PMID: 34267742 DOI: 10.3389/fimmu.2021.599207] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
656 Zhang Z, Tang Y, Liu Y, Zhuang H, Lin E, Xie L, Feng X, Tian K, Zeng J, Liu J, Yu Y. A Novel Immune-Related lncRNA-Based Model for Survival Prediction in Clear Cell Renal Cell Carcinoma. J Immunol Res 2021;2021:9921466. [PMID: 34368371 DOI: 10.1155/2021/9921466] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
657 Song W, He X, Gong P, Yang Y, Huang S, Zeng Y, Wei L, Zhang J. Glycolysis-Related Gene Expression Profiling Screen for Prognostic Risk Signature of Pancreatic Ductal Adenocarcinoma. Front Genet 2021;12:639246. [PMID: 34249078 DOI: 10.3389/fgene.2021.639246] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
658 Shklovskaya E, Rizos H. MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It. Int J Mol Sci 2021;22:6741. [PMID: 34201655 DOI: 10.3390/ijms22136741] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
659 Chiu LC, Lin SM, Lo YL, Kuo SC, Yang CT, Hsu PC. Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC). Vaccines (Basel) 2021;9:689. [PMID: 34201650 DOI: 10.3390/vaccines9070689] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
660 Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Ye D, Agerbaek M, Enting D, McDermott R, Gajate P, Peer A, Milowsky MI, Nosov A, Neif Antonio J Jr, Tupikowski K, Toms L, Fischer BS, Qureshi A, Collette S, Unsal-Kacmaz K, Broughton E, Zardavas D, Koon HB, Galsky MD. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med 2021;384:2102-14. [PMID: 34077643 DOI: 10.1056/NEJMoa2034442] [Cited by in Crossref: 141] [Cited by in F6Publishing: 162] [Article Influence: 70.5] [Reference Citation Analysis]
661 Zhang H, Zhao W, Li X, He Y. Cholesterol Metabolism as a Potential Therapeutic Target and a Prognostic Biomarker for Cancer Immunotherapy. Onco Targets Ther 2021;14:3803-12. [PMID: 34188488 DOI: 10.2147/OTT.S315998] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
662 Borm FJ, Smit J, Oprea-Lager DE, Wondergem M, Haanen JBAG, Smit EF, de Langen AJ. Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with Immunotherapy. Cancers (Basel) 2021;13:3083. [PMID: 34205572 DOI: 10.3390/cancers13123083] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
663 Le T, Su S, Shahriyari L. Immune classification of osteosarcoma. Math Biosci Eng 2021;18:1879-97. [PMID: 33757216 DOI: 10.3934/mbe.2021098] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
664 Haineala B, Zgura A, Diaconu C, Mehedintu C, Bacinschi X, Anghel RM. Long-term Response After Stopping Immunotherapy in a Patient With Metastatic Renal Cancer. In Vivo 2021;35:1805-10. [PMID: 33910866 DOI: 10.21873/invivo.12441] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
665 Sato Y, Fukuda N, Fujiwara YU, Wang X, Urasaki T, Ohmoto A, Nakano K, Ono M, Tomomatsu J, Mitani H, Takahashi S. Efficacy of Paclitaxel-based Chemotherapy After Progression on Nivolumab for Head and Neck Cancer. In Vivo 2021;35:1211-5. [PMID: 33622923 DOI: 10.21873/invivo.12371] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
666 Kobayashi K, Iikura Y, Hiraide M, Yokokawa T, Aoyama T, Shikibu S, Hashimoto K, Suzuki K, Sato H, Sugiyama E, Tajima M, Hama T. Association Between Immune-related Adverse Events and Clinical Outcome Following Nivolumab Treatment in Patients With Metastatic Renal Cell Carcinoma. In Vivo 2020;34:2647-52. [DOI: 10.21873/invivo.12083] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
667 Dias Carneiro APC, Marques Monteiro FS, Soares A. PBRM1 Mutations as a Predictive Biomarker for Immunotherapy in Metastatic Renal Cell Carcinoma: A Systematic Review. KCA 2021;5:79-92. [DOI: 10.3233/kca-210111] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
668 Mullangi S, Ponnam S, Lekkala MR, Koya S. A Case of De Novo Psoriasis Secondary to Nivolumab in a Patient With Metastatic Renal Cell Carcinoma. Cureus 2021;13:e15703. [PMID: 34290912 DOI: 10.7759/cureus.15703] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
669 Tsimafeyeu I. Nivolumab: 5 Years Since FDA Approval of the First Checkpoint Inhibitor for Renal Cell Carcinoma. KCA 2021;5:63-71. [DOI: 10.3233/kca-200109] [Reference Citation Analysis]
670 Araujo DV, Muniz TP, Yang A, Keshavarzi S, Sorotsky H, Butler MO, Saibil S, Spreafico A, Hogg D. Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events. Curr Oncol 2021;28:2173-9. [PMID: 34208089 DOI: 10.3390/curroncol28030201] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
671 Tomita Y, Kimura G, Fukasawa S, Numakura K, Sugiyama Y, Yamana K, Naito S, Kabu K, Tajima Y, Oya M. Efficacy and safety of subsequent molecular targeted therapy after immuno-checkpoint therapy, retrospective study of Japanese patients with metastatic renal cell carcinoma (AFTER I-O study). Jpn J Clin Oncol 2021;51:966-75. [PMID: 33594427 DOI: 10.1093/jjco/hyaa266] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
672 Lee HW. Multidiscipline Immunotherapy-Based Rational Combinations for Robust and Durable Efficacy in Brain Metastases from Renal Cell Carcinoma. Int J Mol Sci 2021;22:6290. [PMID: 34208157 DOI: 10.3390/ijms22126290] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
673 Sliker BH, Campbell PM. Fibroblasts Influence the Efficacy, Resistance, and Future Use of Vaccines and Immunotherapy in Cancer Treatment. Vaccines (Basel) 2021;9:634. [PMID: 34200702 DOI: 10.3390/vaccines9060634] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
674 Marchetti A, Rosellini M, Mollica V, Rizzo A, Tassinari E, Nuvola G, Cimadamore A, Santoni M, Fiorentino M, Montironi R, Massari F. The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What's the Story Morning Glory? Int J Mol Sci 2021;22:6237. [PMID: 34207825 DOI: 10.3390/ijms22126237] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
675 Maiorano BA, Schinzari G, Ciardiello D, Rodriquenz MG, Cisternino A, Tortora G, Maiello E. Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities. Vaccines (Basel) 2021;9:623. [PMID: 34207536 DOI: 10.3390/vaccines9060623] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
676 Koks MS, Ocak G, Suelmann BBM, Hulsbergen-Veelken CAR, Haitjema S, Vianen ME, Verhaar MC, Kaasjager KAH, Khairoun M. Immune checkpoint inhibitor-associated acute kidney injury and mortality: An observational study. PLoS One 2021;16:e0252978. [PMID: 34101756 DOI: 10.1371/journal.pone.0252978] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
677 Stellato M, Santini D, Verzoni E, De Giorgi U, Pantano F, Casadei C, Fornarini G, Maruzzo M, Sbrana A, Di Lorenzo G, Soraru M, Naglieri E, Buti S, De Vivo R, Napolitano A, Vignani F, Mucciarini C, Grillone F, Roviello G, Di Napoli M, Procopio G. Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b). Front Oncol 2021;11:682449. [PMID: 34168997 DOI: 10.3389/fonc.2021.682449] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
678 Martinez Chanza N, Xie W, Issa M, Dzimitrowicz H, Tripathi A, Beuselinck B, Lam E, Zakharia Y, Mckay R, Shah S, Mortazavi A, R Harrison M, Sideris S, Kaymakcalan MD, Abou Alaiwi S, Nassar AH, Nuzzo PV, Hamid A, K Choueiri T, C Harshman L. Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study. J Immunother Cancer 2020;8:e000538. [PMID: 32217762 DOI: 10.1136/jitc-2020-000538] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
679 Garcia-Fabiani MB, Haase S, Comba A, Carney S, McClellan B, Banerjee K, Alghamri MS, Syed F, Kadiyala P, Nunez FJ, Candolfi M, Asad A, Gonzalez N, Aikins ME, Schwendeman A, Moon JJ, Lowenstein PR, Castro MG. Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies. Front Oncol 2021;11:631037. [PMID: 34168976 DOI: 10.3389/fonc.2021.631037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
680 Horn LA, Riskin J, Hempel HA, Fousek K, Lind H, Hamilton DH, McCampbell KK, Maeda DY, Zebala JA, Su Z, Schlom J, Palena C. Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity. J Immunother Cancer 2020;8:e000326. [PMID: 32188703 DOI: 10.1136/jitc-2019-000326] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 18.0] [Reference Citation Analysis]
681 Cowzer D, Mulligan K, Glennon K, Hegarty N, Walsh T, Mccaffrey JA. Clear cell urethral adenocarcinoma – a case report of an exceptional response to immunotherapy in a metastatic rare tumour. Journal of Clinical Urology. [DOI: 10.1177/20514158211022640] [Reference Citation Analysis]
682 Lussier DM, Alspach E, Ward JP, Miceli AP, Runci D, White JM, Mpoy C, Arthur CD, Kohlmiller HN, Jacks T, Artyomov MN, Rogers BE, Schreiber RD. Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads. Proc Natl Acad Sci U S A 2021;118:e2102611118. [PMID: 34099555 DOI: 10.1073/pnas.2102611118] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
683 Lai LT, Gu WG, Hu MB, Wang WJ, Wang SS, Huai YJ, Mei JH, Wang CL. Sex-related differences in the efficacy of immune checkpoint inhibitors in malignancy: a systematic review and meta-analysis. Aging (Albany NY) 2021;13:15413-32. [PMID: 34086601 DOI: 10.18632/aging.203100] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
684 Rachev B, Wilking N, Kobelt G, Spandonaro F, Rajer M, Roediger A, Normand R, Zielinski C. Budget projections and clinical impact of an immuno-oncology class of treatments: Experience in four EU markets. Journal of Cancer Policy 2021;28:100279. [DOI: 10.1016/j.jcpo.2021.100279] [Reference Citation Analysis]
685 Bersanelli M, Buti S, Gnetti L, Varotti E, Carbognani P, Rusca M, Leonardi F, Campanini N, Ziglioli F, Dadomo CI, Pilato FP, Ventura L, Braggio C, Bocchialini G, Cortellini A, Brunelli M, Rapacchi E, Camisa R, Caruso G, Silini EM, Maestroni U, Ampollini L. Pulmonary metastasectomy in renal cell carcinoma: Predictive and prognostic elements from paired histopathological analysis of primary tumors and respective metastases. Journal of Onco-Nephrology 2021;5:96-104. [DOI: 10.1177/23993693211028593] [Reference Citation Analysis]
686 Murakami R, Hamanishi J, Brown JB, Abiko K, Yamanoi K, Taki M, Hosoe Y, Yamaguchi K, Baba T, Matsumura N, Konishi I, Mandai M. Combination of gene set signatures correlates with response to nivolumab in platinum-resistant ovarian cancer. Sci Rep 2021;11:11427. [PMID: 34075161 DOI: 10.1038/s41598-021-91012-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
687 Kretschmer A. Entwicklungen bei der Therapie des metastasierten Nierenzellkarzinoms. Im Fokus Onkologie 2021;24:14-17. [DOI: 10.1007/s15015-021-3494-3] [Reference Citation Analysis]
688 Wu F, Wei H, Liu G, Zhang Y. Bioinformatics Profiling of Five Immune-Related lncRNAs for a Prognostic Model of Hepatocellular Carcinoma. Front Oncol 2021;11:667904. [PMID: 34123835 DOI: 10.3389/fonc.2021.667904] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
689 Zhang X, Huang H, Han L, Li T, Wang Z, Gao Q. Advanced Renal-Cell Carcinoma Pseudoprogression After Combined Immunotherapy: Case Report and Literature Review. Front Oncol 2021;11:640447. [PMID: 34123792 DOI: 10.3389/fonc.2021.640447] [Reference Citation Analysis]
690 Schank TE, Forschner A, Sachse MM, Dimitrakopoulou-Strauss A, Sachpekidis C, Stenzinger A, Volckmar AL, Enk A, Hassel JC. Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival. Cancers (Basel) 2021;13:2616. [PMID: 34073477 DOI: 10.3390/cancers13112616] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
691 Wang L, Liu Z, Zhang W, Zhang A, Qu P. PD-1 Coexpression Gene Analysis and the Regulatory Network in Endometrial Cancer Based on Bioinformatics Analysis. Biomed Res Int 2021;2021:9923434. [PMID: 34124265 DOI: 10.1155/2021/9923434] [Reference Citation Analysis]
692 Tian Y, Huang A, Yang Y, Dang Q, Wen Q, Wang L, Sun Y. Assessment of the Clinical Trials Safety Profile of PD-1/PD-L1 Inhibitors Among Patients With Cancer: An Updated Systematic Review and Meta-Analysis. Front Oncol 2021;11:662392. [PMID: 34109117 DOI: 10.3389/fonc.2021.662392] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
693 Haanen J, Ernstoff M, Wang Y, Menzies A, Puzanov I, Grivas P, Larkin J, Peters S, Thompson J, Obeid M. Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. J Immunother Cancer 2020;8:e000604. [PMID: 32532839 DOI: 10.1136/jitc-2020-000604] [Cited by in Crossref: 53] [Cited by in F6Publishing: 59] [Article Influence: 26.5] [Reference Citation Analysis]
694 Ged Y, Chaim JL, DiNatale RG, Knezevic A, Kotecha RR, Carlo MI, Lee CH, Foster A, Feldman DR, Teo MY, Iyer G, Chan T, Patil S, Motzer RJ, Hakimi AA, Voss MH. DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy. J Immunother Cancer 2020;8:e000230. [PMID: 32571992 DOI: 10.1136/jitc-2019-000230] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 10.5] [Reference Citation Analysis]
695 Yang L, Chen X, Wang Q, Zhu Y, Wu C, Ma X, Zuo D, He H, Huang L, Li J, Xia C, Hu S, Yang X, Feng M. Generation of TIM3 inhibitory single-domain antibodies to boost the antitumor activity of chimeric antigen receptor T cells. Oncol Lett 2021;22:542. [PMID: 34079595 DOI: 10.3892/ol.2021.12803] [Reference Citation Analysis]
696 Rebuzzi SE, Signori A, Banna GL, Maruzzo M, De Giorgi U, Pedrazzoli P, Sbrana A, Zucali PA, Masini C, Naglieri E, Procopio G, Merler S, Tomasello L, Fratino L, Baldessari C, Ricotta R, Panni S, Mollica V, Sorarù M, Santoni M, Cortellini A, Prati V, Soto Parra HJ, Stellato M, Atzori F, Pignata S, Messina C, Messina M, Morelli F, Prati G, Nolè F, Vignani F, Cavo A, Roviello G, Pierantoni F, Casadei C, Bersanelli M, Chiellino S, Paolieri F, Perrino M, Brunelli M, Iacovelli R, Porta C, Buti S, Fornarini G. Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study). Ther Adv Med Oncol 2021;13:17588359211019642. [PMID: 34046089 DOI: 10.1177/17588359211019642] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
697 Azuma T, Takeuchi T, Matayoshi Y, Namiki S, Obara T, Imamura K, Takamori M. Serum alanine aminotransferase as an early marker of outcomes in patients receiving anti-PD-1 or anti-CTLA-4 antibody. Sci Rep 2021;11:10264. [PMID: 33986326 DOI: 10.1038/s41598-021-88744-0] [Reference Citation Analysis]
698 Munari E, Mariotti FR, Quatrini L, Bertoglio P, Tumino N, Vacca P, Eccher A, Ciompi F, Brunelli M, Martignoni G, Bogina G, Moretta L. PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects. Int J Mol Sci 2021;22:5123. [PMID: 34066087 DOI: 10.3390/ijms22105123] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 13.5] [Reference Citation Analysis]
699 Ouyang T, Cao Y, Kan X, Chen L, Ren Y, Sun T, Yan L, Xiong B, Liang B, Zheng C. Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review. Front Oncol 2021;11:621639. [PMID: 34046338 DOI: 10.3389/fonc.2021.621639] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
700 Iaia I, Gammaitoni L, Cattaneo G, Giraudo L, Donini C, Fiorino E, Primo L, Carnevale-Schianca F, Aglietta M, Puliafito A, Sangiolo D. Recruitment, Infiltration, and Cytotoxicity of HLA-Independent Killer Lymphocytes in Three-Dimensional Melanoma Models. Cancers (Basel) 2021;13:2302. [PMID: 34065007 DOI: 10.3390/cancers13102302] [Reference Citation Analysis]
701 Jung EH, Kim SH. Treatment of advanced urogenital cancers with immune checkpoint inhibitors. J Korean Med Assoc 2021;64:349-357. [DOI: 10.5124/jkma.2021.64.5.349] [Reference Citation Analysis]
702 Ukleja J, Kusaka E, Miyamoto DT. Immunotherapy Combined With Radiation Therapy for Genitourinary Malignancies. Front Oncol 2021;11:663852. [PMID: 34041029 DOI: 10.3389/fonc.2021.663852] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
703 Rad Pour S, Pico de Coaña Y, Demorentin XM, Melief J, Thimma M, Wolodarski M, Gomez-Cabrero D, Hansson J, Kiessling R, Tegner J. Predicting anti-PD-1 responders in malignant melanoma from the frequency of S100A9+ monocytes in the blood. J Immunother Cancer 2021;9:e002171. [PMID: 33963011 DOI: 10.1136/jitc-2020-002171] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
704 Sanghavi K, Vuppala P, Ivaturi V, Hamuro L, Roy A, Suryawanshi S. Nivolumab exposure-response analysis for adjuvant treatment of melanoma supporting a change in posology. CPT Pharmacometrics Syst Pharmacol 2021;10:748-59. [PMID: 33955714 DOI: 10.1002/psp4.12642] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
705 Kamran SC, Efstathiou JA. Current State of Personalized Genitourinary Cancer Radiotherapy in the Era of Precision Medicine. Front Oncol 2021;11:675311. [PMID: 34026653 DOI: 10.3389/fonc.2021.675311] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
706 Yan Q, Zheng W, Wang B, Ye B, Luo H, Yang X, Zhang P, Wang X. A prognostic model based on seven immune-related genes predicts the overall survival of patients with hepatocellular carcinoma. BioData Min 2021;14:29. [PMID: 33962640 DOI: 10.1186/s13040-021-00261-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
707 Spaas M, Sundahl N, Hulstaert E, Kruse V, Rottey S, De Maeseneer D, Surmont V, Meireson A, Brochez L, Reynders D, Goetghebeur E, Van den Begin R, Van Gestel D, Renard V, Dirix P, Mestdagh P, Ost P. Checkpoint inhibition in combination with an immunoboost of external beam radiotherapy in solid tumors (CHEERS): study protocol for a phase 2, open-label, randomized controlled trial. BMC Cancer 2021;21:514. [PMID: 33962592 DOI: 10.1186/s12885-021-08088-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
708 Griffin GK, Wu J, Iracheta-Vellve A, Patti JC, Hsu J, Davis T, Dele-Oni D, Du PP, Halawi AG, Ishizuka JJ, Kim SY, Klaeger S, Knudsen NH, Miller BC, Nguyen TH, Olander KE, Papanastasiou M, Rachimi S, Robitschek EJ, Schneider EM, Yeary MD, Zimmer MD, Jaffe JD, Carr SA, Doench JG, Haining WN, Yates KB, Manguso RT, Bernstein BE. Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity. Nature 2021;595:309-14. [PMID: 33953401 DOI: 10.1038/s41586-021-03520-4] [Cited by in Crossref: 60] [Cited by in F6Publishing: 67] [Article Influence: 30.0] [Reference Citation Analysis]
709 Kehl KL, Greenwald S, Chamoun NG, Manberg PJ, Schrag D. Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Non-Small Cell Lung Cancer. JAMA Netw Open 2021;4:e2111113. [PMID: 34019086 DOI: 10.1001/jamanetworkopen.2021.11113] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
710 Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain RK, Chahoud J, Spiess PE, Sexton W, Gilbert SM, Manley BJ. Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma. JAMA Netw Open 2021;4:e2111329. [PMID: 34032854 DOI: 10.1001/jamanetworkopen.2021.11329] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
711 Kiaie SH, Sanaei MJ, Heshmati M, Asadzadeh Z, Azimi I, Hadidi S, Jafari R, Baradaran B. Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development. Acta Pharm Sin B 2021;11:1083-97. [PMID: 34094821 DOI: 10.1016/j.apsb.2020.12.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
712 Inoue S, Kono M, Fukuda H, Shimamoto Y, Nakagawa K, Ohmori M, Iwagami H, Matsuno K, Iwatsubo T, Nakahira H, Matsuura N, Shichijo S, Maekawa A, Kanesaka T, Yamamoto S, Takeuchi Y, Higashino K, Uedo N, Kitamura M, Nakatsuka S, Kunimasa K, Kumagai T, Isei T, Ishihara R. Magnifying endoscopy with crystal violet staining for immune checkpoint inhibitor-associated colitis. J Gastroenterol Hepatol 2021;36:1180-6. [PMID: 32888202 DOI: 10.1111/jgh.15246] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
713 Fakhoury KR, Ney DE, Ormond DR, Rusthoven CG. Immunotherapy and radiation for high-grade glioma: a narrative review. Transl Cancer Res 2021;10:2537-70. [PMID: 35116570 DOI: 10.21037/tcr-20-1933] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
714 Baretti M, Zhu Q, Zahurak M, Bhaijee F, Xu H, Engle EL, Kotte A, Pawlik TM, Anders RA, De Jesus-Acosta A. Prognostic Implications of the Immune Tumor Microenvironment in Patients With Pancreatic and Gastrointestinal Neuroendocrine Tumors. Pancreas 2021;50:719-26. [PMID: 34016898 DOI: 10.1097/MPA.0000000000001831] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
715 Xu Y, Song G, Xie S, Jiang W, Chen X, Chu M, Hu X, Wang ZW. The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer. Mol Ther 2021;29:1958-69. [PMID: 33932597 DOI: 10.1016/j.ymthe.2021.04.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
716 Ruiz de Porras V, Pardo JC, Notario L, Etxaniz O, Font A. Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer? Int J Mol Sci 2021;22:4712. [PMID: 33946818 DOI: 10.3390/ijms22094712] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
717 Dunn GP, Cloughesy TF, Maus MV, Prins RM, Reardon DA, Sonabend AM. Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy. Neuro Oncol 2020;22:1425-38. [PMID: 32615600 DOI: 10.1093/neuonc/noaa154] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
718 Parikh M, Bajwa P. Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma. Semin Nephrol 2020;40:76-85. [PMID: 32130969 DOI: 10.1016/j.semnephrol.2019.12.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
719 Hah YS, Koo KC. Immunology and Immunotherapeutic Approaches for Advanced Renal Cell Carcinoma: A Comprehensive Review. Int J Mol Sci 2021;22:4452. [PMID: 33923219 DOI: 10.3390/ijms22094452] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
720 Borchmann S. An atlas of the tissue and blood metagenome in cancer reveals novel links between bacteria, viruses and cancer. Microbiome 2021;9:94. [PMID: 33888160 DOI: 10.1186/s40168-021-01039-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
721 Marchioni M, Rivas JG, Autran A, Socarras M, Albisinni S, Ferro M, Schips L, Scarpa RM, Papalia R, Esperto F. Biomarkers for Renal Cell Carcinoma Recurrence: State of the Art. Curr Urol Rep 2021;22:31. [PMID: 33886004 DOI: 10.1007/s11934-021-01050-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
722 Roberto M, Botticelli A, Panebianco M, Aschelter AM, Gelibter A, Ciccarese C, Minelli M, Nuti M, Santini D, Laghi A, Tomao S, Marchetti P. Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice. Front Oncol 2021;11:657639. [PMID: 33968762 DOI: 10.3389/fonc.2021.657639] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
723 Fu J, Li WZ, McGrath NA, Lai CW, Brar G, Xiang YQ, Xie C. Immune Checkpoint Inhibitor Associated Hepatotoxicity in Primary Liver Cancer Versus Other Cancers: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:650292. [PMID: 33968750 DOI: 10.3389/fonc.2021.650292] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
724 Zhang M, Zhu Z, Xue W, Liu H, Zhang Y. Human immunodeficiency virus-related renal cell carcinoma: a retrospective study of 19 cases. Infect Agent Cancer 2021;16:26. [PMID: 33882973 DOI: 10.1186/s13027-021-00362-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
725 Guven DC, Kavgaci G, Aktepe OH, Yildirim HC, Sahin TK, Aksoy S, Erman M, Kilickap S, Yalcin S. The burden of polypharmacy and drug-drug interactions in older cancer patients treated with immunotherapy. J Oncol Pharm Pract 2021;:10781552211012038. [PMID: 33878976 DOI: 10.1177/10781552211012038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
726 Cocco C, Morandi F, Airoldi I. Immune Checkpoints in Pediatric Solid Tumors: Targetable Pathways for Advanced Therapeutic Purposes. Cells 2021;10:927. [PMID: 33920505 DOI: 10.3390/cells10040927] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
727 Chen S, Zhang Z, Zheng X, Tao H, Zhang S, Ma J, Liu Z, Wang J, Qian Y, Cui P, Huang D, Huang Z, Wu Z, Hu Y. Response Efficacy of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. Front Oncol 2021;11:562315. [PMID: 33937012 DOI: 10.3389/fonc.2021.562315] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
728 Portenkirchner C, Kienle P, Horisberger K. Checkpoint Inhibitor-Induced Colitis-A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options. Pharmaceuticals (Basel) 2021;14:367. [PMID: 33923423 DOI: 10.3390/ph14040367] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
729 Bakouny Z, Sadagopan A, Ravi P, Metaferia NY, Li J, Abuhammad S, Tang S, Denize T, Garner ER, Gao X, Braun DA, Hirsch L, Steinharter JA, Bouchard G, Walton E, West D, Labaki C, Dudani S, Gan C, Sethunath V, Carvalho FL, Imamovic A, Ricker C, Vokes NI, Nyman J, Park J, Hirsch MS, Haq R, Lee GM, Mcgregor BA, Chang SL, Feldman AS, Wu CJ, Mcdermott DF, Heng DY, Signoretti S, Van Allen EM, Choueiri TK, Viswanathan SR. Integrative Clinical and Molecular Characterization of Translocation Renal Cell Carcinoma.. [DOI: 10.1101/2021.04.14.439908] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
730 Krishna C, DiNatale RG, Kuo F, Srivastava RM, Vuong L, Chowell D, Gupta S, Vanderbilt C, Purohit TA, Liu M, Kansler E, Nixon BG, Chen YB, Makarov V, Blum KA, Attalla K, Weng S, Salmans ML, Golkaram M, Liu L, Zhang S, Vijayaraghavan R, Pawlowski T, Reuter V, Carlo MI, Voss MH, Coleman J, Russo P, Motzer RJ, Li MO, Leslie CS, Chan TA, Hakimi AA. Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy. Cancer Cell 2021;39:662-677.e6. [PMID: 33861994 DOI: 10.1016/j.ccell.2021.03.007] [Cited by in Crossref: 53] [Cited by in F6Publishing: 41] [Article Influence: 26.5] [Reference Citation Analysis]
731 Martínez-Pérez E, Molina-Vila MA, Marino-Buslje C. Panels and models for accurate prediction of tumor mutation burden in tumor samples. NPJ Precis Oncol 2021;5:31. [PMID: 33850256 DOI: 10.1038/s41698-021-00169-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
732 Jiang J, Jin Z, Zhang Y, Peng L, Zhang Y, Zhu Z, Wang Y, Tong, Yang Y, Wang J, Yang Y, Xiao K. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer. Front Immunol 2021;12:646874. [PMID: 33927719 DOI: 10.3389/fimmu.2021.646874] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
733 Yu X, Long Y, Chen B, Tong Y, Jia X, Zhou J, Tang F, Xu P, Cao Y, Huang W, Ren J, Wan Y, Sun J, Jin G, Gong L. The PD-L1 and TLR7 dual-targeting nanobody-drug conjugate exerts potent antitumor efficacy by orchestrating innate and adaptive immune responses.. [DOI: 10.1101/2021.04.11.439388] [Reference Citation Analysis]
734 Wang T, Suita Y, Miriyala S, Dean J, Tapinos N, Shen J. Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy. Pharmaceutics 2021;13:520. [PMID: 33918635 DOI: 10.3390/pharmaceutics13040520] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
735 Georgantzoglou N, Kokkali S, Tsourouflis G, Theocharis S. Tumor Microenvironment in Adrenocortical Carcinoma: Barrier to Immunotherapy Success? Cancers (Basel) 2021;13:1798. [PMID: 33918733 DOI: 10.3390/cancers13081798] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
736 Huinen ZR, Huijbers EJM, van Beijnum JR, Nowak-Sliwinska P, Griffioen AW. Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nat Rev Clin Oncol 2021;18:527-40. [PMID: 33833434 DOI: 10.1038/s41571-021-00496-y] [Cited by in Crossref: 52] [Cited by in F6Publishing: 60] [Article Influence: 26.0] [Reference Citation Analysis]
737 Paludan-Müller AS, Créquit P, Boutron I. Reporting of harms in oncological clinical study reports submitted to the European Medicines Agency compared to trial registries and publications-a methodological review. BMC Med 2021;19:88. [PMID: 33827569 DOI: 10.1186/s12916-021-01955-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
738 Yang X, Lei P, Huang L, Tang X, Wei B, Wei H. Prognostic value of LRRC4C in Colon and Gastric Cancers correlates with Tumour Microenvironment Immunity. Int J Biol Sci 2021;17:1413-27. [PMID: 33867855 DOI: 10.7150/ijbs.58876] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
739 Iinuma K, Kameyama K, Kawada K, Fujimoto S, Takagi K, Nagai S, Ito H, Ishida T, Kawase M, Kawase K, Nakai C, Kato D, Takai M, Nakane K, Koie T. Efficacy and Safety of Nivolumab and Ipilimumab for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Cohort Study. Curr Oncol 2021;28:1402-11. [PMID: 33916792 DOI: 10.3390/curroncol28020133] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
740 Wong A, Vellayappan B, Cheng L, Zhao JJ, Muthu V, Asokumaran Y, Low JL, Lee M, Huang YQ, Kumarakulasinghe NB, Ngoi N, Leong CN, Chua W, Thian YL. Atypical Response Patterns in Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors-Navigating the Radiologic Potpourri. Cancers (Basel) 2021;13:1689. [PMID: 33918397 DOI: 10.3390/cancers13071689] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
741 Spadaccino F, Gigante M, Netti GS, Rocchetti MT, Franzin R, Gesualdo L, Castellano G, Stallone G, Ranieri E. The Ambivalent Role of miRNAs in Carcinogenesis: Involvement in Renal Cell Carcinoma and Their Clinical Applications. Pharmaceuticals (Basel) 2021;14:322. [PMID: 33918154 DOI: 10.3390/ph14040322] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
742 Sabbah M, Najem A, Krayem M, Awada A, Journe F, Ghanem GE. RTK Inhibitors in Melanoma: From Bench to Bedside. Cancers (Basel) 2021;13:1685. [PMID: 33918490 DOI: 10.3390/cancers13071685] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
743 Fidelle M, Derosa L, Routy B, Zitvogel L. Contourner la résistance à l’immunothérapie des cancers : interventions centrées sur le microbiome intestinal. Bulletin de l'Académie Nationale de Médecine 2021;205:364-382. [DOI: 10.1016/j.banm.2021.01.022] [Reference Citation Analysis]
744 Marabelle A. Vaincre les résistances aux antagonistes de checkpoint en augmentant l’immunogénicité de la tumeur. Bulletin de l'Académie Nationale de Médecine 2021;205:340-349. [DOI: 10.1016/j.banm.2021.02.002] [Reference Citation Analysis]
745 Sun S, Xu L, Zhang X, Pang L, Long Z, Deng C, Zhu J, Zhou S, Wan L, Pang B, Xiao Y. Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy. Cancers (Basel) 2021;13:1639. [PMID: 33915876 DOI: 10.3390/cancers13071639] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
746 Seitlinger J, Prieto M, Siat J, Renaud S. Pulmonary metastasectomy in renal cell carcinoma: a mainstay of multidisciplinary treatment. J Thorac Dis 2021;13:2636-42. [PMID: 34012612 DOI: 10.21037/jtd-2019-pm-10] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
747 Seydel F, Delecluse S, Zeier M, Holland-Letz T, Haag GM, Berger AK, Grün BC, Bougatf N, Hohenfellner M, Duensing S, Jäger D, Zschäbitz S. Efficacy and Safety of Checkpoint Inhibitor Treatment in Patients with Advanced Renal or Urothelial Cell Carcinoma and Concomitant Chronic Kidney Disease: A Retrospective Cohort Study. Cancers (Basel) 2021;13:1623. [PMID: 33915693 DOI: 10.3390/cancers13071623] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
748 Gao W, Li L, Han X, Liu S, Li C, Yu G, Zhang L, Zhang D, Liu C, Meng E, Hong S, Wang D, Guo P, Shi G. Comprehensive analysis of immune-related prognostic genes in the tumour microenvironment of hepatocellular carcinoma. BMC Cancer 2021;21:331. [PMID: 33789609 DOI: 10.1186/s12885-021-08052-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
749 Molina GE, Zubiri L, Cohen JV, Durbin SM, Petrillo L, Allen IM, Murciano-Goroff YR, Dougan M, Thomas MF, Faje AT, Rengarajan M, Guidon AC, Chen ST, Okin D, Medoff BD, Nasrallah M, Kohler MJ, Schoenfeld SR, Karp Leaf RS, Sise ME, Neilan TG, Zlotoff DA, Farmer JR, Mooradian MJ, Bardia A, Mai M, Sullivan RJ, Semenov YR, Villani AC, Reynolds KL. Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. Oncologist 2021;26:514-22. [PMID: 33655682 DOI: 10.1002/onco.13740] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
750 Boilève A, Hilmi M, Smolenschi C, Ducreux M, Hollebecque A, Malka D. Immunotherapy in Advanced Biliary Tract Cancers. Cancers (Basel) 2021;13:1569. [PMID: 33805461 DOI: 10.3390/cancers13071569] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
751 Gupta A, Arora P, Brenner D, Vanderpuye-Orgle J, Boyne DJ, Edmondson-Jones M, Parkhomenko E, Stevens W, Dudani S, Heng DYC, Wagner S, Borrill J, Wu E. Risk Prediction Using Bayesian Networks: An Immunotherapy Case Study in Patients With Metastatic Renal Cell Carcinoma. JCO Clin Cancer Inform 2021;5:326-37. [PMID: 33764818 DOI: 10.1200/CCI.20.00107] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
752 Au L, Hatipoglu E, de Massy MR, Litchfield K, Rowan A, Thompson R, Schnidrig D, Byrne F, Beattie G, Horswell S, Fotiadis N, Hazell S, Nicol D, Shepherd STC, Fendler A, Mason R, Attig J, Joshi K, Uddin I, Becker P, Sunderland MW, Akarca A, Puccio I, Yang W, Lund T, Dhillon K, Vasquez MD, Ghorani E, Xu H, López JI, Green A, Mahadeva U, Borg E, Mitchison M, Moore D, Proctor I, Falzon M, Furness A, Pickering L, Reading JL, Salgado R, Marafioti T, Jamal-hanjani M, Kassiotis G, Chain B, Larkin J, Swanton C, Quezada SA, Turajlic S. Determinants of anti-PD1 response and resistance in clear cell renal cell carcinoma.. [DOI: 10.1101/2021.03.19.21253661] [Reference Citation Analysis]
753 Esposito M, Ganesan S, Kang Y. Emerging strategies for treating metastasis. Nat Cancer 2021;2:258-70. [PMID: 33899000 DOI: 10.1038/s43018-021-00181-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 13.5] [Reference Citation Analysis]
754 Zheng W, Zhang S, Guo H, Chen X, Huang Z, Jiang S, Li M. Multi-omics analysis of tumor angiogenesis characteristics and potential epigenetic regulation mechanisms in renal clear cell carcinoma. Cell Commun Signal 2021;19:39. [PMID: 33761933 DOI: 10.1186/s12964-021-00728-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
755 Shiuan E, Reddy A, Dudzinski SO, Lim AR, Sugiura A, Hongo R, Young K, Liu XD, Smith CC, O'Neal J, Dahlman KB, McAlister R, Chen B, Ruma K, Roscoe N, Bender J, Ward J, Kim JY, Vaupel C, Bordeaux J, Ganesan S, Mayer TM, Riedlinger GM, Vincent BG, Davis NB, Haake SM, Rathmell JC, Jonasch E, Rini BI, Rathmell WK, Beckermann KE. Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma. Cancers (Basel) 2021;13:1475. [PMID: 33806963 DOI: 10.3390/cancers13061475] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
756 Kazarian AG, Chawla NS, Muddasani R, Pal SK. Adjuvant Therapy in Renal Cell Carcinoma: Current Status and Future Directions. KCA 2021;5:9-20. [DOI: 10.3233/kca-200105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
757 Jang A, Sweeney PL, Barata PC, Koshkin VS. PD-L1 Expression and Treatment Implications in Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review. KCA 2021;5:31-46. [DOI: 10.3233/kca-200108] [Reference Citation Analysis]
758 Zhang H, Basappa NS, Ghosh S, Joy I, Lalani AA, Hansen AR, Heng DY, Castonguay V, Kollmannsberger CK, Winquist E, Wood L, Bjarnason GA, Breau RH, Kapoor A, Graham J. Real-Word Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis). KCA 2021;5:21-9. [DOI: 10.3233/kca-210110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
759 Zheng Y, Wen Y, Cao H, Gu Y, Yan L, Wang Y, Wang L, Zhang L, Shao F. Global Characterization of Immune Infiltration in Clear Cell Renal Cell Carcinoma. Onco Targets Ther 2021;14:2085-100. [PMID: 33790572 DOI: 10.2147/OTT.S282763] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
760 Krege S, Doehn C. Fortgeschrittenes Nierenzellkarzinom: Neuerungen beim Einsatz zielgerichteter Therapien. Deutsches Ärzteblatt Online 2021. [DOI: 10.3238/personko.2021.03.19.02] [Reference Citation Analysis]
761 Nie RC, Chen GM, Wang Y, Zhou J, Duan JL, Zhou ZW, Yuan SQ. Efficacy of Anti-PD-1/PD-L1 Monotherapy or Combinational Therapy in Patients Aged 75 Years or Older: A Study-Level Meta-Analysis. Front Oncol 2021;11:538174. [PMID: 33816215 DOI: 10.3389/fonc.2021.538174] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
762 Sacdalan DB, Lucero JA. The Association Between Inflammation and Immunosuppression: Implications for ICI Biomarker Development. Onco Targets Ther 2021;14:2053-64. [PMID: 33776452 DOI: 10.2147/OTT.S278089] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
763 Faieta A, Dancik T. Refractory Acute Interstitial Nephritis in the Setting of Nivolumab Therapy. Case Rep Nephrol 2021;2021:6640154. [PMID: 33728076 DOI: 10.1155/2021/6640154] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
764 Castello A, Rossi S, Toschi L, Lopci E. Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors. J Clin Med 2021;10:1251. [PMID: 33803006 DOI: 10.3390/jcm10061251] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
765 Walker JM, Rolig AS, Charych DH, Hoch U, Kasiewicz MJ, Rose DC, McNamara MJ, Hilgart-Martiszus IF, Redmond WL. NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8+ T cell responses capable of curing multi-focal cancer. J Immunother Cancer 2020;8:e000464. [PMID: 32457127 DOI: 10.1136/jitc-2019-000464] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
766 Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suárez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Żołnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ; CheckMate 9ER Investigators. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 2021;384:829-41. [PMID: 33657295 DOI: 10.1056/NEJMoa2026982] [Cited by in Crossref: 445] [Cited by in F6Publishing: 488] [Article Influence: 222.5] [Reference Citation Analysis]
767 Mouri A, Kaira K, Yamaguchi O, Hashimoto K, Miura Y, Shiono A, Shinomiya S, Akagami T, Imai H, Kobayashi K, Kagamu H. Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers. Front Oncol 2021;11:610952. [PMID: 33791204 DOI: 10.3389/fonc.2021.610952] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
768 Nakhoda SK, Olszanski AJ. Addressing Recent Failures in Immuno-Oncology Trials to Guide Novel Immunotherapeutic Treatment Strategies. Pharmaceut Med 2020;34:83-91. [PMID: 32157638 DOI: 10.1007/s40290-020-00326-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
769 Zhang K, Xu C, Liu S, Jiang Y, Zhao X, Ma S, Li Y, Yang F, Wang Y, Meng P, Shi C, Han D, Wen W, Qin W. The Diagnostic and Immunotherapeutic Value of CD248 in Renal Cell Carcinoma. Front Oncol 2021;11:644612. [PMID: 33791227 DOI: 10.3389/fonc.2021.644612] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
770 Scholtes MP, Alberts AR, Iflé IG, Verhagen PCMS, van der Veldt AAM, Zuiverloon TCM. Biomarker-Oriented Therapy in Bladder and Renal Cancer. Int J Mol Sci 2021;22:2832. [PMID: 33799514 DOI: 10.3390/ijms22062832] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
771 Kim J, Park JY, Shin SJ, Lim BJ, Go H. Neo-Fs Index: A Novel Immunohistochemical Biomarker Panel Predicts Survival and Response to Anti-Angiogenetic Agents in Clear Cell Renal Cell Carcinoma. Cancers (Basel) 2021;13:1199. [PMID: 33801954 DOI: 10.3390/cancers13061199] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
772 Canil C, Kapoor A, Basappa NS, Bjarnason G, Bossé D, Dudani S, Graham J, Gray S, Hansen AR, Heng DYC, Karakiewicz PI, Kollmannsberger C, Lalani AA, North SA, Patenaude F, Soulières D, Thana M, Winquist E, Wood LA, Reaume MN, Maloni R, Hotte SJ; Kidney Cancer Research Network of Canada. Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. Can Urol Assoc J 2021;15:84-97. [PMID: 33830005 DOI: 10.5489/cuaj.7245] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
773 Jian Y, Yang K, Sun X, Zhao J, Huang K, Aldanakh A, Xu Z, Wu H, Xu Q, Zhang L, Xu C, Yang D, Wang S. Current Advance of Immune Evasion Mechanisms and Emerging Immunotherapies in Renal Cell Carcinoma. Front Immunol 2021;12:639636. [PMID: 33767709 DOI: 10.3389/fimmu.2021.639636] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
774 Cremolini C, Vitale E, Rastaldo R, Giachino C. Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy. Nanomaterials (Basel) 2021;11:661. [PMID: 33800368 DOI: 10.3390/nano11030661] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
775 Ge Y, Wei F, Du G, Fei G, Li W, Li X, Chu J, Wei P. The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity. BMC Cancer 2021;21:240. [PMID: 33678158 DOI: 10.1186/s12885-021-07978-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
776 Ding R, Liu S, Wang S, Chen H, Wang F, Xu Q, Zhu L, Dong X, Gu Y, Zhang X, Chao CC, Gao Q. Single-cell transcriptome analysis of the heterogeneous effects of differential expression of tumor PD-L1 on responding TCR-T cells. Theranostics 2021;11:4957-74. [PMID: 33754038 DOI: 10.7150/thno.55075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
777 Xu Y, Miller CP, Warren EH, Tykodi SS. Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma. Hum Vaccin Immunother 2021;17:1882-96. [PMID: 33667140 DOI: 10.1080/21645515.2020.1870846] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
778 Rappold PM, Silagy AW, Kotecha RR, Hakimi AA. Immune checkpoint blockade in renal cell carcinoma. J Surg Oncol 2021;123:739-50. [PMID: 33595892 DOI: 10.1002/jso.26339] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
779 Tessier-Cloutier B, Twa DD, Marzban M, Kalina J, Chun HE, Pavey N, Tanweer Z, Katz RL, Lum JJ, Salina D. The presence of tumour-infiltrating neutrophils is an independent adverse prognostic feature in clear cell renal cell carcinoma. J Pathol Clin Res 2021;7:385-96. [PMID: 33665979 DOI: 10.1002/cjp2.204] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
780 Lin E, Liu X, Liu Y, Zhang Z, Xie L, Tian K, Liu J, Yu Y. Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma. Front Immunol 2021;12:653358. [PMID: 33746989 DOI: 10.3389/fimmu.2021.653358] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
781 Mondlane ER, Abreu-Mendes P, Martins D, Cruz R, Mendes F. The role of immunotherapy in advanced renal cell carcinoma: Review. Int Braz J Urol 2021;47:1228-42. [PMID: 33650838 DOI: 10.1590/S1677-5538.IBJU.2020.0681] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
782 Bade RM, Schehr JL, Emamekhoo H, Gibbs BK, Rodems TS, Mannino MC, Desotelle JA, Heninger E, Stahlfeld CN, Sperger JM, Singh A, Wolfe SK, Niles DJ, Arafat W, Steinharter JA, Jason Abel E, Beebe DJ, Wei XX, McKay RR, Choueri TK, Lang JM. Development and initial clinical testing of a multiplexed circulating tumor cell assay in patients with clear cell renal cell carcinoma. Mol Oncol 2021;15:2330-44. [PMID: 33604999 DOI: 10.1002/1878-0261.12931] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
783 Tomioka M, Nakane K, Ozawa K, Iinuma K, Suzui N, Miyazaki T, Koie T. A case of multiple metastatic sarcomatoid renal cell carcinoma with complete response to nivolumab. Cancer Rep (Hoboken) 2021;4:e1356. [PMID: 33656804 DOI: 10.1002/cnr2.1356] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
784 Niu M, Yi M, Li N, Luo S, Wu K. Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC. Exp Hematol Oncol 2021;10:18. [PMID: 33653420 DOI: 10.1186/s40164-021-00211-8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 17.0] [Reference Citation Analysis]
785 Cherri S, Noventa S, Fanelli M, Calandra G, Prochilo T, Bnà C, Savelli G, Zaniboni A. Drug-Related Pneumonitis in Cancer Treatment during the COVID-19 Era. Cancers (Basel) 2021;13:1052. [PMID: 33801385 DOI: 10.3390/cancers13051052] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
786 Mauvais-Jarvis F, Berthold HK, Campesi I, Carrero JJ, Dakal S, Franconi F, Gouni-Berthold I, Heiman ML, Kautzky-Willer A, Klein SL, Murphy A, Regitz-Zagrosek V, Reue K, Rubin JB. Sex- and Gender-Based Pharmacological Response to Drugs. Pharmacol Rev 2021;73:730-62. [PMID: 33653873 DOI: 10.1124/pharmrev.120.000206] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 19.0] [Reference Citation Analysis]
787 Mollica V, Rizzo A, Di Nunno V, Santoni M, Cheng L, Lopez-Beltran A, Scarpelli M, Cimadamore A, Montironi R, Massari F. Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF? Transl Androl Urol 2021;10:1581-7. [PMID: 33850792 DOI: 10.21037/tau-20-1125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
788 Boussios S, Sheriff M, Rassy E, Moschetta M, Samartzis EP, Hallit R, Sadauskaite A, Katsanos KH, Christodoulou DK, Pavlidis N. Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities. Ann Transl Med 2021;9:423. [PMID: 33842644 DOI: 10.21037/atm-20-7361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
789 Laccetti AL, Garmezy B, Xiao L, Economides M, Venkatesan A, Gao J, Jonasch E, Corn P, Zurita-Saavedra A, Brown LC, Kao C, Kinsey EN, Gupta RT, Harrison MR, Armstrong AJ, George DJ, Tannir N, Msaouel P, Shah A, Zhang T, Campbell MT. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. Cancer Med 2021;10:2341-9. [PMID: 33650321 DOI: 10.1002/cam4.3812] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
790 Tulchiner G, Pichler R, Ulmer H, Staudacher N, Lindner AK, Brunner A, Zelger B, Steinkohl F, Aigner F, Horninger W, Thurnher M. Sex-specific hormone changes during immunotherapy and its influence on survival in metastatic renal cell carcinoma. Cancer Immunol Immunother 2021;70:2805-17. [PMID: 33646368 DOI: 10.1007/s00262-021-02882-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
791 Gkolfinopoulos S, Psyrri A, Bamias A. Clear-cell renal cell carcinoma - A comprehensive review of agents used in the contemporary management of advanced/metastatic disease. Oncol Rev 2021;15:530. [PMID: 33747368 DOI: 10.4081/oncol.2021.530] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
792 Kim H, Hong JY, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK, Kim KM, Kim ST. Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. Ther Adv Med Oncol 2021;13:1758835921992992. [PMID: 33717226 DOI: 10.1177/1758835921992992] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
793 Leite LM, Bergerot PG, Dettino ALA, R JA Júnior, Zequi SC, Formiga MNDC. Influence of treatment access on survival of metastatic renal cell carcinoma in brazilian cancer center. Int Braz J Urol 2021;47:566-73. [PMID: 33621005 DOI: 10.1590/S1677-5538.IBJU.2020.0443] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
794 Yirgin IK, Erturk SM, Dogan I, Vatansever S. Are radiologists ready to evaluate true response to immunotherapy? Insights Imaging 2021;12:29. [PMID: 33625595 DOI: 10.1186/s13244-021-00968-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
795 Barber H, Tofias A, Lander B, Daniels A, Gong J, Ren Y, Ren X, Liang Y, White P, Kurian KM. Advanced Molecular Characterization Using Digital Spatial Profiling Technology on Immunooncology Targets in Methylated Compared with Unmethylated IDH-Wildtype Glioblastoma. J Oncol 2021;2021:8819702. [PMID: 33995529 DOI: 10.1155/2021/8819702] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
796 Reese SW, Cone E, Marchese M, Garcia B, Chou W, Ayub A, Kilbridge K, Weinhouse G, Trinh QD. Lessons from Pharmacovigilance: Pulmonary Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy. Lung 2021;199:199-211. [PMID: 33616727 DOI: 10.1007/s00408-021-00425-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
797 Jacob A, Wu J, Kolesar J, Durbin E, Mathew A, Arnold S, Chauhan A. Real world clinicopathologic observations of patients with metastatic solid tumors receiving immune checkpoint inhibitor therapy: Analysis from Kentucky Cancer Registry. Cancer Med 2021;10:2054-62. [PMID: 33619913 DOI: 10.1002/cam4.3802] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
798 Su S, Akbarinejad S, Shahriyari L. Immune classification of clear cell renal cell carcinoma. Sci Rep 2021;11:4338. [PMID: 33619294 DOI: 10.1038/s41598-021-83767-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
799 Luo Q, Vögeli TA. Reclassification of Kidney Clear Cell Carcinoma Based on Immune Cell Gene-Related DNA CpG Pairs. Biomedicines 2021;9:215. [PMID: 33672457 DOI: 10.3390/biomedicines9020215] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
800 Noto-Kadou-Kaza B, Desbuissons G, Isnard CB. Association of Acute Interstitial Nephritis with Nivolumab in Renal Cell Carcinoma: A Case Report. Indian J Nephrol 2021;31:303-6. [PMID: 34376950 DOI: 10.4103/ijn.IJN_62_20] [Reference Citation Analysis]
801 Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduct Target Ther 2021;6:72. [PMID: 33608497 DOI: 10.1038/s41392-020-00449-4] [Cited by in Crossref: 74] [Cited by in F6Publishing: 82] [Article Influence: 37.0] [Reference Citation Analysis]
802 Zhang B, Wang X, Cheng P. Remodeling of Tumor Immune Microenvironment by Oncolytic Viruses. Front Oncol 2020;10:561372. [PMID: 33680911 DOI: 10.3389/fonc.2020.561372] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
803 Greenberg SE, Maese LD, Maughan BL. VON HIPPEL–LINDAU SYNDROME. Cassidy and Allanson's Management of Genetic Syndromes 2021. [DOI: 10.1002/9781119432692.ch62] [Reference Citation Analysis]
804 Fukuda S, Saito K, Yasuda Y, Kijima T, Yoshida S, Yokoyama M, Ishioka J, Matsuoka Y, Kageyama Y, Fujii Y. Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab. J Immunother Cancer 2021;9:e001564. [PMID: 33602695 DOI: 10.1136/jitc-2020-001564] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
805 Wang HY, Deng L, Li YQ, Zhang X, Long YK, Zhang X, Feng YF, He Y, Tang T, Yang XH, Wang F. Pan-cancer Analysis of Tumor Mutational Burden and Homologous Recombination DNA Damage Repair Using Targeted Next-Generation Sequencing. Cancer Res Treat 2021. [PMID: 33677848 DOI: 10.4143/crt.2020.798] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
806 Paderi A, Giorgione R, Giommoni E, Mela MM, Rossi V, Doni L, Minervini A, Carini M, Pillozzi S, Antonuzzo L. Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Cancers (Basel) 2021;13:860. [PMID: 33670634 DOI: 10.3390/cancers13040860] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
807 Iwasaki K, Shin T, Inoue T, Shibuya T, Hirai K, Ando T, Mimata H. Only three cycles of nivolumab showed remarkable durable response and reversible myeloradiculoneuropathy in a patient with metastatic papillary renal cell carcinoma type 2. IJU Case Rep 2021;4:139-42. [PMID: 33977240 DOI: 10.1002/iju5.12262] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
808 Zhou Z, Xie X, Wang X, Zhang X, Li W, Sun T, Cai Y, Wu J, Dang C, Zhang H. Correlations Between Tumor Mutation Burden and Immunocyte Infiltration and Their Prognostic Value in Colon Cancer. Front Genet 2021;12:623424. [PMID: 33664769 DOI: 10.3389/fgene.2021.623424] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
809 Zha H, Jiang Y, Wang X, Shang J, Wang N, Yu L, Zhao W, Li Z, An J, Zhang X, Chen H, Zhu B, Li Z. Non-canonical PD-1 signaling in cancer and its potential implications in clinic. J Immunother Cancer 2021;9:e001230. [PMID: 33593825 DOI: 10.1136/jitc-2020-001230] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
810 Yi M, Zhang J, Li A, Niu M, Yan Y, Jiao Y, Luo S, Zhou P, Wu K. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1. J Hematol Oncol 2021;14:27. [PMID: 33593403 DOI: 10.1186/s13045-021-01045-x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 19.0] [Reference Citation Analysis]
811 Wang Y, Yin C, Geng L, Cai W. Immune Infiltration Landscape in Clear Cell Renal Cell Carcinoma Implications. Front Oncol 2020;10:491621. [PMID: 33665156 DOI: 10.3389/fonc.2020.491621] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
812 Guven DC, Yildirim HC, Bilgin E, Aktepe OH, Taban H, Sahin TK, Cakir IY, Akin S, Dizdar O, Aksoy S, Yalcin S, Erman M, Kilickap S. PILE: a candidate prognostic score in cancer patients treated with immunotherapy. Clin Transl Oncol 2021;23:1630-6. [PMID: 33586122 DOI: 10.1007/s12094-021-02560-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
813 Sheng J, Zhang J, Baudelet C, Roy A. Clinical Benefit-Risk Assessment of Nivolumab 240 mg Every 2 Weeks in Chinese Patients With Advanced and Metastatic Solid Tumors. J Clin Pharmacol 2021;61:1045-53. [PMID: 33501654 DOI: 10.1002/jcph.1821] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
814 Zhong L, Wu Q, Chen F, Liu J, Xie X. Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors. Cancer Immunol Immunother 2021;70:2559-76. [PMID: 33576872 DOI: 10.1007/s00262-020-02803-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
815 Shirotake S, Umezawa Y, Okabe T, Kaneko GO, Kanao K, Nishimoto K, Oyama M. Efficacy of Nivolumab Plus Ipilimumab in a Patient With Renal Cell Carcinoma Concomitant With Cardiac Metastasis: A Case Report. In Vivo 2020;34:1475-80. [PMID: 32354949 DOI: 10.21873/invivo.11932] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
816 Ishihara H, Takagi T, Kondo T, Fukuda H, Tachibana H, Yoshida K, Iizuka J, Okumi M, Ishida H, Tanabe K. Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma. In Vivo 2020;34:1541-6. [PMID: 32354960 DOI: 10.21873/invivo.11943] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
817 Grande E, Glen H, Aller J, Argenziano G, Lamas MJ, Ruszniewski P, Zamorano JL, Edmonds K, Sarker S, Staehler M, Larkin J. Рекомендации по лечению пациентов с прогрессирующим или метастатическим почечно-клеточным раком комбинацией ленватиниба и эверолимуса. Onkourologiâ 2021;16:61-81. [DOI: 10.17650/1726-9776-2020-16-4-61-81] [Reference Citation Analysis]
818 Kelleher T, Cai J, Botwood NA, Labriola DF. Characterizing tumor shrinkage as a measure of clinical benefit for immune checkpoint inhibitors. J Immunother Cancer 2021;9:e001177. [PMID: 33558277 DOI: 10.1136/jitc-2020-001177] [Reference Citation Analysis]
819 Rodler S, Schott M, Tamalunas A, Marcon J, Graser A, Mumm JN, Casuscelli J, Stief CG, Fürweger C, Muacevic A, Staehler M. Safety and Efficacy of Robotic Radiosurgery for Visceral and Lymph Node Metastases of Renal Cell Carcinoma: A Retrospective, Single Center Analysis. Cancers (Basel) 2021;13:680. [PMID: 33567564 DOI: 10.3390/cancers13040680] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
820 Tulchiner G, Brunner A, Schmidinger M, Staudacher N, Orme JJ, Thurnher M, Horninger W, Culig Z, Pichler R. CMTM6 expression as a potential biomarker for immunotherapy in metastatic renal cell carcinoma. BJU Int 2021;128:29-32. [PMID: 33455021 DOI: 10.1111/bju.15341] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
821 Bakouny Z, Braun DA, Shukla SA, Pan W, Gao X, Hou Y, Flaifel A, Tang S, Bosma-Moody A, He MX, Vokes N, Nyman J, Xie W, Nassar AH, Abou Alaiwi S, Flippot R, Bouchard G, Steinharter JA, Nuzzo PV, Ficial M, Sant'Angelo M, Forman J, Berchuck JE, Dudani S, Bi K, Park J, Camp S, Sticco-Ivins M, Hirsch L, Baca SC, Wind-Rotolo M, Ross-Macdonald P, Sun M, Lee GM, Chang SL, Wei XX, McGregor BA, Harshman LC, Genovese G, Ellis L, Pomerantz M, Hirsch MS, Freedman ML, Atkins MB, Wu CJ, Ho TH, Linehan WM, McDermott DF, Heng DYC, Viswanathan SR, Signoretti S, Van Allen EM, Choueiri TK. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun 2021;12:808. [PMID: 33547292 DOI: 10.1038/s41467-021-21068-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 17.5] [Reference Citation Analysis]
822 Qin Z, Hu H, Sun W, Chen L, Jin S, Xu Q, Liu Y, Yu L, Zeng S. miR-224-5p Contained in Urinary Extracellular Vesicles Regulates PD-L1 Expression by Inhibiting Cyclin D1 in Renal Cell Carcinoma Cells. Cancers (Basel) 2021;13:618. [PMID: 33557163 DOI: 10.3390/cancers13040618] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
823 Ravi P, Mantia C, Su C, Sorenson K, Elhag D, Rathi N, Bakouny Z, Agarwal N, Zakharia Y, Costello BA, McKay RR, Narayan V, Alva A, McGregor BA, Gao X, McDermott DF, Choueiri TK. Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma. JAMA Oncol 2020;6:1606-10. [PMID: 32469396 DOI: 10.1001/jamaoncol.2020.2169] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 22.5] [Reference Citation Analysis]
824 McDermott DF, Lee JL, Bjarnason GA, Larkin JMG, Gafanov RA, Kochenderfer MD, Jensen NV, Donskov F, Malik J, Poprach A, Tykodi SS, Alonso-Gordoa T, Cho DC, Geertsen PF, Climent Duran MA, DiSimone C, Silverman RK, Perini RF, Schloss C, Atkins MB. Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. J Clin Oncol 2021;39:1020-8. [PMID: 33529051 DOI: 10.1200/JCO.20.02363] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 22.5] [Reference Citation Analysis]
825 Ghouzlani A, Rafii S, Karkouri M, Lakhdar A, Badou A. The Promising IgSF11 Immune Checkpoint Is Highly Expressed in Advanced Human Gliomas and Associates to Poor Prognosis. Front Oncol 2020;10:608609. [PMID: 33604291 DOI: 10.3389/fonc.2020.608609] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
826 Laskar RS, Li P, Ecsedi S, Abedi-Ardekani B, Durand G, Robinot N, Hubert JN, Janout V, Zaridze D, Mukeria A, Mates D, Holcatova I, Foretova L, Swiatkowska B, Dzamic Z, Milosavljevic S, Olaso R, Boland A, Deleuze JF, Muller DC, McKay JD, Brennan P, Le Calvez-Kelm F, Scelo G, Chanudet E. Sexual dimorphism in cancer: insights from transcriptional signatures in kidney tissue and renal cell carcinoma. Hum Mol Genet 2021;30:343-55. [PMID: 33527138 DOI: 10.1093/hmg/ddab031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
827 Barham W, Guo R, Park SS, Herrmann J, Dong H, Yan Y. Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy. Front Immunol 2020;11:561083. [PMID: 33603731 DOI: 10.3389/fimmu.2020.561083] [Cited by in Crossref: 5] [